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A growing body of evidence suggests that obesity and cardiometabolic 
disorders in adulthood may originate early in life. As adverse early-life size 
and growth patterns may influence pathways determining subsequent adiposity 
and metabolic disease, insights into the determinants of early infant size, 
growth and development would be crucial to understand the pathways 
affecting future metabolic compromise in Asian populations. 
Objectives 
This dissertation aims to: 
i) uncover the factors which influence size and body composition of 
newborns in Singapore 
ii) study the factors that can predict patterns of growth and adiposity in 
early childhood, during the first three years of life 
Methods 
This study is centered on the Growing Up in Singapore Towards healthy 
Outcomes (GUSTO) birth cohort, a comprehensively phenotyped parent-
offspring cohort in the first few years of life, recruited from Singapore’s two 
major public maternity units [National University Hospital (NUH) and KK 
Women’s and Children Hospital (KKH)]. Extensive maternal evaluations 
including ultrasound scans for fetal growth, physical examinations and oral 
glucose tolerance testing were conducted during pregnancy. Umbilical cord 
specimens were obtained at delivery and analysed by genome-wide 
 x 
 
methodologies for RNA expression, DNA methylation characterization and 
genotyping. Infant growth was monitored frequently at multiple timepoints, 
complemented by body composition assessments using multiple measurement 
methods including anthropometry and air displacement plethysmography. 
Results 
A new reference for size-at-birth of Singapore newborns at 35 to 41 weeks of 
gestation was established, as well as a formula for estimating body 
composition amongst Asian neonates using subscapular skinfolds (SSF), 
weight (W), gender (G), and gestational age (GA) [prediction equation for 
neonatal fat mass = -0.022 + (0.307 × W) - (0.077 × G) - (0.019 × GA) + 
(0.028 × SSF), R
2
 = 0.811] 
I. In-utero determinants of size, body composition and growth 
Maternal glycemia at 26-28 weeks' gestation, especially during the fasting 
state, showed strong positive continuous associations across the range of 
glucose levels in relation to excessive neonatal adiposity [for each standard 
deviation increase in fasting glucose, OR=1.31, 95% CI: 1.10–1.55 for large-
for-gestational age; OR=1.72, 95% CI: 1.31–2.27 for percent body fat above 
90
th
 centile; OR=1.64, 95% CI: 1.32–2.03 for sum of skinfolds above 90th 
centile], even at values below those defined as hyperglycemia, after correcting 
for potential confounders. The effect of gestational glycemia on postnatal 
growth was limited to growth deceleration during the first 3 weeks to 3 
months of life [B(95%C.I)= -0.23(-0.42,-0.04) for weight standard deviation 
score (SDS)], followed by transient growth acceleration between 9-15 months 
[B(95%C.I)= 0.26(0.05,0.48) for weight SDS, B(95%C.I)= 0.26(0.05,0.47) for 
 xi 
 
body mass index (BMI) SDS]. The effect of maternal BMI during pregnancy 
on postnatal growth persisted from birth into early childhood. Maternal 
obesity, ethnicity, and parity may confer different susceptibility to greater 
adiposity in response to maternal glycemia only at two years of age. 
II. Postnatal determinants of adiposity and growth 
Varied effects of breastmilk intake on early postnatal growth amongst 
offspring exposed and unexposed to gestational diabetes (GDM) in-utero were 
observed. Offspring of mothers without GDM who were on breastmilk feeding 
predominantly exhibited growth deceleration in the first year of life [B(S.E) = 
-0.31(0.09) for weight SDS; B(S.E) = -0.22(0.09) for length SDS; B(S.E) = -
0.22(0.09) for BMI SDS], whilst offspring of GDM mothers with greater 
estimated breastmilk intake however, did not exhibit the same decelerated 
growth during the early postnatal period [B(S.E) = 0.45(0.19) for weight SDS; 
B(S.E) = 0.46(0.19) for BMI SDS]. 
III. Genetic determinants of size, adiposity and growth 
The transcriptomic profiles of 15 genes (AVP, IFI6, SET, HMGB2, RAD1, 
AIFM1, APAF1, CALM2, NUDT1, IKBKG, CCNL1, LIG1, PITX, TNIP2, 





 trimester of pregnancy, as well as with subsequent postnatal 
growth. Offspring with polymorphic variants of a known adiposity-associated 
gene [melanocortin-3-receptor (MC3R)] also showed greater predisposition to 
overweight and obesity during early childhood [OR=2.23, 95% CI: 1.08-4.61 





This study has identified the various developmental risk factors influencing 
adverse infant size, growth and adiposity outcomes during the first three years 
of life in a multi-ethnic Asian population. Future studies would involve 
examining whether these risk factors that operate during early growth and 
development would have long-term repercussions on increasing prevalence of 
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Chapter 1: Introduction and literature review 
1.1 Introduction 
Chronic non-communicable diseases (NCDs) represent a major burden 
and public health problem in Southeast Asia. Diseases such as stroke, cancer, 
obesity, diabetes and cardiovascular disease threaten this region with a rapidly 
growing population of almost 600 million people(1). The Global Burden of 
Disease projected an estimated 2.6 million people from the 10 countries in 
Southeast Asia died from chronic NCDs in 2005. With increasing exposure to 
risk factors, these numbers are estimated to increase to 4.2 million deaths by 
2030(2). The proportion of age-adjusted deaths due to chronic NCDs was 
observed to be the greatest in countries with highest gross national incomes 
such as Singapore and Brunei, and 30% of all deaths due to chronic NCDs 
occurred in people of age 15-59(1), which represented the labour force of 
Southeast Asia and the most productive age group. This situation not only 
affects families, but entire economies, thus stressing the need for urgent action 
and a strong stance to combat against chronic NCDs.  
1.2 Developmental Origins of Health and Disease 
There is a growing body of research which suggests that adult chronic 
NCDs such as diabetes, obesity and cardiometabolic disorders (hypertension, 
heart disease etc) partly originates during intrauterine life. One of the earliest 
evidence echoing this hypothesis of developmental plasticity conferring later 
disease risk came from the Dutch famine study, which examined the offspring 
of women who conceived during the Dutch famine of 1944, when an embargo 
was placed on all food supplies to the Netherlands(3, 4). It was observed that 
 2 
 
offspring of women exposed to the famine in early gestation showed 
significantly higher body mass index (BMI) and waist circumferences during 
adulthood compared to those who were not exposed to the famine. Later on in 
the 1980s, David Barker and his colleagues conducted a series of retrospective 
cohort studies at regions in England that had the highest rates of infant 
mortality, and observed that these regions also had the highest rates of 
mortality from coronary heart disease decades later(5). As the most commonly 
registered cause of infant mortality at the time was low birthweight, these 
observations led to the hypothesis otherwise known as the “Developmental 
Origins of Health and Disease (DOHaD)”, which states that adverse influences 
early in development, and particularly during intrauterine life, can result in 
permanent changes in physiology and metabolism, which result in increased 
disease risk in adulthood. Over time, numerous epidemiological data and 
studies have demonstrated robust associations between small birth size and a 
greater risk of chronic disease including coronary heart disease(6-8), 
hypertension(9), stroke(7, 10), type 2 diabetes(11), and osteoporosis in later 
life(12, 13) (Table 1.1). These observations have led to a worldwide 
recognition that the DOHaD hypothesis has major public health implications. 
A recent World Health Organization Techinical Consultation concluded that, 
“The global burden of death, disability, and loss of human capital as a result of 
impaired fetal development is huge and affects both developed and developing 
countries”(14). Despite the known associations between small birth size and 
later disease risk, the report advocates a move away from simply low birth 
weight, to broader considerations of maternal well-being, and achieving the 
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optimal environment for the fetus to maximize its potential for a full and 
healthy life. 
Table 1.1 Diseases linked with birthweight 




Coronary artery disease 
Osteoporosis 
 






Elevated clotting factors  
 
Impaired neural development 
Described but less well replicated and accepted association with small birth size 
 















Adapted from de Boo HA et al 2006 (15) 
 
Exposures to risk factors during critical developmental periods can 
have long-term consequences, especially if the environment during childhood 
and adulthood differs from that which is predicted during fetal and infant life. 
This “mismatch” between the exposed environments at different stages in life 
may cue developmental responses leading to increased risk of disease later in 
life(16). Such concepts are crucial to current life-course strategies that aims to 
prevent and treat NCDs. In the life-course approach, risk of future disease 
continually increases as a result of declining plasticity and ability to mount 
sufficient responses to new challenges. Even though the greatest increase in 
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risk occurs in adult life, the trajectory towards that risk occurs much earlier 
before and during pregnancy, influenced by factors such as mother’s diet and 
body composition, and also by fetal, infant and childhood development(17). 
Adopting a life course approach allows for identification of at-risk phenotypes 
and markers of risk at an early stage, with the possibility of implementing 
interventions at varying timepoints. Nutritional and other lifestyle 
interventions in early life may have a large effect on disease risk later, whilst 
later interventions may be impactful for vulnerable groups(17). These 
preventive measures would require a long-term investment, but may be more 
effective than population screening programs that identify the early stages of 
disease.  
 
1.3 Epidemiological observations and experimental studies of DOHaD 
1.3.1 Epidemiological observations 
1.3.1.1 Maternal/in-utero factors 
As described earlier, one of the most convincing evidence linking 
nutritional deficiency during pregnancy with development of adult metabolic 
disease was the Dutch famine study of 1944-1945(3, 4). During this period, 
daily rations to each individual were restricted to 400-800 calories per day, 
and this caloric restriction in pregnant mothers subsequently led to increased 
risks of glucose intolerance and heart disease in their offspring later in 
life(18). Such relationships in global nutrition during pregnancy with future 
disease outcomes have been reported in other epidemiological studies. A study 
on 626 subjects in Scotland whose mothers' food intake had been recorded 
during pregnancy showed that a high-meat, low-carbohydrate diet during 
pregnancy was associated with higher diastolic blood pressure in the offspring, 
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independent of maternal blood pressure, body size and smoking during 
pregnancy(19). In a double blind, randomised controlled trial exploring the 
long-term effect of calcium supplementation during pregnancy on the 
offspring's blood pressure during childhood, the authors found that calcium 
supplementation during pregnancy was associated with  reduced mean systolic 
blood pressure, compared with the placebo group. The risk of high systolic 
blood pressure was also reduced amongst subjects receiving calcium 
supplementation, particularly among overweight children(20). These findings 
were echoed in another observational study by Gillman MW et al, on 936 6-
month old infants from the Project Viva cohort, which showed reduced 
maternal mid-gestational calcium intake was associated with increased systolic 
blood pressure(21).  
Besides maternal nutrition, exposure to an altered in-utero 
environment has been shown to have consequences later in life. Offspring of 
pregnancies complicated by maternal diabetes have been shown to have 
greater birth weight, and an increased risk of developing type 2 diabetes in 
later life as reported by Silverman BL et al(22) and  Plagemann A et al(23). 
Observational studies have also documented how exposure to maternal 
diabetes in-utero may induce cardiovascular dysfunction in offspring during 
adulthood. Offspring of mothers with type 1 diabetes have been shown to have 
higher concentrations of markers of endothelial dysfunction and cholesterol-
to-HDL ratio when compared with offspring of nondiabetic pregnancies(24). 
In another study, Bunt JC et al examined the effect of maternal diabetes status 
during pregnancy with cardiovascular disease in offspring during childhood in 
a cohort of Pima Indians. The authors reported that offspring of diabetic 
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pregnancies had significantly higher concentrations of HbA1c, higher systolic 
blood pressure and lower concentrations of HDL independent of adiposity, 
when compared to offspring of non-diabetic pregnancies(25). Taken together 
these studies highlight how exposure to diabetes in-utero would confer 















Pattern of association 
Ravelli AC et 
al 1976 
702 Amsterdam 
Mothers exposed to famine during 
gestation 
Offspring glucose and  
insulin response 
- 
Prenatal exposure to famine associated with  




Mothers exposed to famine during 
gestation 
Prevalence of coronary 
heart disease 
Birth weight 
Prevalence of coronary heart disease was higher 
 in those exposed to famine in early gestation 
Shiell AW et al 
2001 
626 Scotland 
Consumption of meat and fish 
during pregnancy 
Diastolic blood  
pressure in offspring 
Maternal blood 
pressure,  
body size, smoking 
High-meat, low-carbohydrate diet during pregnancy 
associated with higher diastolic blood pressure in 
the offspring 
Gillman MW 
et al 2004 
936 United States 
Food frequency questionnaires 
during the second trimester of 
pregnancy 
Systolic blood pressure 
in offspring 
demographic, 
anthropometric, dietary,  
social, and economic 
variables 
Reduced maternal mid-gestational calcium intake 
 associated with increased systolic blood pressure 
Belizan JM et 
al 1997 
591 Argentina 
Mothers randomly assigned 
calcium supplementation during 
pregnancy 
Mean blood pressure, 
rate of high blood 
pressure in offspring 
Randomized controlled 
 trial 
Calcium supplementation during pregnancy 
associated with 
 reduced mean systolic blood pressure, compared 
with the placebo group. 
Plagemann A 
et al 1997 
198 Germany 






Age and gender 
Offspring of diabetic mothers showed impaired  
glucose tolerance and higher insulin levels 
Silverman BL 
et al 1991 
124 United States 
Mothers with gestational diabetes 
and pregestational  diabetes 
Offspring birth weight Age and gender 
Offspring of diabetic mothers showed higher birth 
weights (birth weight > 90th percentile) 
Manderson JG 
et al 2002 
118 Belfast Mothers with Type 1 diabetes 
Offspring markers of  
endothelial dysfunction 
(plasma glucose, 
insulin, lipids etc) 
Age, gender and social 
class 
Offspring of diabetic mothers have higher 
concentrations of markers of endothelial dysfunction 
and cholesterol-to-HDL ratio 
Bunt JC et al 
2005 




glucose levels, HbA1c, 
cholesterol 
Age and gender 
Offspring of diabetic pregnancies had significantly 
higher concentrations of  
HbA1c, higher systolic blood pressure and lower 




The observations that small size-at-birth and thinness during infancy is 
associated with increased risk of coronary heart disease, stroke, type 2 
diabetes mellitus and the metabolic syndrome have been extensively 
replicated(26-28). Studies on associations between small size-at-birth and 
subsequent hypertension/coronary heart disease have been confirmed by many 
different groups of investigators in several countries, including the United 
Kingdom(29), United States(30), Sweden(31), Finland(32) and India(33). One 
of the strongest epidemiological data to date was described by Leon DA et al, 
who conducted record linkage between the Swedish Medical Birth Registry, 
the Military Conscription Register and censuses, and studied 165,136 men 
born in Sweden between 1973 and 1976 and conscripted into military service 
from 1990 to 1996. The study reported that systolic pressure was 
independently inversely associated with birthweight-for-gestational age, and 
with gestational age itself but not with birth length for gestational age, 
highlighting that the fetal programming of later blood pressure is a function of 
accretion of fetal soft-tissue mass rather than of linear bone growth(34).  In 
another longitudinal study, Law CM et al examined the blood pressures in 346 
British men and women aged 22 years whose size had been measured at birth 
and for the first 10 years of life. Findings were similar with that of Leon DA et 
al, where systolic pressure was observed to have an inverse association with 
birth weight [systolic pressure increased by 1.3 mm Hg (95% CI: 0.3-2.3) for 




Various epidemiological studies have also linked size-at-birth to risk of 
obesity in later adulthood. The associations between high birth weight and 
future obesity risk have been extensively reported by investigators from 
China(36, 37), Brazil(38) and Argentina(39). A recent meta-analyses also 
revealed that high birth weight (>4000 g) was associated with approximately 
two-fold increased risk of later obesity [OR (95%CI): 2.07(1.91–2.24)] when 
compared to subjects with birth weight less than 4000g(40). In another study 
conducted by Loos RJ et al, each kilogram increase in birth weight amongst 
males predicted an increase in adult body weight by 4.2 kg(41), with similar 
findings observed in females(42). A different picture emerges however when 
looking at the associations between low birth weight and future obesity. A 
meta-analyses of 10 studies showed low birth weight (BW < 2500 g) was 
associated with decreased risk of obesity in comparison to subjects with birth 
weight above 2500g(40). Similarly, in the third National Health and Nutrition 
Examination Survey (NHANES III, 1988–1994), children born small-for-
gestational age (SGA, defined as birth weight <10th percentile for gestational 
age) remained slightly smaller than their peers. Interestingly however, this 
deficiency in size was largely due to reduction in lean tissue mass, without a 
reduction in fat mass, hence indicating that SGA infants had higher percentage 
body fat(43). Gale CR et al also showed similar findings in a cohort of 143 
men and women, aged 70-75 years, where low birth weight was associated 





Being born SGA has also been shown to be associated with various 
metabolic manifestations later in life, such as insulin resistance and type 2 
diabetes(44). The initial hypothesis by Barker and colleagues proposed that 
type 2 diabetes associated with small size-at-birth was due to impaired β-cell 
function at a critical stage of fetal development(45). One of the earliest 
evidence of small size-at-birth being associated with elevated insulin levels in 
adults was published in 1993(46). Since then, insulin resistance has been 
reported in many studies amongst children and adults who were born SGA(47-
49). More importantly, the observation of decreased insulin sensitivity in these 
individuals was independent of confounding factors, such as BMI and age. 
Data from a French cohort of healthy subjects assessed at 20 years old showed 
that insulin and proinsulin concentrations were higher in SGA compared with 
AGA (appropriate-for-gestational age) newborns, after correcting for BMI and 
gender, which may be representative of an early marker of insulin 
impairment(50). The relationship between size-at-birth and later insulin 
resistance, glucose intolerance and type 2 diabetes however, is not restricted 
only to those who were SGA, but for those who had high birth weights as 
well. In Pima Indians, the relationship between birth weight and glucose 
tolerance was U-shaped, with higher plasma glucose concentrations observed 
at both ends of the birth weight spectrum(51). Similar observations were noted 
in a large study of US nurses, where the relationship between birth weight and 













Exposure Outcome Confounders addressed Pattern of association 
Frankel S et al 1996 1258 South Wales Birthweight 
Coronary heart disease deaths 
non-fatal cardiovascular events 
- 
A graded association between  
low birthweight and later 
cardiovascular disease 
Curhan GC et al 
1996 
71100 United States Birthweight 
Blood pressure, physician 
diagnosed hypertension 
Age, BMI, parental history 
of hypertension 
Lower birth weight associated with 
 increased odds of hypertension 
Leon DA et al 1996 15000 Sweden Birthweight 
Mortality from ischaemic heart 
disease 
Period of birth 
Cardiovascular disease showed an 
inverse association with birth weight 
for both men and women 
Eriksson JG et al 
1999 
3641 Finland Birthweight 
Death from coronary heart 
disease 
Gestational age 
Death from coronary heart 
disease was associated with low birth 
weight and, more strongly, with a low 
ponderal index at birth 
Fall CHD et al 1998 506 India 
Birth ponderal 
 index 
Glucose and insulin metabolism - 
High ponderal index at birth 
associated with lower insulin 
increment 
Leon DA et al 2000 165136 Sweden 
Birth weight for 
gestational age 
Systolic blood pressure 
Examination age, year,  
center of conscription 
Systolic pressure was independently 
inversely associated with birthweight-
for-gestational age 
Law CM et al 2002 346 Britain Birth weight Systolic blood pressure BMI 
Systolic pressure was observed to 










Exposure Outcome Confounders addressed Pattern of association 
Hirschler et al 2008 1027 Argentina Birth weight Obesity Gender, Age 
High birth weight (> 4000g) associated 
with increased risk of later obesity 
Montiero et al 2003 1071 Brazil Birth weight Obesity Gestational age, gender 
High birth weight (> 4000g) associated 
with increased risk of later obesity 
Wang et al 2009 10897 China Birth weight Obesity Gestational age 
High birth weight (> 4000g) associated 
with increased risk of later obesity 
Yang wt al 2009 11338 China Birth weight Obesity Parental education, BMI 
High birth weight (> 4000g) associated 
with increased risk of later obesity 
Loos RJ et al 2001 229 Belgium Birth weight Body weight, height , BMI - 
Each kilogram increase in birth weight 
amongst males predicted an increase in 
adult body weight by 4.2 kg 
Loos RJ et al 2002 238 Belgium Birth weight Body weight, height , BMI - 
Each kilogram increase in birth weight 
amongst females predicted an increase in 
adult body weight by 1.3 kg 




mid-upper arm circumference 
mid-upper arm muscle area 
Skinfolds 
Age 
SGA infants remain smaller and LGA 
infants larger in size through early 
childhood. Upon assessment of skinfolds 
and arm circumference measurements, 
the deficiency in size was found to be 
largely due to reduced lean tissue mass 
without a reduction in fat mass 
Gale CR et al 143 United Kingdom Birth weight Body composition Age 
Low birth weight was associated with 
reduced lean tissue mass, but had highest 
total body fat 
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Pattern of association 
Phipps K et al 1993 266 
United 
Kingdom 
Birthweight Impaired glucose tolerance BMI 
Subjects found to have impaired 
glucose tolerance or non-insulin-
dependent diabetes mellitus had 
lower birthweight, a smaller head 
circumference and were thinner at 
birth 







Gestational age, BMI,  
social class 
Men and women who were thin 
at birth, as measured by a low 
ponderal index, were 
more insulin resistant 
Flanagan DE et al 2000 163 Australia 
Birthweight,  
length 
Insulin sensitivity, secretion BMI 
Small size at birth is associated with 
increased insulin resistance and 
hyperinsulinemia in young adult life 




Glucose tolerance, insulin  
sensitivity 
BMI, % body fat 
Reduced insulin sensitivity in  
SGA children 




Insulin, proinsulin levels Gender, BMI 
Insulin and proinsulin 
concentrations were higher in SGA 
compared with AGA (appropriate-
for-gestational age) newborns 
Dabelea D et al 1999 3061 Pima Indians Birthweight 
Glucose, insulin 
concentrations 
Later body size 
2-h glucose concentrations showed 
a  
U-shaped relationship with birth 
weight 
Rich-Edwards JW et al 
1999 
69526 United States Birthweight Type 2 diabetes Age, BMI 
Age-adjusted relative risks 
suggested a reverse J-shape 
association between birthweight and 
risk for type 2 diabetes 
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1.3.1.3 Infant and Childhood growth 
 Infants born small or low birth weight have a predisposition to gain 
weight more rapidly than their peers, and this is particularly true for infants 
who experienced a period of growth restriction in-utero as a result of maternal 
smoking, or due a primiparous pregnancy(53). An article by Melinda Yeung 
had highlighted the role of early postnatal weight gain as a crucial window of 
opportunity to prevent future obesity and related metabolic manifestations 
such as insulin resistance(54). A prospective cohort study conducted on 108 
infants from Santiago, Chile highlighted that fasting insulin was significantly 
higher in SGA infants with catch-up growth in weight compared with those 
who did not exhibit catch-up growth(55). Similarly, another study conducted 
in United Kingdom on 153 children reported that diastolic blood pressure was 
greater in children whose weight z score increased in the first nine months of 
life, with similar findings obtained for mean arterial pressure and systolic 
blood pressure, highlighting how a period of faster weight gain in infancy was 
associated with higher later blood pressure(56). Findings from the Stockholm 
Weight Development Study also echoed similar observations, where rapid 
weight gain in the first six months of life predicted clustered metabolic risk at 
age 17 years(57). Similarly, the Programming Factors for Growth and 
Metabolism (PROGRAM) study reported that rapid weight gain in the first 
three months of life was associated with several determinants of 
cardiovascular disease and type 2 diabetes in early adulthood, such as insulin 
sensitivity, serum high-density lipoprotein cholesterol level and triglyceride 
levels(58). The observations of rapid weight gain and future disease risk is not 
restricted to infancy only, but also during periods of early childhood. A 
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longitudinal study on 4630 men in Helsinki, Finland reported significant 
associations between rapid gain in weight after 1 year of age with increased 
risk of coronary heart disease during adulthood(59). Similar findings were also 
reported in the Brompton study cohort in southern England, where subjects 
who had been small at birth but gained weight rapidly during early childhood 




























Pattern of association 
Soto N et al 2003 108 Chile 





Fasting insulin was significantly higher 
in SGA infants with catch-up growth in 
weight compared with those who did not 
exhibit catch-up growth. 
Singhal A et al 2007 153 United Kingdom 
SGA with catch-up 
growth 
Blood pressure 
Age, gender, social 
class 
Diastolic blood pressure was greater in 
children whose weight z score increased 
in the first 9 months of life 
Ekelund U et al 2007 128 Sweden 




Gender, birth weight, 
gestational age, height, 
maternal fat mass, and 
socioeconomic status 
Rapid weight gain during the first 6 
months of life predicted clustered 
metabolic risk at age 17 years 
Leunissen RWJ et al 
2009 
217 Netherlands 




Gestational age, gender,  
age, social class 
Rapid weight gain in the first 3 months 
of life was associated with several 
determinants of cardiovascular disease 
and type 2 diabetes 





After age 1 year, rapid gain in weight 
and body mass index increased the risk 
of coronary heart disease 
Law CM et al 2002 346 Britain 
Birth weight and weight 




Lower birth weight and greater weight 
gain between 1 and 5 years of age were 
associated with higher systolic blood 
pressure in young adult life 
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1.3.2 Experimental studies of DOHaD 
One of the most widely accepted explanations underlying the DOHaD 
hypothesis is programming, whereby insults or stimulus that occurs during 
critical periods in the differentiation and maturation of cells and tissues may 
have irreversible long-term effects on development(15). Mechanisms which 
are well-recognized illustrating the effects of programming on future 
development include altered maternal and fetal nutrition, especially maternal 
under- and over-nutrition(60). Many studies have proven that it is remarkably 
easy to alter postnatal physiology by manipulation of maternal nutrition during 
pregnancy in experimental animals. A recent study documented that offspring 
of rat dams who were fed a high fat diet during pregnancy and lactation had 
significantly smaller pups, but had elevated adiposity compared to controls, 
regardless of the diet post-weaning. These rat offspring also exhibited 
hyperinsulinemia and hyperleptinemia(61). An earlier study by Bayor et al 
examining the effect of maternal “junk food” diet during pregnancy on 
offspring adiposity also echoed similar observations. The authors found that 
offspring of dams fed on “junk food” diet during pregnancy exhibited 
increased adiposity, which was not reversible when the offspring were 
switched to a normal chow diet after weaning(62). Taken together, these two 
studies highlighted the importance influence of maternal overnutrition during 
pregnancy in long-term health of offspring, which may have implications in 
preventing of later childhood obesity. In addition, animal studies have also 
illustrated how offspring of rats exposed to a high-fat diet during pregnancy 
demonstrate impaired glucose tolerance, glucose homeostasis and 
hypertension later in life(63, 64).  
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 Evidence linking maternal undernutrition (e.g. protein and/or caloric 
restriction) and future disease risk have come largely from animal models. A 
recent study has shown how protein restriction during pregnancy consequently 
led to intrauterine growth restriction in the offspring, which was followed by 
catch-up growth and an impairment in insulin signaling pathways in adipose 
tissue(65). Other studies have also found how protein restriction during 
pregnancy in rats consequently leads to hyperinsulinemia and impaired 
glucose tolerance(66). Similarly, offspring of rats who were exposed to a 
period of caloric restriction during late gestation in pregnancy demonstrated 
insulin resistance and changes in vascular function in adulthood(67). Many rat 
model studies on caloric restriction during pregnancy have also been shown to 
result in lower body weight, and subsequent development of metabolic 
syndrome traits such as adiposity, hyperinsulinemia and hyperleptinemia in 
the offspring later in life(68-70). These effects were not only restricted to rats; 















Animal model Exposure Outcome Pattern of association 
Howie GJ et al 2008 24 Rats 
Maternal high fat diet 
during pregnancy 
Litter weight and adiposity 
Rat dams who were fed a high fat diet 
during pregnancy and lactation had 
significantly smaller pups, but had elevated 
adiposity compared to controls 
Bayol SA et al 2008 24 Rats 
Maternal "junk food" 
diet during pregnancy 
Litter perirenal fat depots 
Offspring of mothers fed with junk food diet 
exhibited increased perirenal fat pad mass 
relative to body weight and adipocyte 
hypertrophy compared with offspring which 
were never exposed to the junk food diet. 
Taylor PD et al 2005 20 Rats 
Maternal high fat diet 
during pregnancy 
Whole body insulin  
sensitivity 
Rats exposed to a high-fat diet during 
pregnancy demonstrate impaired glucose 
tolerance and homeostasis in adulthood 
Fernandez-Twinn DS  
et al 2004 
8 Rats 
Maternal isocaloric low 
protein diet 
Litter weight, glucose 
tolerance, insulin 
measurements 
Protein restriction during pregnancy in rats 
consequently leads to hyperinsulinemia and 
impaired glucose tolerance 
Berends LM et al 
2013 
8 Rats 
Maternal isocaloric low 
protein diet 
Litter weight, glucose 
tolerance, insulin 
measurements 
Protein restriction during pregnancy 
consequently led to intrauterine growth 
restriction in the offspring, which was 
followed by catch-up growth and an 
impairment in insulin signaling pathways in 
adipose tissue 
Holemans K et al 
1998 
18 Rats 
Food-restricted during  
pregnancy 
Litter vascular function 
Food restriction during the second half of 
pregnancy and/or lactation may effect subtle 
changes in vascular function 
Kind KL et al 2002 31 Guinea pigs 
Food-restricted during  
pregnancy 
Offspring blood pressure 
Maternal feed restriction reduced birth 
weight and increased systolic blood pressure 
in young adult male offspring 
Gardner DS et al 2005 10 Sheep 
Nutrient-restriction 
during early & late  
gestation 
Offspring adiposity, glucose 
tolerance 
Prenatal undernutrition, specifically during 






1.4 Determinants of infant size and early-life growth patterns 
 Given that adverse size-at-birth, body composition and early-life 
growth patterns might influence the pathways determining disease outcome in 
later life, it could be postulated that prenatal, perinatal and postnatal factors 
that determine subsequent infant size, body composition and growth patterns 
may also have potential roles in influencing future disease risk. Birth size and 
body composition of newborns is often determined by a complex interplay of 
both environmental and genetic/epigenetic factors. Recent epidemiologic 
observations have highlighted the influence of perinatal events on fetal size, 
body composition and growth(73, 74). There is also evidence of relationships 
amongst maternal nutrition and metabolic status during pregnancy with 
neonatal size, body composition and later health outcomes(60, 75), illustrating 
how perinatal events affecting birth outcomes and early postnatal growth may 
contribute to a greater risk of disease in adulthood. In addition, recent data has 
also suggested that postnatal events influencing size and growth of the infant 
may also play a key role in the programming of metabolic diseases in later life 
1.4.1 Maternal/in-utero determinants 
 Nutrition during pregnancy is a key regulator of fetal growth, and 
hence represents an important determinant of birth size and body composition. 
Studies have shown that imbalances in maternal diet during pregnancy would 
affect both birth weight as well as placental weight, as highlighted by Godfrey 
et al(76). Moore VM et al also reported how percentage of energy derived 
from protein showed a positive association with birth and placental weight, 
independent of energy intake and weight gain during pregnancy, and after 
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correcting for confounders such as maternal age, parity, and smoking, 
supporting the proposition that maternal dietary composition has an influence 
on fetal growth(77). Similarly in the Pune Maternal Nutrition Study, it was 
shown that higher fat intake during pregnancy was associated with neonatal 
length, birth weight and triceps skinfold thickness (SFT). The study also noted 
interesting findings of strong associations between folate status and intakes of 
foods rich in micronutrients with birth weight, suggesting the role of maternal 
micronutrient intake as a plausibly important limiting factor for fetal 
growth(78).  
In addition, exposure to an altered in-utero environment has been 
shown to be an important determinant of birth size and body composition. The 
recent Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study 
documented how a standard deviation (SD) increase in fasting, 1-hour and 2-
hour plasma glucose levels during 24-32 weeks of gestation was associated 
with a 38-42% increase in odds of having a large-for-gestational age baby, 36-
42% increase in odds of having a baby with sum of SFT above 90
th
 percentile 
and 35-44% increase in odds of having a baby with percent body fat above the 
90
th
 percentile(73, 74). Findings from the Exeter Family Study of Childhood 
Health (EFSOCH) study also reported a positive association between maternal 
glycemia during pregnancy with birth weight, with the effects showing no 
demonstrable difference by three months of age(79). Touger et al however, 
reported that offspring of diabetic pregnancies had a dramatically different 
postnatal growth pattern from offspring of non-diabetic pregnancies. Offspring 
of diabetic pregnancies showed reduced change in weight z-score and attained 
height in the first 1.5 years of life. Subsequently, these offspring exhibited 
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greater weight gain and catch-up growth in height compared to offspring of 
non-diabetic pregnancies(80). Findings from the Exploring Perinatal 
Outcomes among Children (EPOCH) study also echoed similar observations; 
offspring of diabetic pregnancies showed higher BMI growth velocity between 
10-13 years of age, increasing by 4.56 kg/m
2
 compared to 3.51 kg/m
2
 in 
offspring of non-diabetic pregnancies, and independent of demographic 
variables, socioeconomic factors and maternal pre-pregnancy BMI(81). Taken 
together, these studies highlight how maternal glucose during pregnancy may 
be an important determinant of birth size, neonatal adiposity as well as 
offspring postnatal growth. 
 Maternal factors during pregnancy are also known to play a significant 
role in influencing infant postnatal growth. In the ALSPAC birth cohort, it was 
shown that maternal factors such as mother’s pregnancy weight gain, smoking 
during pregnancy and parity were closely related to postnatal catch-up and 
catch-down growth in the infant, and the effect was observed to be more 
striking amongst primiparous infants, who were more likely to be growth-
restrained in-utero, were thinner at birth and showed greater postnatal catch-
up growth(53). Multiparous infants however, were more likely to show catch-
down growth. More recently, a study using data from three contemporary 
cohorts based in Portugal, Italy and Chile showed how prenatal maternal 
characteristics such as maternal smoking, pre-pregnancy overweight and 
underweight, parity and gestational hypertension were associated with 
different aspects of infant growth related to size, velocity and tempo, offering 










Exposure Outcome Confounders addressed Pattern of association 
Godfrey K et al 
1996 
596 United Kingdom 
Maternal average daily nutrient 
intake during pregnancy 
Birth & placental 
 weight 
Gender, gestational age,  
maternal height, BMI 
High carbohydrate intake in early pregnancy 
suppresses placental growth, especially if 
combined with a low dairy protein intake in 
late pregnancy. 
Moore VM et al 
2004 
556 Australia 
Maternal estimated daily intakes of 
protein, fat and carbohydrate 
Birth & placental 
 weight 
Maternal age, parity, 
smoking 
Percentage of energy derived from protein 
was positively associated with birth and 
placental weight 
Rao S et al 2001 633 India 
Maternal estimated daily intakes of 
macro- & micronutrients 
Birth weight, length, 
skinfold thickness 
Gender, parity,  
gestational age 
Higher fat intake during pregnancy was 
associated with neonatal length, birth weight 
and triceps skinfold thickness. Birth isze 
showed strong associations with folate status 
and with intakes of foods rich in 
micronutrients 
Metzger B et al 
2008 
25505 Multi-countries 
Maternal glycemia during  
pregnancy 
LGA 
Gender, ethnicity, parity 
study center, BMI, 
smoking, alcohol use, 
family history of diabetes 
Continuous association of maternal glucose 
level with offspring increased birthweight 
Touger L et al 
2005 
249 Pima Indian 
Mothers with diabetes before or 
during pregnancy 
Offspring growth up 
to 7.7 years 
Age and gender 
Offspring of diabetic mothers showed 
significant "catch-down" in weight by 1.5 
years, and subsequently exhibited greater 
weight gain and catch-up growth in height 
compared to offspring of non-diabetic 
pregnancies 
Ong KK et al 
2002 
1335 United Kingdom 
Maternal smoking, parity,  
pregnancy weight gain 
Offspring growth up 
to 5 years 
Age and gender 
Pregnancy weight gain, smoking during 
pregnancy and parity were closely related to 
postnatal catch-up and catch-down growth in 
the infant 
Pizzi C et al 2014 4622 
Portugal, Italy,  
Chile 
Maternal smoking, pre-pregnancy 
BMI, parity, gestational hypertension 
Offspring growth 
size, velocity and 
tempo 
Gender, gestational age 
Maternal smoking, pre-pregnancy overweight 
and underweight, parity and gestational 
hypertension, are associated with different 
aspects of infant weight growth 
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1.4.2 Postnatal determinants 
 Of the numerous biological and environmental factors that are known 
to affect growth and adiposity during infancy and childhood, infant feeding is 
often recognised to be one of the most prominent determinants(83). One of the 
first few documented studies on infant nutrition and growth was conducted by 
Katherine Dewey, as part of the Davis Area Research on Lactation, Infant 
Nutrition and Growth (DARLING) Study(84). The authors reported that 
infants who were breastfed had significantly lower weights between 6-18 
months of age, and had lower weight-for-length z-scores between 4-18 months 
of age compared to formula-fed infants. Breastfed infants also gained weight 
less rapidly after three months of age, highlighting the differing influences of 
breast- and formula-milk on early infant growth. Other studies reviewed by 
Dewey K et al also reported similar observations, where breastfed infants 
gained significantly less weight in the first year of life(85). More recently, 
findings from the Southampton Women’s Survey showed that infants who 
were breast fed in the first six months of life gained weight, length and 
adiposity more slowly than formula-fed infants, independent of age at 
introduction of solids and maternal factors(86). Findings from the Millennium 
Cohort Study also echoed similar observations; infants who did not receive 
breast milk grew faster than those whose mothers initiated breastfeeding, as 
did those who were breastfed for less than four months versus those breastfed 
for four months or longer(87). Earlier data from the Avon Longitudinal Study 
of Parents and Children (ALSPAC) cohort also highlighted the influence of 
infant energy intake on postnatal weight gain and adiposity. The authors noted 
that infants who had higher energy intake at 4 months predicted greater weight 
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gain between 0-1, 0-2 or 0-3 years of age, and higher body weight and BMI at 
1-5 years of age(88). More recently, findings from the Generation R cohort 
study showed that shorter breastfeeding duration as well as non-exclusive 
breastfeeding was associated with higher childhood general and abdominal fat 
measures(89). Taken together, these studies highlight how infant feeding is 
often one of the most prominent determinants of infant growth and adiposity.  
 As of late, there is a growing body of research looking at other infant 
mediators and determinants of growth and adiposity, such as infant sleep and 
temperament. One of the first few documented studies on infant temperament 
and later adiposity was conducted by Pereira GR et al, who examined the 
relationship between infant temperament and adiposity in healthy infants(90). 
The authors found that infants who exhibited higher scores for difficult 
temperament correlated positively with SFT at 18 months of age. Another 
study by Wells JCK et al also showed that infants who were much more easily 
soothed had significantly leaner SFTs at 2.5-3 years of age(91). In a 
longitudinal study by Carey WB et al, weight-for-height percentile gains 
between 4-5 and 8-9 years of age showed significant correlations with eight of 
nine difficult temperament characteristics, and also with a cumulative "index 
of difficulty"(92). Findings from Colorado Adoption Study also showed that 
male infants with less attention span, and female infants who were more easily 
soothed showed greater increases in weight z-scores and were more likely to 
be overweight/obese by 6 years of age(93). While the role of infant 
temperament in pediatric growth and obesity onset warrants greater research, 
these studies highlight the plausibility of infant temperament as a determinant 
for later growth and adiposity. 
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 In parallel with the current obesity epidemic, many studies in children 
have shown an inverse relationship between sleep duration with adiposity 
measures. A systematic review of 4 cohort studies (San Francisco, Ho Chih 
Minh, NHANES and ALSPAC) reported that short sleep duration was 
associated with increased risk of overweight and obesity(94). Another 
systematic review of 20 longitudinal studies reported a consistent positive 
relationship between short sleep duration with childhood weight gain(95). 
Similarly, a meta-analysis of 30 published studies on sleep duration and 
obesity risk in children showed that a shorter sleep duration was associated 
with 89% increase in odds of obesity during childhood(96). While there is still 
a need for a greater knowledge base regarding the association between sleep 
duration with weight gain and obesity, these studies again highlight the 















Population source Exposure Outcome Confounders addressed Pattern of association 
Dewey K et al 
1993 
87 United States 
Breast- or formula-feeding in first 
12 months 
Infant weight, length,  
weight-for-length z-
score, rate of weight and 
length gain 
Age and gender 
Infants who were breastfed had significantly 
lower weights between 6-18 months of age,had 
lower weight-for-length z-scores between 4-18 
months of age and also gained weight less rapidly 
after 3 months of age, compared to formula-fed 
infants. 
Baird J et al 
2008 
1335 United Kingdom 
Infant milk feeding and dietary  
assessment 
Conditional growth 




Infants who were breast fed in the first 6 months 
of life gained weight, length and adiposity more 
slowly than formula-fed infants, independent of 
age at introduction of solids and maternal factors 
Ong KK et al 
2006 
582 United Kingdom 
Estimated energy intake of breastfed, 
mixed- and formula-fed infants 
Weight gain and BMI Gender 
Infants who had higher energy intake at 4 months 
predicted greater weight gain between 0-1, 0-2 or 
0-3 years of age, and higher body weight and 
BMI at 1-5 years of age. 
Durmus B et 
al 2014 
5063 Netherlands 
Breastfeeding duration, exclusivity, 
age of introduction of soild foods 






Shorter breastfeeding duration as well as non-
exclusive breastfeeding was associated with 
higher childhood general and abdominal fat 
measures 
Wells JCK et 
al 1997 
30 United Kingdom Infant temperament 
Childhood body 
composition 
Infant percentage fat,  
skinfold thicknesses 
Infants who were much more easily soothed had 
significantly leaner skinfold thicknesses at 2.5-3 
years of age 
Carey WB et 
al 1988 
138 United States Infant temperament Weight gain and obesity - 
Weight-for-height percentile gains between 4-5 
and 8-9 years of age showed significant 
correlations with eight of nine difficult 
temperament characteristics, and also with a 
cumulative "index of difficulty 
Marshall NS 
et al 2008 
11335 
United States, United 
Kingdom, Vietnam 
Infant sleep duration Childhood BMI Race, gender, education   
Negative linear relationship between sleep 
duration and childhood BMI 
Magee L et al 
2012 
10959 
United States, United 
Kingdom, New 
Zealand, Canada 
Infant/child sleep duration Childhood weight gain 
Race, gender, education, 
media use, smoking, 
breastfeeding, physical 
activity 
Significant negative relationship between sleep 
duration and weight gain 
Cappuccio FP 






Child sleep duration Childhood obesity Age, gender 
Short sleep duration in children was associated 
with increased odds of childhood obesity 
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1.4.3 Genetic determinants 
Individuals born small, or have undergone a period of growth-restraint 
in-utero, are often at greater risk of developing chronic diseases later in life. 
The relationship between fetal growth and size-at-birth with future disease risk 
is usually explained by uteroplacental insufficiency of the maternal intra-
uterine environment(97, 98), which may alter organ function and metabolic 
milieu of the individual, thereby increasing risk of disease in adulthood(26, 
27). In addition to this, there may also be genetic or epigenetic factors that 
function to reduce fetal growth and size-at-birth, which may also increase 
susceptibility to diseases later in life(99).  
Over the last decade, with advances in the area of genetic 
epidemiology, a great number of gene expression studies have been 
performed, and significant associations were found between birth weight and 
gene expression levels. Studies involving candidate gene approach have 
identified significant associations with birth weight for placental expression 
levels of PHLDA2(100), FTO(101), IGF-1, IGFBP-1(102), 11β-HSD1(103) 
and 11β -HSD2(104). Microarray experiments on growth-restricted placentas 
have also identified increased expression of certain genes such as leptin, 
soluble vascular endothelial growth factor receptor, human chorionic 
gonadotropin, follistatin-like 3, and hypoxia-inducible factor 2α(105). 
Experimental studies in animals have also yielded similar observations; a 
recent study involving a non-human primate model identified genes involved 
in key metabolic signalling pathways were differentially expressed according 
to the birth weight of the primate(106).  
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In addition, genes influencing fetal growth and size-at-birth may also 
affect postnatal growth. Some of these genes include IGF-1, IGF-2 and IGF-
1R. Genes which encode insulin receptors and also the post-receptor signalling 
cascades might also be implicated in postnatal growth. Findings from the 
ALSPAC birth cohort reported that 8 variants of genes known to be associated 
with childhood and adult BMI (FTO, MC4R, TMEM18, GNPDA2, KCTD15, 
NEGR1, BDNF, and ETV5) had large positive effects on early infancy weight 
and length gain, as well as reduced risk of early infancy failure to thrive(107). 
A retrospective study conducted by Keen RW et al demonstrated that variants 
in the Vitamin D receptor (VDR) gene had a significant trend association with 
infant weight at 1 year of age, with the homozygote recessive group exhibiting 
higher weights(108), indicating that early fetal or infant environment may 
interact with an individual’s underlying genotype to program early growth 
outcomes.  
 It has also been suggested that early-life environmental exposures 
inducing altered phenotypes later in life may be mediated by epigenetic 
mechanisms, which involve changes in gene expression without alterations to 
the genetic material(17). Such changes would include DNA methylation, 
covalent modification of histones as well as non-coding RNAs. Evidence from 
animal models have demonstrated how epigenetic processes in non-imprinted 
genes may be an important link between early life exposures during pregnancy 
and later cardiometabolic outcomes during adulthood(109). Lilycrop K et al 
had earlier described how offspring of protein-restricted rats showed reduced 
methylation in glucocorticoid receptor (GR) and peroxisome proliferator-
activated receptor (PPAR) genes(110). Sinclar KD et al also described how 
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restricting the supply of vitamin B12 in periconceptional diet of mature female 
sheep altered the methylation status of 4% of 1,400 CpG islands in the 
offspring, and that this modest early dietary intervention led to adult offspring 
that were both heavier and fatter(111). In humans, earlier studies on a variety 
of pathological states (such as Russell-Silver Syndrome) have provided 
evidence on the relationship between DNA methylation patterns with retarded 
fetal growth(112). Evidence has also pointed to a similar relationship between 
DNA methylation patterns and fetal growth amongst a set of clinically normal 
newborns(113). Until recently, data describing observations on how 
epigenetics may mediate the relationship between early environmental 
exposure with altered growth and body composition in humans were limited. 
However, a recent study by Godfrey K et al(114) on women from the 
Southampton Women’s Survey showed associations between levels of 
retinoid-X receptor alpha (RXRA) methylation with carbohydrate intake, and 
that higher methylation of a single CpG within the RXRA promoter measured 
in umbilical cord was robustly associated with greater adiposity in their 
offspring at later childhood, thus providing novel evidence of the putative role 
for epigenetic changes in non-imprinted genes in relation to early development 












Tissue specimen Gene Outcome Pattern of association 
Bassols J et al 
2010 
147 Placenta FTO 
Fetal weight and  
length gain 
Placental FTO mRNA expression was associated with increased 
fetal-to-placental weight ratio in infants from primiparous women, 
and was associated with increased fetal weight and length and 
placental weight in infants from nonprimiparous women 
Apostolidou S 
et al 2006 
200 Placenta PHLDA2 Birth weight 
Maternally expressing PHLDA2 expression levels in placenta 
negatively correlated with size-at-birth 
Koutsaki M et 
al 2011 
47 Placenta IGF-I, IGFBP-1 
Fetal growth 
restriction 
IGF-I and IGFBP-1 exhibited significantly lower expression levels 
in FGR group compared to controls 
McTernan CL 
et al 2001 
86 Placenta 11β -HSD2 
Fetal growth 
restriction 
Placental 11beta-HSD2 mRNA levels were significantly decreased 
in intrauterine growth restriction pregnancies when compared with 
gestationally matched, appropriately grown placentae 
Mericq V et al 
2009 
74 Placenta 11β -HSD1, 11β -HSD2 Size-at-birth 
Lower expression and activity of 11beta-HSD1 in the chorionic plate 
of the small-for-getational age placentas 
McCarthy C 






Microarray experiments identified increased expression of certain 
genes including leptin, soluble vascular endothelial growth factor 
receptor, human chorionic gonadotropin, follistatin-like 3, and 
hypoxia-inducible factor 2  in the IUGR 
Emerald BS 
et al 2011 
8 








1973 genes which were differentially expressed in the three tissue 
types between average and low birth weight animals 
Keen RW et 
al 1996 et al 
66 Blood samples Vitamin D receptor Weight at 1 year 
Statistically significant trend for VDR genotype against weight at the 
age of 1 year, with the ‘‘tt’’ homozygote group having 7% higher 
weight 
Elks CE et al 
2010 
7146 Blood samples 




Early infancy and 
childhood 
weight gain 
8 variants of genes known to be associated with childhood and adult 
BMI had large positive effects on early infancy weight and length 
gain, as well as reduced risk of early infancy failure to thrive 
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Outcome Pattern of association 
Lilycrop KA 
et al 2007 
10 rat 
pups 
Liver Maternal nutrition 
DNA 
methylation 
PPARα and GR1 
expression 
Unbalanced prenatal nutrition induces persistent, gene-specific 
epigenetic changes that alter mRNA expression in  PPARα and 
GR1 
Sinclair KD 










Clinically relevant reductions in specific dietary inputs to the 
methionine/folate cycles during the periconceptional period can 
lead to widespread epigenetic alterations to DNA methylation in 
offspring, which led to both heavier and fatter adult offspring 











Higher methylation of RXRA was associated with lower 
maternal carbohydrate intake in early pregnancy, previously 
linked with higher neonatal adiposity 
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1.5 Rationale of study 
Currently there is a great concern regarding the predicted increase of 
metabolic diseases in both developed and developing Asian countries, which 
suggests that the pattern of development of metabolic disease merits a more 
detailed investigation(115). Multi-ethnic populations, such as that of 
Singapore (consisting of Chinese, Malays and Indians), may exhibit a 
physiological difference in susceptibility to metabolic risk(116). Statistics 
from the National Health Survey in Singapore reported that the prevalence of 
type 2 diabetes in Singapore has increased from 1.9% in 1975 to 11.2% in 
2010, which is now one of the highest in the developed world. Findings from 
the survey also reported a 10.8% obesity prevalence in Singapore (117), and a 
recent study reported that amongst Singaporean Chinese pre-schoolers aged 6-
72 months, the prevalence of overweight and obesity was 7.0% and 5.3% 
respectively(118). While this is lower than other developed countries such as 
the United States, it is still a cause for concern as childhood obesity can persist 
into adulthood, increasing the risk of later cardiovascular diseases.  
There is also scarcity of data on early-life outcomes in Asian 
populations. Given that early-life growth patterns influence the pathways 
determining metabolic disease, new insights into early infant development 
would be crucial for the understanding of pathways to metabolic disease in 
Asian populations. Interventions that were targeted towards modifying 
lifestyles of adults have yielded disappointing results thus far, and hence it is 
apparent that other approaches focused on prevention should be explored. 
Identifying the prenatal, perinatal and postnatal factors that determine 
subsequent growth and body composition of infants may enable clinicians to 
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select individuals who are at risk of developing metabolic disease in later life. 
Clinical intervention at early stages for individuals at risk may allow for 
prevention of metabolic disease outcomes in the future. 
To examine the potential roles of fetal and developmental factors 
influencing infant size, body composition and subsequent growth, data from 
the Growing Up in Singapore Towards healthy Outcomes (GUSTO) study was 
utilized. This birth cohort is one of the first in Singapore, and comprises the 
most comprehensively phenotyped parent-offspring cohort during the first few 
years of life(119). One of the primary objectives of the study is to examine 
developmental factors that can predict patterns of growth and body 
composition in infancy and childhood, and if these factors that operate during 
early development would affect pathways to future metabolic compromise and 
altered body composition. Other study objectives include identifying maternal 
determinants of the offspring’s epigenetic state and associations with other 
indices of early life experience that may influence growth and body 
composition. 
 Given the scarcity of data on early-life outcomes in Asian populations, 
this study would help to fill this gap in knowledge with tracking of 
development, growth and other parameters throughout the antenatal period, 
birth and the first few years of life, providing new insights into development in 
the early part of the human life course. Infant growth is monitored frequently 
at multiple timepoints, complemented by body composition assessments using 
multiple measurement methods including anthropometry, magnetic resonance 
imaging (MRI), bioelectrical impedance analysis (BIA) and air displacement 
plethysmography (PEA POD). This presents an important opportunity to 
 35 
 
investigate the developmental pathways underlying infant size, body 
composition and subsequent growth, which may in turn explain variable 




















1.6 Study aims, objectives and hypotheses 
This study aims to add new information on the developmental risk 
factors that can influence size-at-birth, adiposity as well as patterns of growth 
during infancy and childhood in a multi-ethnic Asian birth cohort.  
The main hypothesis in this dissertation relates to the developmental origins of 
growth and adiposity, which is: 
 Exposure to an adverse in-utero and postnatal environment, as well as 
having certain predisposing genetic risk factors would influence an 
offspring’s  size-at-birth, adiposity as well as patterns of growth during 
infancy and childhood  
1.6.1 Aims 
1. To establish new norms for size-at-birth and body composition in a 
cohort of Singapore infants (Chapters 3 & 4), as tools necessary to 
explore later hypotheses on size-at-birth and infant adiposity 
a. To establish reference values and charts for size-at-birth from 
35-41 weeks of gestation, based on the healthy GUSTO infants 
b. To establish and validate a fat-mass prediction formula that is 
specific for the GUSTO cohort during the early postnatal 
period, using PEA POD® measurements as reference, and to 
compare the performance of the prediction equation with that 
of Slaughter's, for estimating neonatal fat mass in our cohort 
2. To examine the associations of maternal/in-utero factors with size and 
adiposity of Singapore infants at birth (Chapter 5) 
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a. To investigate the relationship between maternal glycemia 
during pregnancy with neonatal size and adiposity in GUSTO 
infants 
b. To compare fasting with post-challenge glucose levels in 
influencing excessive neonatal adiposity outcomes in Asian 
mothers 
3. To examine the associations of maternal/in-utero factors with early 
postnatal growth and adiposity during the first three years of life 
(Chapter 6) 
a. To examine the influence of maternal body mass index (BMI) 
during pregnancy on early postnatal growth of offspring during 
the first three years of life in the GUSTO cohort 
b. To examine the influence of maternal glycemia during 
pregnancy (fasting and post-challenge glucose levels) on early 
postnatal growth of offspring during the first three years of life 
in the GUSTO cohort 
4. To examine the associations of postnatal factors with early postnatal 
growth and adiposity during the first three years of life (Chapter 7) 
a. To examine the effect of infant milk feeding on early postnatal 
growth of offspring in the first three years of life, exposed and 
unexposed to gestational diabetes in-utero in the GUSTO 
cohort 
5. Finally, to identify potential genetic markers of fetal growth, 
subsequent postnatal catch-up growth and adiposity in a cohort of 
Singapore infants (Chapters 8 & 9) 
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a. To evaluate the relationship between fetal growth and 
subsequent postnatal growth with transcriptomic profiles of 
umbilical cords in the GUSTO cohort 
b.  To evaluate the association between polymorphic variants of 
known adiposity-associated genes (melanocortin-3-receptor 
[MC3R] and fat-mass and obesity associated gene [FTO]) with 
early childhood adiposity 
1.6.2 Hypotheses 
I. Anthropometric measures such as body weight and SFT are predictive 
of fat mass in newborns  
II. Higher maternal glucose levels during pregnancy is associated with 
higher neonatal adiposity. 
III. Higher maternal glucose and adiposity during pregnancy leads to 
increased adiposity and postnatal growth during the first 3 years of life  
IV. Offspring of mothers exposed to gestational diabetes in-utero (ODM) 
who have greater estimated breastmilk intake and less formula milk 
exposure will exhibit reduced weight gain, compared to ODM’s who 
have reduced breastmilk intake and more formula milk exposure.  
V. Offspring with growth restriction in-utero and subsequent catch up 
growth have unique gene expression profile which is predictive of 
catch up growth  
VI. Offspring with polymorphic variants of known adiposity-associated 
genes (MC3R and FTO) are predisposed to overweight and obesity 




Chapter 2: Materials and Methods 
2.1 Study population 
The Growing Up in Singapore Towards Healthy Outcomes (GUSTO) 
study is a population-based prospective cohort study, designed to test specific 
hypotheses related to the developmental pathways to obesity and cardio-
metabolic disorders in Chinese, Malay and Indian participants in Singapore. 
The study has been described in detail(119). Briefly, pregnant women aged 18 
years and above were recruited during their first trimester antenatal ultrasound 
dating scan at Singapore’s two major public maternity units, namely National 
University Hospital (NUH) and KK Women’s and Children Hospital (KKH), 
between June 2009 and September 2010. Subjects approached were Singapore 
citizens or permanent residents who were of Chinese, Malay or Indian 
ethnicity with homogeneous parental ethnic background, had the intention of 
delivering in NUH or KKH and residing in Singapore for the next five years. 
Informed written consent was obtained from each participant on the day of the 
study. This study was approved by both the National Healthcare Group 
Domain Specific Review Board and Sing Health Centralized Institutional 
Review Board. 
2.2 Details of eligibility criteria 
The following eligibility criteria were used for consideration of recruitment to 
the GUSTO study: 
 Subjects receiving chemotherapy or psychotic drugs were excluded 
 Subjects with type I diabetes mellitus were excluded 
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 Only women who agreed to donate birth tissues (umbilical cord, cord 
blood, placenta) at delivery were included 
 Subjects less than 18 years of age were excluded 
 Subjects who had no intention to deliver in NUH or KKH were 
excluded 
 Subjects who were of more than 14 weeks of gestation at the point of 
recruitment were excluded 
 Subjects who had non-homogeneous parental ethnic background, or 
were not of Chinese, Malay or Indian ethnicity were excluded 
 Subjects who were not Singaporean or Singapore Permanent Residents 
were excluded 
 Subjects who suffered miscarriage, planned to terminate their 
pregnancy, or had multiple in-vitro fertilization (IVF) pregnancies 
were excluded 
Figure 2.1 illustrates the process of recruitment in the GUSTO study. 
A total of 3751 families were screened, of which 2034 met the eligibility 
criteria and 1247 women (response rate 61.3%) were recruited for the study. 
During recruitment, the eligibility criteria were designed to allow examination 
of differences between ethnically homogeneous groups, hence recruitment was 
completed with oversampling of Malays and Indians. Of the 1247 women, 
1162 conceived naturally and 85 conceived through IVF. A total of 1176 
babies were delivered, the first baby was born on 30 November 2009 and the 



























 Families assessed for eligibility 
n = 3751 
 Eligible families 
n = 2034 
 Recruited 
n = 1247 
 Ineligible (n=1717) 
Not willing to participate (n=787) 
 
Main GUSTO 
n = 1162 
GUSTO IVF 
n = 85 
Deliveries 
n = 1176 
Postnatal visits 
 
3 weeks (n=1051) 
3 months (n=1034) 
6 months (n=1000) 
9 months (n=967) 
12 months (n=977) 
15 months (n=973) 
18 months (n=954) 
24 months (n=965) 
36 months (n=892) 
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Table 2.1: Reasons for ineligibility of the 1717 families 
Reasons n Percentage (%) 
No intention to deliver in NUH or KKH 469 27.3 
More than 14 weeks gestation 416 24.2 
Non-homogeneous parental ethnic background 330 19.2 
Not residing in Singapore for the next 5-years 178 10.3 
Miscarriage 151 8.8 
No intention to donate cord, cord blood and/or 
placenta 
71 4.1 
Planned to terminate pregnancy 36 2.1 
In-vitro fertilization multiple pregnancies 30 1.7 
Less than 18 years old 14 0.8 
Non-Singaporean or Singapore Permanent Resident 14 0.8 
Chronic diseases (e.g. Type 1 Diabetes Mellitus) 6 0.4 
Not of Chinese, Malay or Indian ethnicity 3 0.2 













2.3 Clinical measurements 
2.3.1 Antenatal period 
2.3.1.1 General questionnaire and physical examinations 
During the recruitment visit (< 14 weeks gestation) and at the first 
clinic visit (26-28 weeks gestation), questionnaires were administered to the 
pregnant women to ascertain demographic, socio-economic, lifestyle (e.g. 
physical activity and exercise, alcohol consumption) maternal well-being, 
obstetric and medical history data. Physical examinations were conducted 
during the first clinic visit, where anthropometry such as weight (SECA 803 
Weighing Scale, SECA Corp, Hamburg, Germany), height (SECA 213 
Portable stadiometer, SECA Corp), skinfold thicknesses (measured on the 
right side of the body using Holtain skinfold calipers, Holtain Ltd, Crymych, 
UK) and mid-arm circumferences (SECA 212 Measuring Tape, SECA Corp) 
were measured. Routine antenatal clinical and laboratory data were abstracted 
from the hospital case notes, including measurements of blood pressure, full 
blood count and urine dipstick. Blood was collected for an oral glucose 
tolerance test at 26–28 weeks of gestation and analyses of other biochemical 
markers. Hair samples were collected for toxicology screening (exposure to 
lead, metals) and to determine steroid levels. Buccal swabs were collected for 
DNA to investigate the role of epigenetic processes. 
2.3.1.2 Oral Glucose Tolerance Testing 
All participants underwent a 75-gram oral glucose tolerance test 
(OGTT) after an overnight fast between 26-28 weeks of gestation, and venous 
glucose was measured by colorimetry (Advia 2400 Chemistry system 
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[Siemens Medical Solutions Diagnostics, Deerfield, IL, USA] and Beckman 
LX20 Pro analyser [Beckman Coulter, USA]). During the study period, 
glucose management was performed when mothers were diagnosed with 
gestational diabetes by World Health Organization criteria(120) (fasting or 2-
hr plasma glucose concentrations greater than 7.0 or 7.8 mmol/L respectively). 
Results of the study were communicated to health practitioners, and mothers 
that were positively diagnosed were placed under either a diet- or insulin-
treatment for management. Mothers with elevated fasting or 2-hour plasma 
glucose were subjected to the same glucose management protocol. 
2.3.1.3 Foetal biometry and assessment of gestational age 
Gestational age (GA) was assessed by ultrasonography (Aloka SSD-
4000, Osaka, Japan). In all women, GA was first assessed in the first 
ultrasound dating scan during recruitment in the first trimester. They returned 
to the hospital again at 19-21, 26-28 and 32-34 weeks gestation to have 
follow-up ultrasound scans for assessment of fetal biometry. Intrauterine 
growth parameters, namely biparietal diameter, head and abdominal 
circumferences, femur as well as humerus lengths were measured at the 
above-mentioned timepoints. Scans were conducted in a standard manner at 
both hospitals by trained ultrasonographers. 
2.3.2 Post-natal period 
2.3.2.1 Anthropometry and body composition measurements 
Within the first 24-hr after delivery, body composition of the neonate 
was assessed by anthropometry. Two SFTs (triceps and subscapular) were 
measured in triplicates using Holtain skinfold calipers (Holtain Ltd, Crymych, 
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UK) on the right side of the body, recorded to the nearest 0.2 mm. Percent 
body fat (%BF) and fat mass was measured using bioelectrical impedance 
analysis (BIA) as well as PEA POD, a non-invasive air-displacement 
plethysmography (Life Measurement Inc., Concord, CA, USA), which 
measured body volume and coupled with body weight, was used to calculate 
body density. %BF could then be calculated from the body density, assuming 
that the body consists of two components, fat mass and fat-free mass, each 
with a known density, from the following equation(121): 
 
Where DF = density of fat mass, DFFM = density of fat-free mass and DB = body density 
Serial anthropometric measures of early growth trajectories at 3 weeks 
post-delivery as well as at 3, 6, 9, 12 and 15 months of age are made in the 
child’s home by trained observers. At 18, 24 and 36 months of age, 
anthropometry measurements were assessed during routine clinic visits. Infant 
weight from birth to 18 months of age was measured to the nearest gram using 
a calibrated scale (SECA 334 Weighing Scale, SECA Corp). Weight at 24 and 
36 months was measured to the nearest kg using calibrated scales (SECA 813 
Weighing scale, SECA Corp). Standard test weights of 1, 2, 5, 10 and 20kg 
were used to calibrate the weighing scale. Recumbent length from birth to 24 
months of age was measured from the top of the head to the soles of the feet 
using an infant mat (SECA 210 Mobile Measuring Mat, SECA Corp), to the 
nearest 0.1 cm, with the aid of two research staff. One person supported the 
infant’s head and ensures that the head is positioned in the Frankfort 
horizontal plane. A second person aligned the legs by placing one hand gently 
but with mild pressure over the knees. The child’s standing height at age 18, 
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24 and 36 months was also measured using a stadiometer (SECA 213 Portable 
Stadiometer, SECA Corp). Head circumference was also measured with the 
aid of two research staff. The infant is held by a health professional while the 
examiner uses a tape measure to measure the child’s head. Maximum head 
circumference was measured across the frontal bones of the skull and over the 
occipital prominence at the back of the head, using a non-stretchable 
measuring band (SECA 212 Measuring Tape, SECA Corp). Mid-arm and 
abdominal circumferences were also measured using a non-stretchable 
measuring band. For reliability, all measurements were taken in duplicates. 
2.3.2.2 Infant feeding assessment 
Mothers were asked on the process of infant milk-feeding, based on a 
24-hour recall, at routine house visits when the infants are 3 weeks, 3, 6, 9 and 
12 months of age. In accordance with World Health Organization (WHO) 
guidelines(122), milk-feeding practices were classified into the following: 
i. Exclusive breastfeeding: Infant received only breastmilk from his/her 
mother or a wet nurse, and no other liquids or solids, with the exception of 
drops or syrups consisting of vitamins, mineral supplements or medicines  
ii. Predominant breastfeeding: Infant predominantly received breastmilk, and 
may also have received water or water-based drinks (sweetened and 
flavoured water, teas), fruit juice, oral rehydration salts solutions, drops 
and syrup forms of vitamins, minerals and medicines. 
iii. Partial breastfeeding: Infant is receiving breastmilk, but is also being given 
other food or food-based fluids, such as formula milk or weaning foods.  
iv. Formula-feeding: Infants receives no breastmilk at all 
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 In our data collection, breastmilk intake either directly from the breast 
or expressed, were classified as breastfeeding.   
2.4 Biospecimens 
2.4.1 Collection and analysis of biospecimens 
Rinsed umbilical cord, cord blood and placenta were obtained at 
delivery by trained personnel. Umbilical cord specimens were analysed by 
genome-wide methodologies for RNA expression, DNA methylation 
characterization and genotyping. Methods to survey gene expression analysis 
include the Illumina HumanHT-12 v4 Expression BeadChips (cat#BD-103-
0204, Illumina) with 47,231 transcript probes, and the Illumina Infinium 
Methylation human 450K bead array, a bead-based technology for genome-
wide methylation analysis. Genotyping was also performed on DNA extracted 
from frozen umbilical cords using the Illumina omniexpress + exome array 
platform. 
2.4.2 RNA extraction  
Umbilical cord tissue (300mg) was first placed in a sterile Dispomix 
tube and homogenized for 55s for 3 cycles in 3 ml of Trizol using the 
Dispomix (Medic Tools, AG, Zug, Switzerland). After spinning down the 
debris, the supernatants were divided equally into three 2ml tubes. 200ul of 
chloroform were added to each tube, vortexed vigorously and centrifuged for 
15min at 4˚C. The aqueous phase was carefully transferred to a new tube 
containing 1ul of linear acrylamide. An equal amount of isopropanol was 
added and mixed by inversion. After incubating at -20˚C overnight to 
precipitate the RNA, the pellet was obtained by centrifuging at 13,200 rpm for 
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10 min at 4˚C. The RNA pellet was washed twice in 70% (v/v) ethanol, air-
dried and resuspended in RNase-free water. The isolated RNA was then 
purified using the RNeasy Mini Kit (Qiagen, Hilden, Germany). On-column 
DNase digestion was carried out before the first wash step according to the 
manufacturer’s instructions.  The purified RNA was then eluted in 30 µl of 
RNase-free water and stored at -80°C. RNA concentration and purity were 
measured using a nanodrop ND-8000 spectrophotometer (Nanodrop 
Technologies, Wilmington, DE, USA), and RNA integrity was determined 
using the Agilent 2100 Bioanalyzer and RNA 6000 Nano Labchips (Agilent 















Chapter 3: A new reference for gestational age-specific size-at-birth of 
Singaporean infants 
3.1 Summary 
Background: There is a lack of representative data for local gestational age-
specific size-at-birth percentile charts. We aim to construct reference values 
and charts for size-at-birth from 35 to 41 weeks of gestation, based on a 
healthy local population sample. 
Methods: A prospective observational birth cohort study which recruited 
pregnant mothers from two major public hospitals with obstetric service in 
Singapore at <14 weeks gestation, and data was collected for birth weight, 
length and head circumference of infants born from November 2009 to May 
2011. Percentile curves were created separately for male and female infants 
using the lambda-mu-sigma (LMS) method. 
Results: Smoothened curves for birth weight, length and head circumference 
centiles were created from 863 infants (460 males, 403 females). For a male 
and female Singapore infant at 38 weeks gestation, the 10-50-90th centile 
values for weight would be 2663-3096-3597 vs. 2571-2966-3417 grams, for 
length 46.4-48.6-51.1 vs. 45.6-48.0-50.4 cm, and for head circumference 32.0-
33.5-35.2 vs. 31.4-32.9-34.6 cm. There were no statistically significant 
differences between ethnic groups. 
Conclusion: The new centile charts in this study may be used as reference 





Size-at-birth (birth weight, length and head circumference) is a simple 
clinical measure that is of importance to both neonatologists and obstetricians. 
It is commonly used in clinical practice to assess neonatal health. Birth weight 
and length have been demonstrated to be determinants of perinatal morbidity 
and survival(123); they are important clinical indicators that are widely used 
for evaluation of prenatal growth and for identifying infants who are at higher 
risk of mortality(124, 125). Head circumference is often used by clinicians to 
identify infants with malformations in the central nervous system and carry 
prognostic implications(126). Size-at-birth charts thus provide a basis for the 
assessment of growth and monitoring. 
There are readily available size-at-birth-for-gestational age reference 
charts for newborns of several populations, such as Canada(127), 
Sweden(128), United States(129, 130) and United Kingdom(131). Despite 
evidence to assume postnatal growth trajectories are similar across countries 
and ethnicity(132-134), there is insufficient data on whether size-at-birth-for-
gestational age is comparable across countries and ethnicity. In addition, some 
of these suffer from limitations related to the measurement of gestational age. 
Some of the charts measured gestational age to the nearest week(135), rather 
than truncating it to completed weeks, as recommended by World Health 
Organization guidelines(136). Even for charts that were measured in 
completed weeks, they are limited by using gestational age based on date of 
onset of last menstrual period(137) which has been shown to underestimate 
those born preterm and overestimate those with post-term gestational ages 
when compared with early ultrasound measurements(138). Thus in this study, 
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we aimed to construct gestational age-specific size-at-birth percentile charts, 
based on healthy infants from the Growing Up in Singapore Towards Healthy 
Outcomes (GUSTO) Birth Cohort study, which would overcome some of the 



















3.3 Materials and Methods 
3.3.1 Study population, assessment of gestational age (GA) and neonatal 
anthropometry measurements 
 Details regarding the study population, assessment of gestational age 
and measurement of neonatal anthropometry have been described in Section 
2.1, Section 2.3.1.3 and Section 2.3.2.1.  
3.3.2 Exclusion criteria 
In order to give size-at-birth reference values based on a “healthy” 
cohort, we excluded deliveries with (a) stillbirths, (b) twins, (c) complications 
during pregnancy with potential effects on fetal growth (gestational diabetes 
mellitus, anaemia, hypertension / pre-eclampsia) and (d) newborns with 
significant neonatal malformations. There were also a limited number of 
observations in the lower gestational ages (less than 35 weeks); these data 
were also excluded from the analysis. Outlying data points more than three 
times the inter-quartile range were identified using box-whisker plots, by 
gestational age and gender for each variable. These data points were then 
cross-referenced against hard-copy data; incorrect entries were then rectified 
into the database to ensure high-quality data was used for analysis.  
3.3.3 Statistical analysis and chart development 
 The LMS method(139) using maximum penalized likelihood was 
utilized to create anthropometric centiles for birth weight, length and head 
circumference. This method estimates anthropometric measurement centiles in 
terms of three age-sex specific cubic spline curves: L curve (measure of 
skewness based on the Box-Cox transformation), M curve (median) and the S 
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where t represents GA and y represents anthropometric measurement. 
Knowing the values of the three parameters L(t), M(t) and S(t), the 100α 
percentile is given by: 
      P100α(t) = M(t) [1 + L(t)S(t)Zα]
1/L(t) 
where Zα is the standard normal deviate that gives 100α% cumulative 
probability, 















 percentiles were generated using LMS Chartmaker software 
(Medical Research Council, UK). The modeling process began with an initial 
set of “equivalent degrees of freedom” (EDFs) for the parameters L, M and S 
respectively and the transformation that gave the lowest deviance was 
preferred. The EDFs were then changed, first for M, then S and L, using the 
GAIC(3) [Generalised Akaike Information Criterion with a penalty constant of 
3] as a guide. Graphical examinations are then used to fine-tune and confirm 
the choice of parameters to be used.  







 percentiles were performed to assess their association with GA and 
ethnicity. The interaction effect between GA and ethnicity were also explored 




3.4.1 Demographics and clinical characteristics 
Anthropometric measurements were completed on the infants of 1163 
mothers. A total of 300 infants were excluded from analysis as a result of 
being born with significant neonatal malformations, or born to mothers with 
pregnancy complications (gestational diabetes, anaemia, pre-eclampsia). 
Infants whose mothers had no oral glucose tolerance test (OGTT) data were 
also excluded in this study. After exclusion, 863 infants were included in the 
analysis. Table 3.1 summarizes the characteristics of the mothers and study 
infants. 
3.4.2 Gestational age-specific size-at-birth of Singapore infants 
Tables 3.1 and 3.2 shows the frequency distribution (n) of GA, LMS 
values and the observed 3rd, 10th, 25th, 50th, 75th, 90th, 97th percentile of 
size-at-birth variables for male and female infants. At each GA, male infants 
consistently exceeded female infants in all three variables. The EDFs for the 
fitted LMS spline curves for both male and female infants were respectively: 
2, 3 and 1 for weight and head circumference; and 2, 2 and 1 for length. 
Increasing any of the LMS parameters by one EDF for birth weight, birth 
length and head circumference only increased the GAIC(3) score by 2.3, 2.5 
and 2.9 units respectively. Figures 3.1-3.3 show the gestational age-specific 
smoothed percentile curves for birth weight, length and head circumference 
respectively, for each gender. The curves are smoothed and evenly spaced 










Mean (SD) or 
% 
Maternal Age (yr)  863 30.4 ± 5.1 
Marital Status (%)  
 
 
 Married  812 96.1 
 Single 33 3.9 
Highest Education attained (%)  
 
 
 Below ""A" levels / diploma 356 41.8 
 “A” levels / diploma or higher 496 58.2 
Type of housing (%)  
 
 
 Government  734 86.2 
 Private 118 13.8 
Household Income (%) 
 
 
 Below $6000 572 71.0 




 Chinese 507 58.7 
 Malay 227 26.3 
 Indian 129 14.9 
Infant gender (%) 
 
 
 Male 460 53.3 
 Female 403 46.7 
Gestational age at delivery (wks) 863 38.4 ± 1.2 
Infant birth weight (g) 863 3109 ± 411 
Infant birth length (cm) 863 48.7 ± 2.1 
Infant birth HC (cm) 863 33.4 ± 1.8 
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Table 3.2: Birth weight (g), length (cm) and head circumference (cm) centiles by gestational age (weeks) for boys 
GA: Gestational age 
Birth weight 















35 6 -1.15 2566 0.12 2108 2234 2379 2566 2789 3027 3310 
36 24 -0.76 2756 0.12 2248 2390 2552 2756 2990 3233 3509 
37 80 -0.38 2937 0.12 2376 2537 2716 2937 3182 3428 3697 
38 142 0.02 3096 0.12 2481 2663 2860 3096 3350 3597 3858 
39 127 0.43 3248 0.12 2576 2780 2996 3248 3511 3757 4010 
40 75 0.83 3391 0.12 2657 2888 3124 3391 3661 3907 4152 
41 6 1.23 3532 0.12 2731 2992 3250 3532 3810 4055 4294 
Birth length 















35 6 -4.12 46.5 0.04 43.7 44.5 45.4 46.5 47.7 49.0 50.5 
36 24 -3.07 47.2 0.04 44.3 45.1 46.1 47.2 48.5 49.7 51.1 
37 80 -2.01 47.9 0.04 44.8 45.8 46.7 47.9 49.2 50.4 51.7 
38 142 -0.96 48.6 0.04 45.4 46.4 47.4 48.6 49.9 51.1 52.3 
39 127 0.09 49.4 0.04 46.0 47.0 48.1 49.4 50.6 51.8 53.0 
40 75 1.14 50.1 0.04 46.5 47.6 48.8 50.1 51.3 52.5 53.6 
41 6 2.19 50.8 0.04 47.0 48.3 49.5 50.8 52.1 53.2 54.3 
Birth head circumference 















35 6 -1.52 32.3 0.04 30.2 30.9 31.5 32.3 33.1 33.9 34.7 
36 24 -1.59 32.7 0.04 30.7 31.3 32 32.7 33.6 34.4 35.2 
37 80 -1.67 33.2 0.04 31.1 31.7 32.4 33.2 34 34.8 35.7 
38 142 -1.75 33.5 0.04 31.4 32.0 32.7 33.5 34.3 35.2 36.0 
39 127 -1.83 33.8 0.04 31.7 32.3 33 33.8 34.7 35.5 36.4 
40 75 -1.91 34.1 0.04 32 32.6 33.3 34.1 35 35.8 36.7 
41 6 -1.99 34.3 0.04 32.2 32.8 33.5 34.3 35.2 36.1 37.0 
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Table 3.3: Birth weight (g), length (cm) and head circumference (cm) centiles by gestational age (weeks) for girls 
GA: Gestational age 
Birth weight 















35 10 1.19 2424 0.11 1907 2074 2241 2424 2604 2765 2921 
36 18 0.81 2620 0.11 2084 2252 2425 2620 2817 2997 3177 
37 51 0.43 2800 0.11 2250 2418 2595 2800 3014 3215 3420 
38 118 0.05 2966 0.11 2404 2571 2751 2966 3196 3417 3650 
39 127 -0.33 3125 0.11 2554 2719 2902 3125 3371 3615 3879 
40 73 -0.71 3289 0.11 2708 2873 3058 3289 3552 3821 4123 
41 6 -1.09 3444 0.11 2854 3018 3205 3444 3724 4020 4365 
Birth length 















35 10 2.07 45.5 0.04 42.0 43.2 44.3 45.5 46.7 47.7 48.7 
36 18 1.68 46.3 0.04 42.9 44.0 45.1 46.3 47.5 48.6 49.7 
37 51 1.35 47.2 0.04 43.7 44.8 45.9 47.2 48.4 49.5 50.6 
38 118 1.11 48 0.04 44.5 45.6 46.7 48.0 49.2 50.4 51.5 
39 127 0.96 48.8 0.04 45.2 46.4 47.5 48.8 50.1 51.2 52.4 
40 73 0.83 49.6 0.04 46.0 47.1 48.3 49.6 50.9 52.1 53.3 
41 6 0.71 50.4 0.04 46.8 47.9 49.1 50.4 51.8 53.0 54.2 
Birth head circumference 















35 10 -2.68 32 0.04 30 30.6 31.2 32 32.8 33.7 34.6 
36 18 -2.23 32.3 0.04 30.3 30.9 31.5 32.3 33.2 34 34.9 
37 51 -1.78 32.6 0.04 30.5 31.2 31.8 32.6 33.5 34.3 35.2 
38 118 -1.31 32.9 0.04 30.7 31.4 32.1 32.9 33.8 34.6 35.5 
39 127 -0.83 33.2 0.04 31 31.7 32.4 33.2 34.1 34.9 35.8 
40 73 -0.33 33.7 0.04 31.4 32.1 32.8 33.7 34.5 35.4 36.2 
41 6 0.17 34.1 0.04 31.8 32.5 33.3 34.1 35 35.8 36.6 
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Figure 3.3: Birth head circumference for gestational age centiles for boys (A) 


































































Quantile regression models for 10th, 50th and 90th percentiles of the 
size-at-birth variables showed no statistically significant evidence for 
association between the size-at-birth variables and ethnicity for both genders 
in models with quadratic terms for gestational age and ethnic-GA interaction 
terms (each P>0.05).  In more parsimonious models that excluded the 
statistical non-significant quadratic and interaction terms (Table 3.4), out of 18 
regression analyses (2 gender * 3 anthropometric variables * 3 percentiles), 
there was only 1 statistically significant ethnic difference: median head 
circumference was 0.5 cm smaller in Indian boys than Chinese boys (P<0.05) 
(Table 3.4). 
3.4.3 Comparison of reference size-at-birth values with other cohorts 
We also compared the birth weights of male and infants in our cohort 
with population-based references for singleton infants from Finland(140). 
When compared with infants from the Finland cohort, GUSTO male term and 
preterm infants had birth weights between 28 to 423 gram lower at the 10th, 
50th and 90th percentiles (corresponding to -1.28SD, mean and +1.28SD for 
the Finland cohort) respectively. GUSTO female preterm and term infants had 
birth weights between 5 to 488 grams lower at the 10th, 50th and 90th 















B = regression coefficient 
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-1.28SD Mean +1.28SD 
35 2234 2566 3027 
 
2175 2731 3287 
 
2074 2424 2765 
 
2079 2642 3205 
36 2390 2756 3233 
 
2418 2991 3564 
 
2252 2620 2997 
 
2323 2899 3475 
37 2537 2937 3428 
 
2663 3239 3815 
 
2418 2800 3215 
 
2561 3132 3703 
38 2663 3096 3597 
 
2892 3456 4020 
 
2571 2966 3417 
 
2774 3326 3878 
39 2780 3248 3757 
 
3075 3625 4175 
 
2719 3125 3615 
 
2948 3483 4018 
40 2888 3391 3907 
 
3216 3766 4316 
 
2873 3289 3821 
 
3094 3624 4154 
41 2992 3532 4055 
 
3325 3883 4441 
 
3018 3444 4020 
 




We report the percentiles and smoothened curves of size-at-birth 
variables in a cohort of Singapore neonates born at 35-41 completed weeks of 
gestation. Our study utilized more precise dating and measurement techniques 
which differed from population-based references.  Also, the present sample is 
selected from GUSTO to form a “healthy” cohort for the purpose of providing 
growth standards. These charts assume optimal growth and can be used to 
identify near-term or term newborns at risk of adverse health outcomes 
associated with abnormal intrauterine growth. There has been much 
controversy on inclusion of only "healthy newborns" in deriving growth 
charts. Ideally, a study population which includes both low- and high-risk 
pregnancies and both normal and abnormal perinatal outcomes would be more 
suitable as a reference chart. Standard charts on the other hand are based on 
low-risk pregnancies with a normal outcome, and the growth curves would 
reflect optimal, healthy, linear growth of newborns who fully expressed their 
growth potential. When “population referenced” and “standard” charts are 
applied to an individual fetus or infant, interpretation of the findings would 
differ. Using a population referenced would yield a relative fetal size in 
relation to the total population; a standard chart will assess a fetal size in 
comparison to normally grown fetuses. Thus, a standard chart may have more 
clinical utility than a population referenced chart(141). 
The availability of local gestational age-specific size-at-birth percentile 
charts is essential for obstetricians & neonatologists in their perinatal practice. 
Earlier charts generated by Cheng et al(135) for the Singaporean population 
are now several decades old; this would not be reflective of infants that were 
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born in more recent years, where there has been a rapid improvement in the 
quality of living and health indices. For example, Cheng et al’s charts showed 
that at 40 weeks gestation, birthweight at 50
th
 percentile was approximately 
3.0kg, whereas the GUSTO charts showed birthweight at 50
th
 percentile was 
approximately 3.3kg for the same gestational age. It has been well established 
that increased maternal education, income, and social status contribute to 
increased birth weight(142), thus our charts takes into account an improved 
standard of living, of which more than half of mothers in the cohort are better-
educated (completed at least GCE 'A' Levels or polytechnic education) and 
resided in better accomodation (at least 4-5 room HDB flats). The average 
maternal age of the GUSTO participants was 30.4 years, slightly older than 
that reported in birth weight charts by Tan et al(137) at 29.2 years; this 
appears to be reflective of the trend of delayed childbearing amongst women 
here in Singapore(143).  
Our charts also pooled Chinese, Malay and Indian infants together into 
one chart. Earlier studies on birth weights in the Singapore population had 
identified that Indians have the highest proportion of low birth weight(144, 
145), and also tend to weigh lesser than their Chinese and Malay 
counterparts(146). Similarly, Indians in our study sample exhibited smaller 
birth weights compared to Chinese and Malays; however these differences 
were not statistically significant. Additionally, there was no statistical 
evidence to suggest that size-for-gestational age pattern was different between 
ethnic groups at the 10th, 50th and 90th percentiles. In a recent discussion 
about the cross-ethnic applicability of the WHO Multicenter Growth 
Reference Study child growth standards, it was suggested that a difference in 
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median of less than +/- 0.4 SD is a clinically non-significant difference(147). 
In the present study, there was a lack of clinical significance between the three 
ethnic groups. Comparing the statistically significant difference in median 
head circumference between Indian and Chinese boys and the statistically non-
significant differences in medians of birth weight and length against the SD 
reflected by the M and S curves of the LMS models, there was no clinically 
significant difference across ethnic groups. These observations substantiate 
our pooling of the three ethnic groups together into one overall chart, rather 
than stratifying into ethnic-specific charts. These factors differentiate the 
GUSTO charts from other local published charts, hence providing a new 
reference for size-at-birth of Singapore newborns. 
Despite evidence to assume postnatal growth trajectories is similar 
across countries and ethnicity(132-134), there is much less data on whether 
size-at-birth is comparable across countries and ethnicity. We compared the 
birth weights of our infants with published gender-specific references for birth 
weight-for-gestational age from the Finland cohort(140); both the GUSTO as 
well the Finland study reported gestational age based on ultrasound 
assessment, and only "healthy newborn" infants were included. The time 
period of the Finland study was from 1996-2008, relatively closer with that of 
GUSTO and hence allowing for comparison of the growth curves between 
these two studies. GUSTO term infants were observed to be lighter across the 
10th, 50th and 90th percentiles when compared with the Finland cohort. This 
implies that the use of non-local charts could lead to misclassification of 
small-for-gestational-age (SGA) or large-for gestational-age (LGA) infants. 
Using the Finland charts with our data led to overestimation of SGA infants 
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and underestimation of LGA infants; the consequence of which some infants 
appropriate-for-gestational-age (AGA) would be wrongly identified as SGA 
and LGA infants would be overlooked as AGA. This supports the suggestion 
that population-specific growth charts should be used for classification of 
infants into SGA, AGA or LGA; additionally, it seems that compared with 
Caucasian infants, Asian infants are smaller at birth.   
The use of ultrasound for more precise dating of GA, performed at the 
first trimester period presents as a strength of this study. Ultrasound dating 
measurements are usually used to confirm last menstrual period dates or if 
menstrual history is unreliable(148). Unlike other studies(135, 137) where GA 
was based on date of onset of last menstrual period, which can underestimate 
the number born preterm, and overestimate post-term GA, ultrasound dating 
helps to avoid erroneous estimation of GA(138). Some studies have used 
anthropometric data documented in birth records(149). While this technique 
allows for inclusion of a large sample number of infants, it often necessitates 
statistical exclusion of extreme outliers arising from errors in 
documentation(150, 151). Questions may also arise whether anthropometric 
data from past records have been reliably measured. Thus, the prospective 
nature of the GUSTO cohort adds strength to the study; it ensures all 
anthropometric variables were accurately and reliably measured, hence 
exclusion of extreme outliers in data was not required.  
Similar to most population-based references, our growth charts have 
one important limitation, which is the cross-sectional nature of the data. The 
data analyzed in this study are based on size-at-birth anthropometrics of 
different newborns at different gestational ages, which is not reflective of the 
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intrauterine growth of the fetus. Hence, these charts would not be suitable for 
evaluation of fetal growth velocity. A longitudinal analysis of individual 
fetuses would be required for a more detailed study on intrauterine growth 
velocity. Another limitation of the present study is that the sample size of 
GUSTO was not estimated for the purpose of constructing size at birth 
reference charts. However, the use of modern analytic methods like LMS 
makes good use of data in that each data point contributes toward the 
estimation of the centiles of not only the gestational age interval it belongs to 
but also the adjacent gestational ages. Hence the relatively small sample size 
was partially compensated by the relatively efficient statistical methods. 
Future studies with even larger sample size and for a wider range of 
gestational weeks will be useful. Additionally, the GUSTO sample in this 
study does not represent the local newborn population; practical logistic issues 
hindered obtaining samples from other maternity units, which could have 
further strengthened the applicability of the findings. The GUSTO data 
however, was collected from two of Singapore's major maternity units (NUH 
and KKH) which strengthen the applicability of the findings as compared to 
single-center studies. 
Our study also lacks sufficient sample size at preterm (less than 37 
weeks), as well as at post-term GA (41 weeks). Our cohort is also limited by 
the small sample size for the Indian population, which necessitates the need 
for further research especially regarding the size-for-gestational age pattern for 
the Indian population. Whilst growth curves at the lower gestational ages (24-
34 weeks) would add significant clinical value, our charts would still be useful 
for clinicians and researchers; it represents a new reference for birth weight, 
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length and head circumference based on a recent population of near-term and 
term infants, which would be crucial to evaluate birth size correctly. Birth size 
references representing optimal foetal growth and based on the current 
population are sparse especially for Singapore, where existing charts are based 
on populations that are decades old. As changing social trends may influence 
birth size, birth size references based on a more recent population would be 
useful for correct evaluation of newborns as small-, appropriate- or large-for-
gestational age. Correct identification of SGA infants is important since these 
infants are at an increased risk of perinatal morbidity and mortality and long-
term adverse consequences such as neurodevelopmental problems, adult-onset 
cardiovascular disease, and metabolic alterations(16). For researchers, our 
charts would allow for proper categorization of groups of infants to study 
etiologic determinants of birth size as well as short- or long-term prognosis. 
Our study findings provide a new standard chart for size-at-birth of 
Singapore newborns 35-41 weeks of gestational age. For clinicians, it allows 
for a more suitable classification of infants as small-, appropriate- or large-for-
gestational age. Given the importance of the relationship between size-at-birth 
and future health risks, these charts would be useful for the care of newborns, 








Chapter 4: Body fat in Singaporean infants: Development of body fat 
prediction equations in Asian newborns 
4.1 Summary 
Background: Prediction equations are commonly used to estimate body fat 
from anthropometric measurements, but are often population-specific. We 
aimed to establish and validate a body composition prediction formula for 
Asian newborns, and compared its performance with that of a published 
equation. 
Methods: Two hundred and sixty-two neonates from a prospective cohort 
study had body composition measured using air-displacement 
plethysmography (PEA POD). Using fat mass measurement by PEA POD as a 
reference, stepwise linear regression was utilized to develop a prediction 
equation in a randomly selected subgroup of 62 infants measured on days 1–3, 
which was then validated in another subgroup of 200 infants measured on days 
0–3. 
Results: Subscapular skinfold thickness, weight, gender and gestational age 
were significant predictors of neonatal fat mass, explaining 81.1% of the 
variance, but not triceps skinfold or ethnicity. By Bland–Altman analyses, our 
prediction equation revealed a non-significant bias with limits of agreement 
(LOA) similar to those of a published equation for infants measured on days 
1–3 (95% LOA: (-0.25, 0.26) kg vs. (-0.23, 0.21) kg) and on day 0 (95% LOA: 
(-0.19, 0.17) kg vs. (-0.17,0.18) kg). The published equation, however, 
exhibited a systematic bias in our sample. 
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Conclusion: Our equation requires only one skinfold site measurement, which 




Excess adiposity is a major risk factor for adverse health outcomes and 
chronic diseases(152). Body fat assessment in infants is important not only as 
an indicator of nutritional status, but also because of the increasing evidence 
of its role in the developmental origins of health and disease later in life. 
Techniques such as dual-energy X-ray absorptiometry (DXA) and quantitative 
nuclear magnetic resonance have been used in research studies, which provide 
non-invasive, accurate and precise measurements of body composition, but 
both techniques are generally unsuitable for large scale pediatric use. DXA 
often requires infants to lie still during scanning thus making the 
implementation of the technique challenging. Additionally, estimates of infant 
body composition measured by quantitative nuclear magnetic resonance 
without appropriate mathematical adjustment fares poorly when compared to 
4-compartment model, deuterium oxide dilution (D2O) technique, and air-
displacement plethysmography (ADP) for infants(153). The infant-sized ADP 
instrument, PEA POD
®
 provides a reliable and accurate assessment of body 
fat in infants(154-156), and has been shown to provide better estimates than 
other techniques such as DXA(157). A recent study by Ellis KJ et al(158)  on 
49 healthy infants demonstrated no significant difference in the mean percent 
body fat (%BF) obtained from PEA POD
®
  (16.9 ± 6.5%) and the reference 
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four-compartment model (16.3 ± 7.2%), and the regression between %BF 
obtained by both did not deviate significantly from the reference line of 
identity y=x (R
2
 = 0.95; SEE = 1.4%BF), thus making the PEA POD
®
 a 
reasonably accurate method for body composition assessment in children. 
Additionally, PEA POD
®
 takes into account that the hydration status of 
neonates differs from adults and that hydration of fat-free mass decreases with 
age(159, 160) unlike other reference methods such as DXA, which assumes 
constant hydration. The machine however, is bulky and expensive, and its use 
is restricted only to fixed locations such as hospital settings. Therefore, it 
would be desirable to have a prediction equation for estimation of total body 
fat in infants using a combination of anthropometric variables. This would 
allow for quick estimations of body composition without the need for 
specialized laboratories or expensive equipment.  
Skinfold thickness (SFT) measurements provide estimates of 
subcutaneous fat layer(161) which can be easily converted into values of %BF 
or fat mass via prediction formulas(162, 163). SFT measurements are fast and 
non-invasive bedside methods, which can be performed with high 
reproducibility so long as great care is taken with fieldworker training and 
quality control. SFT measurements for body composition assessment in 
adolescents and children have been widely used in clinical research and 
epidemiological settings(164, 165). Studies have shown that SFT 
measurements from single-site SFTs were highly correlated with total fat mass 
in infant subjects(166). In older children, SFT measurements have been shown 
to correlate with body fat measured by DXA(167). Questions have been raised 
however, on their validity in infancy, given the age-related variability in 
 72 
 
hydration status as well as variability in skinfold compressibility among 
neonates(168, 169). Generalized skinfold prediction equations, such as those 
by Slaughter(170) for estimating body composition in infants have been 
developed, although these equations are population-specific(171) and may not 
be suitable for Asian infants. In the GUSTO study, %BF and fat mass data as 
measured by PEA POD® was collected from a subgroup of infants. Thus in 
this study, we aimed to establish and validate a fat-mass prediction formula 
that is specific for the GUSTO cohort during the neonatal period using PEA 
POD® measurements as reference, and hypothesized that anthropometric 
measures such as body weight and SFT would be predictive of fat mass in 
newborns. Additionally, we compared the performance of our prediction 
equation with that of a published equation(170), for estimating neonatal fat 












4.3 Materials and Methods 
4.3.1 Study population and body composition assessment 
Details regarding the study population and body composition 
assessment were described in detail in Section 2.1 and Section 2.3.2.1. For our 
analysis population, only healthy, singleton, term infants ranging in gestational 
age between 37 to 40 weeks was considered. A subgroup of babies born in 
KKH whose parents consented had PEA POD measurements. In order to give 
reference values based on a “healthy” cohort, we excluded data from infants 
with birthweight below 2.5kg and also those with %BF below 5%, as we have 
reason to believe that PEAPOD measurements of less than 5% body fat for 
healthy term infants may have been erroneously taken by the observers. After 
exclusion, a total of 262 infants, from day 0-3 after birth, were analyzed in this 
study. 
4.3.2 Model Derivation 
For purposes of model derivation, infants whose measurements were 
taken at day 0 (< 24 hours after delivery) were excluded; this was based on a 
recent study that had suggested there was a significant weight loss during the 
time period of less than 24 hours after delivery(172). Hence, in deriving the 
prediction model for neonatal fat mass, only infants whose measurements 
were taken from day 1-3 were considered (n = 88). The subjects were divided 
into two groups using the SPSS random number generator. The “derivation 
group” included two-thirds of the subjects and was used to derive the 
prediction equation for neonatal fat mass. The “validation group” consisted of 
the remaining subjects. Stepwise linear regression was utilized to derive the 
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best model to predict neonatal fat mass from the “derivation group”. The 
starting maximum model included all independent variables. It is well-
documented that body composition differs significantly between male and 
female infants(173, 174); thus infant gender was included in the equation. The 
dependent variable was fat mass (in kg) as measured by PEA POD
®
. The 
independent variables used for development of the prediction equation were 
gender, ethnicity, weight, abdominal circumference, triceps and subscapular 
SFT, gestational age (GA) and day of measurement post-delivery. 
4.3.3 Statistical analysis 
The reliability of the newly-derived model and the published equation 
were assessed on the “validation” group and the subgroup of day 0 infants; 
differences between measured and predicted values were tested for 
significance from zero using one-sample paired t-tests. Technical errors (TEs) 
and intraclass correlations (ICC) were computed to evaluate reproducibility of 
SFT measurements(175, 176) TEs were calculated by: 
     TE = √(Σd2 / 2N)  
where d = difference between smallest and largest measurements for an individual 
 
 
%BF values predicted from Slaughter's equation(170) were converted 
to fat mass using the following equation: 
      Fat mass Slaughter = (%BF Slaughter / 100) x weight 
 Bland & Altman analysis(177) was used to compare fat mass 
prediction from Slaughter’s equation and the newly-derived model with 
measurements obtained from PEA POD
®
, by determining the bias and limits 
of agreement (L.O.A). Bias was defined as (Fat Mass prediction - Fat Mass 
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PEAPOD). L.O.A was determined by mean bias ± 1.96 SD, to indicate the 
possible extent of variation between predicted fat mass and PEA POD
®
 
measurement for any subject. All analysis was performed using SPSS version 
19.0 (IBM SPSS Statistics, Armonk, NY).  
4.4 Results 
4.4.1 Demographics and clinical characteristics 
Baseline characteristics of the infants at day 0 and days 1-3 are 
illustrated in Table 4.1. No significant differences were observed in the 
anthropometric measurements between derivation and validation groups. The 
reproducibility of SFT measurements in our study are illustrated in Table 4.2. 
We noted small mean differences between smallest and largest measurements 
for triceps (0.16mm for boys, 0.15mm for girls) and subscapular SFT 
(0.15mm for boys, 0.14mm for girls). ICC for triceps SFT was high in both 
boys (r = 0.994) and girls (r = 0.997), and the same observation was noted for 
subscapular SFT (r = 0.996 for boys, r = 0.997 for girls). TE for triceps 
(0.19mm for boys, 0.15mm for girls) and subscapular SFT (0.15mm for boys, 
0.14mm for girls) were also quite small in our study, indicating high 
reproducibility of SFT measurements.  
4.4.2 Predictors of neonatal fat-mass in a cohort of Singaporean neonates 
Stepwise linear regression analysis identified GA, weight, subscapular 
SFT and gender to be significant predictors of neonatal fat mass (Table 4.3), 
which explained 81.1% of the variance in neonatal fat mass (R
2 
= 0.811). Day 
of measurement post-delivery, abdominal circumference, triceps skinfold and 
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ethnicity were not significant predictors of neonatal fat mass. The final 
GUSTO equation, which was used in subsequent analyses, was: 
Fat MassGUSTO = -0.022 + (0.307*weight) - (0.077*Gender) + 
(0.028*subscapular SFT) - (0.019*GA),  
where gender = 1 for male, 0 for female 
   
Table 4.1: Characteristics of study subjects 




Day 1-3 (n = 88)  
Day 0 
(n = 174) 
Derivation 
(n =  62) 
Validation 
(n = 26) 
 
Male (%) 50.0 73.1  49.7 
Chinese (%) 45.2 34.6  48.0 
Malay (%) 38.7 46.2  36.3 
Indian (%) 16.1 19.2  15.7 
Fat mass by PEAPOD (kg)*  0.36 ± 0.14 0.36 ± 0.14  0.34 ± 0.11 
Gestational age (wks)* 38.5 ± 1.1 38.5 ± 0.9  38.5 ± 1.0 
Weight (kg)* 3.2 ± 0.4 3.4 ± 0.4  3.2 ± 0.3 
Abdominal Circumference 
(cm)* 
29.4 ± 2.3 28.8 ± 2.4  28.8 ± 1.9 
Subscapular skinfold (mm)* 5.1 ± 1.0 5.1 ± 1.0  5.3 ± 1.1 
Tricep skinfold (mm)* 5.7 ± 1.2 5.5 ± 1.2  5.9 ± 1.2 
day of measurement (days) 
  
  
1st day (%) 48.4 57.7  - 
2nd day (%) 41.9 19.2  - 
3rd day (%) 9.7 23.1  - 
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Values are presented as mean ± SD 
TE: Technical error of measurement 
ICC: Intraclass correlation 
 
Table 4.3: Regression coefficients of independent variables for prediction models of fat mass (Dependent variable: fat mass in kg measured by 
PEAPOD) 
Predictive Variables 





Prediction equations for  









       
0.623  -0.638 + 0.307*W 
 
W + G 0.853* 
 
-0.303* 
     
0.736  -0.655 + 0.326*W - 0.087*G 





   
0.774  0.437 + 0.350*W - 0.087*G - 0.030*G.A 








0.811  -0.022 + 0.307*W - 0.077*G - 0.019*G.A + 0.028*SSF 
* p < 0.05 for statistically significant standardized regression coefficient 
W = Weight in kg, G = Gender (male = 1, female = 0), G.A = gestational age in weeks, SSF = subscapular skinfold
 
Mean difference ± SD between minimum 
and maximum measurements  
 TE (mm) 
 
ICC 
Boys (n = 136) 
     










Girls (n = 126) 
     












4.4.3 Comparison with other published fat-mass estimating equations 
Fat mass predicted using the GUSTO equation exhibited a moderately 
strong correlation with Fat mass PEAPOD [r = 0.567, p = 0.003], which is similar 
compared with fat mass predicted using Slaughter’s equations [r = 0.570, p = 
0.002].  
The accuracy of each prediction equation for the “validation group” 
was assessed using Bland-Altman plots (Figures 4.1A-B), which revealed the 
bias and L.O.A for body fat predicted by GUSTO and Slaughter's equation. 
The mean bias for GUSTO equation is 0.003kg (p > 0.05), similar with the 
mean bias for Slaughter’s equation, at -0.01kg (p > 0.05). The L.O.A for 
GUSTO equation was (-0.25, 0.26) kg, which is also similar with Slaughter’s 
equation, (-0.23, 0.21) kg. There was no significant relationship between the 
mean and difference of the measured and predicted values, but the relationship 
approached significance for Slaughter’s equation.  (r = 0.05, p = 0.802 for 
GUSTO equation; r = -0.40, p = 0.063 for Slaughter’s).  
 We also assessed GUSTO and Slaughter's equation with infants who 
had their measurements taken on day 0, as illustrated in Figures 4.2A-B. The 
mean bias for GUSTO equation is -0.01kg (p > 0.05), similar with the mean 
bias for Slaughter's equation, at 0.002kg (p > 0.05). The L.O.A for GUSTO 
equation was (-0.19, 0.17) kg; again, this is similar with that of Slaughter's 
equation, (-0.17, 0.18) kg. There was no significant relationship between the 
mean and difference of the measured and predicted values for the GUSTO 
equation (r = 0.102, p = 0.126), but the relationship was significant for 
Slaughter's equation (r = -0.252, p = 0.001). Again, this is indicative that 
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Slaughter's equation has a tendency to underestimate fat mass as body fatness 
increased, and overestimate as body fat decreases. 
 
Figure 4.1A: Bland-Altman plot comparing measured fat mass against predicted 










































Figure 4.1B: Bland-Altman plot comparing measured fat mass against predicted 















































Figure 4.2A: Bland-Altman plot comparing measured fat mass against predicted 











































Figure 4.2B: Bland-Altman plot comparing measured fat mass against predicted 













































 We have developed a new fat mass prediction equation for neonates 
and compared it with the equation of Slaughter et al and with measurements 
obtained by PEA POD
®
. To our knowledge, this study is one of the few that 
incorporates PEA POD
®
 as a reference method to cross-validate fat mass 
prediction equations. Our study utilized absolute fat mass rather than relative 
body fat (i.e. %BF) as the outcome variable, as early studies have identified 
absolute fat mass as a more desirable outcome when estimating body 
composition from anthropometric variables in infants and children(178). 
Recent studies had also identified poor predictability when attempting to 
correlate anthropometric measurements with relative body fat(179). SFT 
measurements have also been identified to be more useful in estimating fat 
mass rather than relative body fat(166). Consistent with other studies, we 
found that weight, gender and gestational age were significant contributors in 
estimating neonatal fat mass(179, 180). Our study found that subscapular SFT 
improved the prediction of fat mass. SFT has been widely accepted as a 
predictor of body fat(181) and can be measured directly using well-calibrated 
callipers. As with all quantitative biological measures, it is important to 
minimize error. In our study, we observed a high reproducibility of SFT 
measurements consistent with other studies conducted in children(182) which 
reflected that our observers were well-versed and trained in SFT measurement.  
In our stepwise multiple regression analysis, it was somewhat 
surprising that triceps skinfold was not a significant predictor but subscapular 
skinfold is. This might be due to greater within-subject variability for triceps 
SFT measurements as observed in our study group. Subcutaneous fat is also 
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known to be unevenly distributed around the circumference of the limbs, 
which may explain why triceps SFT is not predictive of fat mass. Early studies 
have also highlighted that subscapular SFT are more predictive of fat mass 
than other single-skinfold sites for infants(166). Given the difficulty in 
performing skinfold measurements in newborns, and wide inter- and intra-
individual variability in such measurements, our equation can significantly 
reduce time and effort in large birth studies. Ethnicity was also not a 
significant contributor in predicting neonatal fat mass. The lack of 
contribution of ethnicity in the prediction of body fat is also consistent with 
earlier literature on adult Singaporean Chinese, Malays and Indians, which had 
noted a similar observation(183, 184). This allowed us to derive a prediction 
model which does not require input of ethnicity for fat mass prediction, and 
thus may be helpful in its application to other Asian neonatal populations. We 
still believe there is significant difference in body composition between 
Caucasian and Asian babies, but our study appeared to suggest that the 
difference between Asian babies of different ethnicity is much less.      
Our model was derived from infants whose measurements were taken 
on days 1-3, and excluded infants whose measurements were taken on day 0. 
This was based on a recent report that had identified significant initial weight 
loss measured at day 0(172) due to differences in hydration status. It is well-
documented that neonates become lighter than they were at birth because of 
change in hydration status(159, 160, 185). We chose to exclude infants with 
anthropometric measurements taken on day 0 as the difference in hydration 
status may influence body fat estimates made by PEA POD®, which may in 
turn impact the ability of our model to estimate neonatal fat mass if day 0 
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infants were included. We also showed that our model, derived from infants at 
days 1-3 post delivery, could still estimate neonatal fat mass of infants at day 0 
with a small mean bias and no significant systematic bias, unlike Slaughter's 
equation (Fig. 2A-B). This illustrates the applicability of our model for other 
newborns in the GUSTO cohort who did not have PEA POD® measurements.  
Earlier studies(183, 184) highlighted that existing prediction formulas 
for body fat(186) were not applicable for Singaporean adults and adolescents, 
because of the populations in which these equations were developed in, which 
were mainly Caucasian. Our study revealed that Slaughter’s equation may not 
be as applicable in Singaporean infant population, as evident by the systematic 
bias exhibited. This is indicative that prediction formulas for body fatness are 
population-specific, and existing equations may not be entirely useful for 
multi-ethnic Asian populations. The GUSTO equation had no significant 
systematic bias when estimating neonatal fat mass, indicating that the equation 
is in agreement with PEA POD®-derived fat mass and a general applicability 
of the equation to other newborns in the GUSTO cohort who did not have 
PEA POD® measurements. Given that the GUSTO equation was developed in 
a largely Asian cohort, it could also be applied to estimate body fat of Asian 
newborns in other studies. 
Our model has its limitations; it was based on healthy, term infants and 
thus, not representative of small (i.e. preterm, low birth weight) infants. Our 
study sample had a wide distribution of fat mass, ranging from 0.13kg to 
0.86kg with majority of the infants having fat mass ranging from 0.20kg to 
0.50kg. Our model estimated neonatal fat mass with a coefficient of 
determination (R
2
) of 81.1%, which is slightly lower than R
2
 values reported 
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in other studies(180, 181). This might be explained by differences in 
methodologies (such as availability of SFT sites) used in other studies; our 
study lacked suprailiac and biceps SFT, which are also surrogate measures of 
central and peripheral adiposity respectively(187). The addition of these SFT 
sites to our model might improve the prediction of neonatal fat mass. 
Additionally, though we demonstrated high technical precision of SFT 
measurements, our model also showed somewhat broad limits of agreement. 
While this suggests that error in individual measurements could be large, the 
small mean bias observed in our equation suggests that our model is suitable 
for comparisons between groups of infants. 
In conclusion we have developed a new fat mass prediction equation 
for use in Asian neonates. This equation can be used as a non-invasive method 
to obtain quick in-vivo estimate of fat mass in groups of infant subjects, but 
would be of almost no use in any individual infant. In order to obtain more 
accurate assessments of body composition of an individual infant, prediction 
estimates should be followed up with more sophisticated techniques of body 
composition measurement such as PEA POD. Given that our equations were 
developed in a largely Asian cohort, it can be extrapolated to estimate body fat 
of Asian newborns in other studies. More importantly, the GUSTO equation 
can be utilized to estimate fat-mass of neonates in the GUSTO cohort who did 
not have body composition measurements by PEA POD, which would be 





Chapter 5: Effect of maternal glycemia on neonatal adiposity in a multi-
ethnic Asian birth cohort 
5.1 Summary 
Background: Gestational hyperglycemia increases the risk of obesity and 
diabetes in offspring later in life. We examined the relationship between 
gestational glycemia and neonatal adiposity in a multi-ethnic Asian cohort. 
Methods: A prospective mother-offspring cohort study recruited 1247 
pregnant mothers and performed 75-g, 2-hour oral glucose tolerance tests at 
26–28 weeks’ gestation. Glucose levels were available for 1081 participants. 
Neonatal anthropometry (birth weight, length, triceps, and subscapular SFT) 
was measured, and percentage body fat (%BF) was derived using our 
equation. Associations of maternal glucose with excessive neonatal adiposity 
[large for gestational age (LGA); %BF; and sum of SFT (ΣSFT) > 90th centile] 
were assessed using multivariable logistic regression analyses 
Results: Strong positive continuous associations across the range of maternal 
fasting and 2-hour glucose in relation to excessive neonatal adiposity were 
observed; each SD increase in fasting glucose was associated with 1.31 
(95%CI: 1.10– 1.55), 1.72 (95%CI: 1.31–2.27) and 1.64 (95%CI: 1.32–2.03) 
increases in odds ratios for LGA, %BF and ΣSFT>90th centile, respectively. 
Corresponding odds ratios for 2-hour glucose were 1.11 (95% CI 0.92–1.33), 
1.55 (95% CI 1.10–2.20), and 1.40 (95% CI 1.10–1.79), respectively. The 
influence of high maternal fasting glucose on neonatal ΣSFT was less 
pronounced in Indians compared with Chinese (interaction P < 0.005). 
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Conclusion: A continuous relationship between maternal glycemia and 
excessive neonatal adiposity extends across the range of maternal glycemia. 
Compared with Chinese infants, Indian infants may be less susceptible to 
excessive adiposity from high maternal glucose levels. 
5.2 Introduction 
 Obesity presents a massive health challenge as it rapidly becomes a 
worldwide epidemic(188). Increasingly, recent evidence has pointed to 
significant relationships between hyperglycemia during pregnancy and 
increased adiposity and later life glucose intolerance in the offspring(189). It is 
also well established that maternal hyperglycemia is associated with increased 
birth weight and macrosomia, and studies have identified its long-lasting 
effects on the offspring, resulting in higher obesity rates(190, 191) and type 2 
diabetes(192). More recently, the Hyperglycemia and Adverse Pregnancy 
Outcomes (HAPO) Study showed the effect of maternal glycemia on neonatal 
adiposity and adverse neonatal outcomes is continuous across the range of 
maternal glucose concentrations, even at levels below diagnostic criteria for 
gestational diabetes (GDM)(73, 74).  
Both fasting and 2-hour post-challenge glucose levels contribute to 
GDM; however the relative contributions of fasting and post-challenge 
hyperglycemia towards excessive neonatal adiposity remain uncertain. Past 
studies have shown that post-challenge glucose levels exhibit a strong linear 
relationship with adverse birth weight outcomes (large-for-gestational age or 
macrosomia)(74, 193, 194). Other studies however, reported fasting glucose 
levels were better than post-challenge levels in identifying risk of 
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macrosomia(195, 196). Recent diagnostic criteria by the International 
Association of Diabetes and Pregnancy Study Groups (IADPSG) have 
highlighted the importance of fasting glucose in the detection and diagnosis of 
hyperglycemic disorders during pregnancy, which may in turn play a crucial 
role in identifying risk of excessive neonatal adiposity. Thus in this study, we 
investigated the relationship between maternal glycemia with neonatal 
adiposity, and hypothesized that higher maternal glucose levels during 
pregnancy would be associated with increased neonatal adiposity, and also 
compared fasting with post-challenge glucose levels in influencing excessive 















5.3 Materials and Methods 
5.3.1 Study population, general questionnaires and oral glucose tolerance 
testing 
Details regarding the study population, questionnaires to ascertain 
demographics, lifestyle and socio-economic status and oral glucose tolerance 
testing have been described in Section 2.1, Section 2.3.1.1, Section 2.3.1.2. 
5.3.2 Neonatal anthropometry measurements and body composition 
 Details regarding neonatal anthropometry measurements have been 
described in Section 2.3.2.1. Neonatal fat-mass was estimated using the 
following validated equation as described in Chapter 4 from our GUSTO 
cohort:  
Fat Mass = -0.022 + (0.307*weight) - (0.077*Gender) + (0.028*subscapular 
 SFT) - (0.019*Gestational Age)  
 where gender = 1 for male, 0 for female 
Predicted fat mass values were converted to %BF using the following 
equation: 
 %BF = (Predicted fat mass / 100) x weight in kg 
5.3.3 Definition of excessive neonatal adiposity outcomes 
Large-for-gestational age (Birth weight > 90th centile):  Centile charts for 3 
newborn gender-ethnic groups (Chinese, Malay and Indian) in the GUSTO 
cohort were determined using the LMS method, and were described in detail 
in Chapter 3. Briefly, this method estimates the anthropometric measurement 
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centiles in terms of three age-sex specific cubic spline curves: L curve 
(measure of skewness based on the Box-Cox transformation), M curve 
(median) and the S curve (coefficient of variation). A newborn would be 
considered to have birth weight-for-gestational age above 90th percentile if the 
weight was greater than 90th centile for the infant’s gender and gestational 
age.  
Percent body fat (%BF) > 90th centile: %BF above 90th centile was defined 
using the same methods as for birthweight-for-gestational age > 90th centile, 
with gestational ages of 34-41 weeks included. 
Sum of SFT (ΣSFT) > 90th centile: ∑SFT above 90th centile was defined 
using the same methods as for %BF > 90th centile, with gestational ages of 
34-41 weeks included.  
5.3.4 Statistical analyses 
 Descriptive statistics were reported as means and standard deviations 
for continuous variables and percentages for categorical variables. Differences 
in demographic and clinical characteristics across ethnicities were calculated 
using chi-square analysis and one-way analysis-of-variance (ANOVA). 
Fasting and 2-hour glucose measurements were divided into six categories, 
adapted from the HAPO Study protocol(74). For fasting glucose: Category 1 
(< 4.2 mmol/l), Category 2 (4.2-4.4), Category 3 (4.5-4.7), Category 4 (4.8-
4.9), Category 5 (5.0-5.2), Category 6 (≥ 5.3). For 2-hour glucose level during 
OGTT: Category 1 (< 5.1 mmol/l), Category 2 (5.1-6.0), Category 3 (6.1-6.9), 
Category 4 (7.0-7.7), Category 5 (7.8-8.7), Category 6 (≥ 8.8) 
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Our primary explanatory variables for analyses were maternal blood 
glucose levels, considered as a categorical and continuous variable. As a 
categorical variable, odds ratios were calculated for each measure of fasting 
and 2-hour glucose, higher by one category (categories 2-6), with reference to 
the lowest glucose category (category 1). For glucose as a continuous variable, 
odds ratios were calculated for each measure of fasting and 2-hour glucose 
higher by 1 unit (i.e. 1 mmol/L), and also by 1 standard deviation score (SDS) 
of glucose. The primary outcomes analysed were large-for-gestational age, 
%BF and ΣSFT > 90th percentile. For each outcome, two logistic regression 
models were used for calculation of odds ratios, with Model I including 
adjustment for variables used to define the 90th centile (i.e. gender and 
gestational age at delivery) and Model II including additional adjustment for 
maternal age, BMI at time of OGTT, education (below or above "A" 
levels/diploma), parity (nulliparous or multiparous), and ethnicity (Chinese, 
Malay, Indian). To account for the impact of ethnic differences in socio-
economic status on the outcome, an interaction term between education and 
ethnicity was included as a covariate in the model. All analysis was performed 










5.4.1 Demographics and clinical characteristics 
Data on glucose levels were available for 1081 subjects. 
Characteristics of these participants are shown in Table 5.1; 57.2% were 
Chinese, 25.5% Malay and 17.3% Indian. Mean maternal BMI at the time of 
OGTT was 26.2 kg/m
2
, with Malay mothers exhibiting the highest BMI across 
the three ethnic groups (p<0.001). The mean glucose levels for the participants 
were 4.4 mmol/L and 6.6 mmol/L for fasting and 2-hour plasma glucose, 
respectively, with Indian mothers exhibiting the highest fasting glucose 
(p=0.018). Mean gestational age at delivery was 38.2 weeks and the mean 
birthweight was 3089 g. Skinfold measurements were available for 959 infants 
whose mothers had corresponding glucose measurements. 
5.4.2 Relationship between maternal glycemia during pregnancy and 
frequency of excessive neonatal adiposity outcomes 
Overall, we observed that the frequency of excessive neonatal 
adiposity outcomes rose in a linear fashion across increasing fasting and 2-
hour glucose categories, even across the normal range (Figures 5.1A-C). The 
proportion of infants increased from 7.1% to 26.8% for LGA, 2.4% to 17.9% 
for %BF > 90th centile and 7.7% to 38.2% for ∑SFT > 90th centile across six 
fasting glucose categories. Across 2-hour glucose categories, the proportion of 
infants increased from 6.1% to 17.9% for LGA, 0.7% to 8.0% for %BF > 90th 
centile and 4.5% to 18.3% for ∑SFT > 90th centile. A chi-square test revealed 
a significant linear trend for all three excessive adiposity outcomes only for 
fasting glucose (λ2 = 30.08 for LGA, λ2 = 25.26 for ∑SFT > 90th percentile, λ2 
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= 39.73 for ∑SFT > 90th percentile; p < 0.001 for all three outcomes), but not 
for 2-hour glucose. To test for the possible non-linear relationship between 
fasting glucose and birth size, squared terms for fasting glucose SDS was 
added to a regression model; the coefficient of the squared fasting glucose 
term was not statistically significant, hence highlighting that the relationship 
between fasting glucose and birth size is not non-linear 
Table 5.1: Demographics and clinical characteristics of mothers and newborns 
 #








N = 618 
Malay 
N = 276 
Indian 
N = 187 
Total 
N = 1081 
P value# 
Age (yr)  31.7 ± 4.8 29.0 ± 5.5 29.9 ± 4.7 30.7 ± 5.1 < 0.001 
Marital Status (%)  
 
   0.301 
 Married  96.5 94.8 98.3 96.4  
 Single 3.3 5.2 1.7 3.5  
 Divorced 0.2 0.0 0.0 0.1  
Highest Education attained (%)  
 
   < 0.001 
 Below ""A" levels / diploma 30.7 69.9 31.1 40.8  
 “A” levels / diploma or higher 69.3 30.1 68.9 59.2  
Type of housing (%)  
 
   < 0.001 
 Government  81.2 93.4 87.4 85.4  
 Private 18.8 6.6 12.6 14.6  
Parity (%) 
 
   0.003 
 Nulliparious 50.3 41.7 38.0 46.0  
 Multiparous 49.7 58.3 62.0 54.0  
Body Mass Index (kg/m2 )  25.0 ± 3.5 28.2 ± 5.4 27.1 ± 4.3 26.2 ± 4.4 < 0.001 
Plasma Glucose (mmol/l)  
 
    
 Fasting  4.3 ± 0.5 4.4 ± 0.7 4.5 ± 0.5 4.4 ± 0.5 0.018 
 2-hr  6.6 ± 1.4 6.4 ± 1.9 6.6 ± 1.5 6.6 ± 1.6 0.056 
Received glucose management (%)     0.001 
 No 80.7 89.5 77.4 82.4  
 Yes 19.3 10.5 22.6 17.6  
Neonates      
Gestational Age (weeks)  38.3 ± 1.5 38.1 ± 1.3 38.1 ± 1.8 38.2 ± 1.5 0.020 
Gender (%)      
 Male 52.3 55.4 51.9 53.0 0.642 
Birth weight (g) 3105 ± 440 3113 ± 416 3000 ± 504 3089 ± 447 0.010 
Predicted Body fat (%) 9.9 ± 2.3 10.0 ± 2.4 9.5 ± 2.2 9.9 ± 2.3 0.127 
Sum of skinfold thickness (mm) 10.4 ± 2.3 10.4 ± 2.3 10.0 ± 2.1 10.3 ± 2.3 0.132 
 95 
 
Figure 5.1: Fasting and 2-hour glucose associations with excessive adiposity 
outcomes; (A) Large-for-gestational-age, (B) %BF > 90
th
 percentile and (C) 
ΣSFT > 90th percentile.  
 
For fasting glucose (mmol/L): Category 1 (< 4.2 ), Category 2 (4.2-4.4), Category 3 (4.5-4.7), 
Category 4 (4.8-4.9), Category 5 (5.0-5.2), Category 6 (≥ 5.3). For 2-hour glucose level during 
OGTT (mmol/L): Category 1 (< 5.1), Category 2 (5.1-6.0), Category 3 (6.1-6.9), Category 4 







5.4.3 Association between maternal glycemia during pregnancy with 
excessive neonatal adiposity outcomes 
The associations of maternal glucose with excessive neonatal adiposity 
outcomes are illustrated in Table 5.2, including odds ratios (OR) and 95% 
confidence intervals for each category compared to the lowest category. For 
all three measures of excessive neonatal adiposity, we observed a continuous 
and graded association across increasing levels of maternal glycemia for both 
fasting and 2-hour glucose. For the outcome of LGA in Model I, the OR was 
4.18 for highest category for fasting glucose, and 3.18 for highest 2-hour 
glucose category; there was modest attenuation of the odds ratios with 
adjustment for additional confounders in Model II for both glucose measures. 
For %BF and ∑SFT > 90th centile, the OR for fasting glucose were 
attenuated, but became larger for 2-hour glucose. OR of having LGA and 
∑SFT > 90th centile were elevated within the normal fasting glucose range 
(category 4, 4.8-4.9 mmol/L), and also for the outcome of %BF and ∑SFT > 
90th percentile for normal 2-hour glucose range of 6.1-7.7 mmol/L (categories 
3 and 4). Additionally, we observed significant trends (p < 0.0005) of 
increasing likelihood of having LGA, %BF and ∑SFT > 90th centile with 
fasting glucose levels in six increasing categories; on the contrary, no 
significant trend was observed for likelihood of having excessive adiposity 






Table 5.2: Odds ratios for association between maternal glucose categories and excessive neonatal adiposity 
FPG: Fasting plasma glucose; 2-hr PG: 2-hour plasma glucose; OR: odds ratio 
*Adjusted for variables used in estimating 90th percentiles (gender and gestational age at delivery) 
#
Adjusted for gestational age at delivery, ethnicity, gender, maternal age, parity, maternal education, maternal education*ethnicity and maternal BMI @ 26 weeks pregnancy 
a
 For fasting glucose: Category 1 (< 4.2 mmol/l), Category 2 (4.2-4.4), Category 3 (4.5-4.7), Category 4 (4.8-4.9), Category 5 (5.0-5.2), Category 6 (≥ 5.3).  
b 





%BF > 90th percentile 
 




*Model I OR 
(95% CI)  
#
Model II OR 
(95% CI) 
n 




Model II OR 
(95% CI) 
n 




Model II OR 
(95% CI) 
1 365 ref ref  296 ref  ref  336 ref  ref 
2 323 1.19 (0.68-2.09)  1.24 (0.70-2.21)  251 1.69 (0.63-4.51)  1.61 (0.59-4.37)  292 0.93 (0.51-1.69)  0.89 (0.48-1.68) 
3 205 1.79 (1.01-3.20)  1.68 (0.92-3.06)  159 2.44 (0.89-6.71)  2.28 (0.82-6.39)  180 1.74 (0.96-3.16)  1.66 (0.88-1.60) 
4 80 2.69 (1.33-5.43)  2.50 (1.19-5.25)  58 3.24 (0.91-11.49)  3.15 (0.87-11.48)  68 2.65 (1.26-5.58)  2.74 (1.26-5.96) 
5 47 3.96 (1.80-8.71)  3.49 (1.53-7.98)  37 8.56 (2.68-27.35)  7.14 (2.09-24.38)  41 2.48 (1.00-6.15)  1.80 (0.66-4.96) 












Model II O.R 
(95% CI) 
 n 




Model II O.R 
(95% CI) 
 n 




Model II O.R 
(95% CI) 
1 164 ref  ref  134 ref  ref  154 ref  ref 
2 252 1.80 (0.84-3.86)  1.71 (0.79-3.74)  206 3.91 (0.47-32.90)  4.43 (0.51-38.52)  232 1.97 (0.81-4.77)  2.01 (0.80-5.03) 
3 281 2.03 (0.96-4.27)  1.90 (0.89-4.08)  227 9.20 (1.20-70.49)  11.11(1.40-88.48)  253 2.78 (1.19-6.49)  3.08 (1.28-7.43) 
4 166 2.10 (0.95-4.66)  1.68 (0.74-3.82)  126 9.04 (1.11-73.39)  9.51(1.13-80.30)  148 3.09 (1.26-7.60)  2.70 (1.05-6.97) 
5 120 2.03 (0.87-4.75)  1.76 (0.73-4.26)  86 11.61 (1.40-96.26)  12.00(1.37-105.50)  104 3.57 (1.40-9.09)  3.54 (1.31-9.60) 




0.207  0.484   0.102  0.106   0.026  0.050 
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We also analyzed the relationships between maternal glucose analysed 
as a continuous variable and excessive neonatal adiposity outcomes; each 1 
mmol/L increase in fasting glucose was associated with 1.64 (95% CI 1.20-
2.25), 2.73 (1.64-4.53) and 2.50 (1.68-3.71) increases in odds ratios for LGA 
and %BF and ΣSFT > 90th centile, respectively. Corresponding odds ratios for 
2-hour glucose were 1.07 (0.95-1.19), 1.32 (1.06-1.64) and 1.24 (1.06-1.44), 
respectively (data not shown). For all three measures of excessive neonatal 
adiposity, there were significant associations with both measures of maternal 
glycemia, except for the relationship between 2-hour glucose and LGA. We 
also noted that the strength of association between fasting glucose and 
excessive neonatal adiposity was greater for all three outcomes as compared to 
2-hour glucose. In view of the greater variability in measurement for 2-hour 
glucose, we also analyzed the odds ratios of having excessive adiposity 
outcomes for each measure of glucose higher by 1 standard deviation score 
(SDS). Each 1 SDS increase in fasting glucose was associated with 1.31 (95% 
CI 1.10-1.55), 1.72 (1.31-2.27) and 1.64 (1.32-2.03) increases in odds ratios 
for LGA and %BF and ΣSFT > 90th centile, respectively (Table 5.3). 
Corresponding odds ratios for 2-hour glucose were 1.11 (0.92-1.33), 1.55 
(1.10-2.20) and 1.40 (1.10-1.79), respectively (Table 5.3). Similarly, we noted 
that for all three measures of excessive neonatal adiposity, there were 
significant associations with both measures of maternal glycemia, except for 
the relationship between 2-hour glucose and LGA. Additionally, there were no 





Table 5.3: Relationship between maternal glucose and excessive neonatal 
adiposity 
*Adjusted for gestational age at delivery and gender 
#
Adjusted for gestational age at delivery, ethnicity, gender, maternal age, parity, maternal BMI 
at OGTT, maternal education, maternal education*ethnicity 
+ 
Odds ratios are per 1 SD increase in glucose 
 
5.4.4 Effect of ethnicity on the association between maternal glycemia 
during pregnancy and excessive neonatal adiposity outcomes 
When birth weight, %BF and ∑SFT were modeled as continuous 
variables in multiple linear regression analyses with adjustment for the same 
confounders in model II, mean differences between the higher (categories 2-6) 
and lowest categories (category 1) for both glucose measures ranged between 
0.03-0.18kg for birth weight, 0.17-1.90% for %BF and 0.12-1.58mm for 
∑SFT (p < 0.05 for both glucose measures in all outcomes). Additionally, we 
identified a significant negative interaction [B = -2.65 (95% C.I: -4.49,-0.81), 
p = 0.005] between high fasting glucose levels (category 6) with Indian 
ethnicity (relative to Chinese), in relation to outcome of ∑SFT. Compared to 
Chinese, Indians with high fasting glucose levels (category 6) is associated 
with lesser increase in neonatal ∑SFT. A subgroup analysis amongst women 
of the three ethnic groups with abnormally high glucose levels (i.e. fasting or 






   
Fasting glucose
+ 
1.40 1.18-1.65  1.31  1.10-1.55 
2-hour glucose
+ 1.18 0.99-1.39  1.11 0.92-1.33 
%BF > 90th percentile
 
 
    
Fasting glucose
+ 
1.91 1.46-2.49  1.72  1.31-2.27 
2-hour glucose
+ 
1.66 1.20-2.29  1.55 1.10-2.20 
ΣSFT > 90th percentile 
  
   
Fasting glucose
+ 
1.77 1.44-2.17  1.64 1.32-2.03 
2-hour glucose
+ 
1.45 1.16-1.80  1.40 1.10-1.79 
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2-hour OGTT category ≥ 5) also identified a significant interaction between 
fasting glucose with Indian ethnicity [B = -0.71 (95% C.I: -1.41,-0.02), p = 
0.032] for the outcome of ∑SFT. Compared to Chinese, every SD increase in 
fasting glucose in Indians is associated with lesser increase in neonatal ∑SFT; 
these are demonstrated graphically in Figure 5.2. No significant interactions 
were noted for 2-hour glucose with ethnicity in relation to excessive neonatal 
adiposity outcomes within the same subgroup. 
Figure 5.2: Association between fasting glucose SDS with sum of SFT in relation 
to ethnicity. Open circles (o) represent Chinese, crosses (x) represent Malays and 
triangles (∆) represent Indians. Dark solid line represents Chinese, dotted line 






Interaction term Indians vs. Chinese (ref) 




Our findings in this study have demonstrated a continuous association 
between maternal glycemia and measures of excessive neonatal adiposity. The 
relationship was present for each maternal glucose measurement and persisted 
even when potential confounders such as BMI, age, ethnicity, gestational age 
and socio-economic status were taken into account. Firstly, consistent with 
that of the HAPO study, we observed that maternal glucose measured at a 
single point during pregnancy was effective in identifying excessive neonatal 
adiposity outcomes. Secondly, we noted that the relationship was graded 
across the range of maternal glucose levels. Hence, maternal glycemia appears 
to influence neonatal adiposity not just at high glucose levels, but across the 
normal range of glucose. In our cohort, we noted significant increases in 
excessive adiposity outcomes at glucose levels below those defined as 
hyperglycemia, similar to findings from the HAPO study. 
Interestingly, in our cohort we noted that the trend of graded increases 
in the frequency and likelihood of excessive neonatal adiposity outcomes 
across the range of maternal glucose categories were significant only for 
fasting glucose but not for 2-hour glucose. Significant interactions for fasting 
glucose and Indian ethnicity in relation to ΣSFT > 90th percentile were also 
observed, especially amongst the subgroup of women with abnormally high 
glucose levels. Collectively, our results led us to speculate that fasting glucose 
might have a greater influence on excessive neonatal adiposity outcomes 
compared with post-challenge glucose, and that the influence of raised 
maternal fasting glucose levels on neonatal ∑SFT may be less pronounced for 
Indian mothers compared to Chinese mothers. We observed that amongst all 
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three ethnic groups, Malays formed the significantly smallest proportion 
(10.5%) that received management for gestational diabetes compared to 
Chinese and Indians, who appear to have relatively similar proportions that 
had received management (Chinese 19.3% vs. Indians 22.6%); this suggests 
that glucose management may not have confounded the ethnic difference 
between Indians and Chinese in the relationship between maternal glycemia 
and excessive neonatal adiposity outcomes that was observed in our study. 
The observed effect of ethnicity on the relationship between maternal 
glycemia and excessive neonatal adiposity may also imply the possibility of 
having different glucose management thresholds according to ethnicity. 
There have been documented reports of fasting glucose better 
identifying the risk of macrosomia or excessive adiposity outcomes, as 
highlighted in recent studies by Ben Haroush et al(197) and Disse et al(198). 
In our study, though the variability in measurement for 2-hour glucose was 
larger, the strength of association between maternal glycemia with excessive 
adiposity outcomes was slightly greater for fasting glucose as compared to 2-
hour glucose, when considered as SDS.  Fasting glucose SDS was also 
significantly associated with all three measures of excessive neonatal 
adiposity; 2-hour glucose however showed no significant relationship with 
LGA. As such, our findings may highlight that fluxes of maternal glucose 
during the fasting state may have a slightly greater influence on excessive 
adiposity outcomes; nonetheless, our findings still illustrate that the dose-
response effect of maternal glycemia on excessive neonatal adiposity is 
continuous across all glucose levels. 
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The classic Pedersen's hypothesis postulated that maternal 
hyperglycemia transmitted to the fetus would result in fetal hyperinsulinemia, 
which in turn can attribute to increased fetal fat accretion(199, 200). His 
findings however, were based on women with type-1 diabetes; over the years, 
there have been increases in the occurrences of GDM and type-2 
diabetes(201). The underlying physiology of type-1 diabetes and type-2 
diabetes/GDM are fundamentally different and as such, the metabolic 
environment that the developing fetus is exposed to would be different(202). 
Thus, the finding of a continuous association between maternal glycemia and 
neonatal adiposity provides us with a better understanding of the influence of 
maternal glycemia, with the effect not only restricted to maternal 
hyperglycemia, but extending throughout the range of glycemia. Other than 
the recent HAPO study, there are few published studies relating maternal 
metabolic factors with neonatal body composition. Past studies that have 
identified relationships between birth size and later adiposity are also based 
primarily on birthweight without any information regarding adiposity at 
birth(189). Thus, our study provides useful, informative data on the 
relationship between maternal glycemia and neonatal body composition in a 
multi-ethnic cohort independent from the HAPO study, and the consistency in 
the findings from both cohorts confirm the link between maternal glycemia 
and neonatal adiposity.  
Our study has some limitations; glucose data was collected only at 
fasting and 2-hour post-challenge, but not at 1-hour post-challenge. Data on 1-
hour glucose would have allowed us to better address the role of maternal 
glycemia with neonatal adiposity. Also, %BF was not measured directly, but 
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estimated using an equation based on the infant's gender, gestational age, 
weight and subscapular SFT, as described in Chapter 4. SFT is an indirect 
measure of adiposity; however the formula has been validated by infant body 
composition measurements with PEA POD. 
In conclusion, our study involving an Asian population revealed a 
continuous dose-response relationship between maternal glycemia and 
neonatal adiposity which extends across the entire range of glycemia. The 
consistency of our findings with the HAPO study also confirms the link 
between maternal glycemia and neonatal adiposity. It remains to be seen 
however, if the observed association between maternal metabolic factors and 
neonatal body composition has long-term repercussions on the increasing 













Chapter 6: Effect of maternal gestational glycemia and adiposity on early 
postnatal growth of offspring in the first three years of life 
6.1 Summary 
Background: Gestational hyperglycemia increases the risk of obesity and 
diabetes in offspring later in life. We examined the relationship between 
gestational glycemia and body mass index (BMI) on early postnatal growth of 
offspring in a multi-ethnic Asian birth cohort. 
Methods: Pregnant mothers took 75g 2-hour oral glucose tolerance tests at 
26-28 weeks gestation. In 1152 naturally-conceived singleton offspring, 
measurements included weight and length at birth, 3 weeks, and 
3,6,9,12,15,18,24 and 36 months of age, and multivariable linear regression 
analysis was used to estimate the associations between gestational glycemia 
and BMI on offspring growth. 
Results: Maternal fasting plasma glucose (FPG) was positively associated 
with birthweight [B(95%CI)=0.12(0.06,0.18)], birth BMI [0.19(0.13,0.25)], as 
well as length at 3 weeks [0.14(0.08,0.17)], but not from 3 months. 2-hour 
post-challenge glucose had little impact. Maternal BMI at 26-28 weeks 
gestation was positively associated with offspring weight and BMI throughout 
the first three years of life. Offspring born to mothers with higher FPG showed 
significant weight deceleration [B(95%C.I)=-0.23(-0.42,-0.04)] early in life (3 
weeks-3 months), followed by statistically significant accelerated weight and 
BMI gain at 9-15 months. The effect of raised FPG on birth size was greater in 
obese women. The effect of raised maternal FPG on higher offspring weight, 
BMI and overweight status was significant for non-obese, multiparous and 
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Chinese women only at two-years of age (interaction p<0.05 for all), but not 
anymore at three years.  The relationship between child overweight status and 
increasing maternal FPG in obese pregnant mothers has an unexpected pattern, 
where the risk of offspring being overweight is highest in those born to 
mothers who are obese and in the lowest fasting glucose category.  
Conclusions: FPG is associated with growth deceleration over a short period 
after birth independent of maternal BMI, followed by transient growth 
acceleration between 9-15 months. The impact of maternal adiposity persists 
from birth into early childhood. Maternal obesity, ethnicity, and parity may 
confer different susceptibility to greater adiposity in response to maternal 
glycemia only at two years of age. Pregnancy fasting glycemia and obesity in 
tandem continues to exert an effect on risk of childhood overweight status at 
three years.   
6.2 Introduction 
 Obesity and type 2 diabetes present massive health challenges as they 
rapidly become a worldwide epidemic(1), hence understanding the 
pathogenesis is important in order to formulate treatment and prevention 
strategies.  Developmental influence on obesity risk originating from the 
maternal intrauterine environment has been put forth as one of the 
mechanisms which confer susceptibility to excessive adiposity(203). One of 
the earliest evidence of developmental plasticity conferring obesity 
susceptibility came from the Dutch famine study, which studied the offspring 
of women who conceived during the Dutch famine of 1944, when an embargo 
was placed on all food supplies to the Netherlands(3, 4). Studies have 
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documented that maternal obesity and hyperglycemia during pregnancy are 
associated with higher birth weight of offspring, and carried with it an 
inherently greater risk of diabetes and obesity in later life(204-207). There is 
also evidence that early postnatal growth pattern predicts subsequent adiposity 
and obesity risk in childhood, as demonstrated by the 
Quebec Longitudinal Study of Child Development (208) and the Fels 
Longitudinal Study (209), which highlighted that offspring with the highest 
quintiles of weight gain during early life had increased odds of 
being overweight at later ages.  
It is believed that excessive exposure to increased glucose from the 
mother may contribute to excessive weight gain of offspring born to diabetic 
mothers(210). The influence of maternal glycemia during pregnancy on early 
postnatal growth has been described(80, 211), but can still be better defined, 
especially for the impact on postnatal growth pattern across the range of 
glucose levels, even for those that are below the diagnostic cutoff for 
gestational diabetes (GDM) (fasting glucose > 7.0 mmol/L or 2h glucose > 7.8 
mmol/L)(120). In addition, studies on maternal glycemia during pregnancy 
influencing early postnatal growth in Asian populations are scarce, and since 
the Asian phenotype and susceptibility towards obesity and metabolic disease 
differs from that of Caucasians(115), further studies on the impact of maternal 
glycemia during pregnancy on offspring growth in Asian populations is 
merited. Thus in this study, we sought to examine the impact of maternal 
glycemia and body mass index (BMI) on birth measures and postnatal growth 
of offspring, and hypothesized that higher maternal glucose and adiposity 
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during pregnancy leads to increased adiposity and postnatal growth in the first 
three years of life. 
6.3 Materials and Methods 
6.3.1. Study population and assessment of gestational age 
 Details on the study population and assessment of gestational age have 
been described in Section 2.1 and Section 2.3.1.3. 
6.3.2 Oral glucose tolerance testing and anthropometry measurements 
 Details regarding oral glucose tolerance testing and measurement of 
anthropometry in the first three years of life have been described in Section 
2.3.1.2 and Section 2.3.2.1.  
6.3.3 Statistical analysis 
Descriptive statistics were reported as means and standard deviations 
for continuous variables and percents for categorical variables. Fasting plasma 
glucose (FPG) and 2-hour post-challenge glucose (2h-PG) measurements were 
divided into quartiles For FPG: 1st quartile (< 4.1mmol/l), 2
nd
 quartile (4.1 - < 
4.3), 3
rd
 quartile (4.3 - < 4.6), 4
th
 quartile (≥ 4.6). For 2h-PG: 1st quartile (< 
5.5mmol/l), 2
nd
 quartile (5.5 - < 6.3), 3
rd
 quartile (6.3 - < 7.3), 4
th
 quartile (≥ 
7.3). Age- and gender-specific standard deviation scores (SDS) were 
calculated for weight, length and body mass index (BMI) for infants at all 
timepoints, referencing WHO Child Growth Standards(212). SDS was also 
produced for maternal glucose and BMI at 26-28 weeks gestation.  
One-way analysis of variance (ANOVA) was used to assess the 
differences in child growth measures at each time point between the glucose 
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categories. Multiple linear regression analyses were used to estimate the 
association between maternal glucose level and offspring weight, length and 
BMI at birth to two years using SDS to enable comparison both between 
variables and across time points, in all cases adjusting for ethnicity, parity, 
maternal age, maternal education, maternal BMI at 26-28 weeks gestation, 
maternal height and breastfeeding duration. In view of mothers who received 
treatment for hyperglycemia, we additionally corrected for potential 
confounding by glucose management in the regression models. Potential effect 
modifications by ethnicity, parity and pregnancy obesity (BMI ≥ 30 kg m-2) 
were also investigated, by adding the interaction term of maternal glucose with 
ethnicity/obesity/parity to the fully adjusted model.  
Conditional growth models for weight, length and BMI SDS were built 
using linear regression analysis(213). Here, weight SDS is used as an 
example: conditional growth in weight SDS from birth to 3 weeks is 
equivalent to the standardised residuals resulting from the linear regression 
model of weight SDS at 3 weeks on weight SDS at birth. Accordingly, the 
conditional growth in weight SDS from 3 weeks to 3 months is given as the 
standardised residuals obtained from regressing weight SDS at 3 months on 
weight SDS at 3 weeks and at birth simultaneously. This process is continued 
for each subsequent time point, resulting in measures of growth that are 
uncorrelated. All analysis was performed using SPSS version 20.0 (IBM, 






6.4.1 Demographics and clinical characteristics 
 Characteristics of the study participants were described in Table 6.1. 
55.2% of the study participants were Chinese, 27.0% Malay and 17.8% Indian. 
Chinese mothers in our cohort tended to be slightly older (mean age = 31.4 
years), and more educated (68% of them had at least 12 years of education). 
More Chinese mothers also breastfed their offspring for more than 4 months 
(27.8%) compared with other ethnicities. The mean maternal BMI at the time 
of OGTT was 26.1 kg m
-2
 and mean glucose levels for the participants were 
4.4 mmol/L and 6.5 mmol/L for FPG and 2h-PG respectively. Mean 
gestational age at delivery was 38.3 weeks and the mean offspring birth 
weight, length and BMI were 3.09kg, 48.6cm and 13.0 kg m
-2
, respectively.  
Table 6.1: Demographics and clinical characteristics of study subjects 
Mothers 
Chinese 
N = 561 
Malay 
N = 274 
Indian 
N = 181 
Total 
N = 1016 
P 
value# 
Age (yr)  31.4 ± 5.0 28.9 ± 5.4 29.8 ± 4.7 30.4 ± 5.2 <0.001 
Marital Status (%)      0.225 
 Married  96.4 95.1 98.3 96.4  
 Single 3.6 4.9 1.7 3.6  
No. of years of education(%)     <0.001 
 < 12 years 31.4 70.3 31.6 41.9  
 ≥ 12 years 68.6 29.7 68.4 58.1  
Type of housing (%)      <0.001 
 Government  88.7 99.3 91.5 92.0  
 Private 11.3 0.7 8.5 8.0  
Breastfeeding Duration (%)     <0.001 
 Formula only 14.5 21.3 14.5 16.3  
 Less than 4 months 57.7 68.6 63.5 61.6  
 More than 4 months 27.8 10.0 22.0 22.1  
Parity (%)     0.010 
 Primiparious 52.5 59.7 64.2 56.5  
 Multiparous 47.5 40.3 35.8 43.5  
Body Mass Index (kg/m2 )  24.9 ± 3.4 28.0 ± 5.4 27.2 ± 4.5 26.1 ± 4.5 <0.001 
Plasma Glucose (mmol/l)       
 Fasting  4.3 ± 0.4 4.3 ± 0.5 4.5 ± 0.5 4.4 ± 0.5 0.003 
 2-hr  6.6 ± 1.4 6.2 ± 1.4 6.5 ± 1.5 6.5 ± 1.4 0.001 
Received glucose management (%)     0.001 
 No  79.9 89.8 77.9 82.2  
 Yes 20.1 10.2 22.1 17.8  
Gestational Age at time of OGTT 26.8 ± 1.1 26.1 ± 1.2 26.8 ± 1.3 26.8 ± 1.2 0.248 
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Table 6.1(continued): Demographics and clinical characteristics of study 
subjects 
#






N = 561 
Malay 
N = 274 
Indian 
N = 181 
Total 
N = 1016 
P 
value# 
Gestational Age (weeks)  38.4 ± 1.5 38.2 ± 1.3 38.2 ± 1.5 38.3 ± 1.5 0.127 
Gender (%)     0.664 
 Male 52.0 55.2 52.0 52.8  
Weight (kg)      
 Birth (n=1005) 3.1 ± 0.4 3.1 ± 0.4 3.0 ± 0.5 3.1 ± 0.4 0.158 
 Week 3 (n=904) 4.0 ± 0.5 3.9 ± 0.5 3.8 ± 0.5 3.9 ± 0.5 <0.001 
 Month 3 (n=889) 6.3 ± 0.8 6.0 ± 0.8 5.8 ± 0.7 6.1 ± 0.8 <0.001 
 Month 6 (n=847) 7.8 ± 0.9 7.7 ± 0.9 7.5 ± 0.9 7.7 ± 0.9 0.021 
 Month 9 (n=808) 8.6 ± 1.0 8.6 ± 1.0 8.7 ± 1.0 8.6 ± 1.0 0.698 
 Month 12 (n=829) 9.4 ± 1.1 9.3 ± 1.1 9.5 ± 1.2 9.4 ± 1.1 0.138 
 Month 15 (n=835) 10.0 ± 1.1 10.0 ± 1.2 10.3 ± 1.3 10.1 ± 1.2 0.020 
 Month 18 (n=797) 10.7 ± 1.3 10.7 ± 1.4 11.1 ± 1.5 10.7 ± 1.3 0.002 
 Month 24 (n=803) 11.9 ± 1.5 12.0 ± 1.6 12.2 ± 1.7 12.0 ± 1.6 0.121 
 Month 36 (n=810) 14.1 ± 1.8 14.3 ± 2.3 14.6 ± 2.5 14.2 ± 2.1 0.024 
Length (cm)      
 Birth (n=1002) 48.8 ± 2.3 48.2 ± 2.0 48.7 ± 2.2 48.6 ± 2.2 0.009 
 Week 3 (n=902) 53.2 ± 2.2  52.2 ± 2.0 52.7 ± 2.0 52.9 ± 2.2 <0.001 
 Month 3 (n=889) 61.4 ± 2.5 60.0 ± 2.4 61.0 ± 2.2 60.9 ± 2.5 <0.001 
 Month 6 (n=851) 67.4 ± 2.7 66.1 ± 2.7 67.4 ± 2.5 67.1 ± 2.7 <0.001 
 Month 9 (n=809) 71.9 ± 3.0 70.6 ± 2.8 72.1 ± 2.5 71.6 ± 2.9 <0.001 
 Month 12 (n=830) 75.7 ± 3.1 74.1 ± 2.9 76.3 ± 2.8 75.4 ± 3.1 <0.001 
 Month 15 (n=828) 79.1 ± 3.2 77.4 ± 3.0 80.1 ± 3.0 78.8 ± 3.2 <0.001 
 Month 18 (n=694) 82.2 ± 3.4 81.1 ± 3.1 83.3 ± 3.4 82.1 ± 3.4 <0.001 
 Month 24 (n=708) 87.9 ± 3.7 86.3 ± 3.1 88.5 ± 3.7 87.6 ± 3.6 <0.001 
 Month 36 (n=804) 94.9 ± 3.8 93.5 ± 3.6 96.2 ± 3.8 94.8 ± 3.9 <0.001 
BMI (kg/m
2
)      
 Birth (n=1002) 13.0 ± 1.3 13.3 ± 1.3 12.8 ± 1.3 13.0 ± 1.3 <0.001 
 Week 3 (n=901) 13.9 ± 1.2 14.2 ± 1.2 13.5 ± 1.3 13.9 ± 1.3 <0.001 
 Month 3 (n=889) 16.7 ± 1.5 16.7 ± 1.6 15.7 ± 1.4 16.5 ± 1.6 <0.001 
 Month 6 (n=847) 17.1 ± 1.6 17.6 ± 1.8 16.6 ± 1.5 17.1 ± 1.7 <0.001 
 Month 9 (n=808)  16.6 ± 1.4 17.2 ± 1.5 16.6 ± 1.5 16.8 ± 1.5 <0.001 
 Month 12 (n=827) 16.3 ± 1.3 16.9 ± 1.5 16.3 ± 1.5 16.4 ± 1.4 <0.001 
 Month 15 (n=828) 16.0 ± 1.3 16.6 ± 1.6 16.0 ± 1.5 16.2 ± 1.4 <0.001 
 Month 18 (n=692) 15.8 ± 1.3 16.1 ± 1.5 15.9 ± 1.5 15.9 ± 1.4 0.032 
 Month 24 (n=708) 15.4 ± 1.3 15.9 ± 1.5 15.5 ± 1.5 15.5 ± 1.4 <0.001 
 Month 36 (n=804) 15.6 ± 1.3 16.2 ± 1.8 15.7 ± 1.8 15.7 ± 1.6 <0.001 
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6.4.2 Relationship of birth and early infant anthropometry with maternal 
glycemia and adiposity 
Table 6.2 describes the association of maternal glycemia with offspring 
weight, length and BMI in the first three years of life. Maternal FPG SDS had 
significant positive associations with weight SDS [B(95%CI) = 
0.12(0.06,0.18), p < 0.001)] and BMI SDS [B(95%CI) = 0.19 (0.13,0.25), p < 
0.001)] at birth, and length SDS at 3 weeks of age conditional upon birth 
length SDS [B(95%CI) = 0.14(0.08,0.20), p <0.001], but no significant 
associations were observed from months 3 to 36, after adjusting for potential 
confounders. Maternal 2h-PG SDS also showed significant positive 
associations with infant weight SDS at birth only [B(95%CI) = 
0.07(0.001,0.08), p = 0.03] (data not shown); no significant associations were 
observed between 2h-PG SDS and offspring’s weight and BMI SDS from 
week 3 to month 36. Maternal BMI SDS showed significant association with 
infant weight at birth [B(95%CI) = 0.16 (0.10,0.22), p <0.001], and at 18, 24 
and 36 months conditional upon birth weight SDS. Maternal BMI SDS also 
showed significant positive association with infant BMI SDS at birth, and at 9 
to 36 months of life conditional upon BMI SDS at birth (Table 6.2), indicating 
that maternal BMI at 26-28 weeks of pregnancy is a strong correlate of 








Table 6.2: Regression analysis with offspring weight, length and BMI SDS as the response variables, and maternal FPG SDS & maternal pregnancy 
BMI SDS, as the explanatory variables 
 
Variables also in model but not shown are gestational age, parity, ethnicity, maternal education, breastfeeding duration, glucose management, maternal height and maternal 
age 
+
SDS values for weight, length and BMI at week 3 – month 36 are conditional upon SDS values at birth 
a
 B = beta coefficient; 95%CI = 95% confidence intervals 
FPG = Fasting plasma glucose; BMI = Body Mass Index 






























+  Month 36
+ 
B (95%CI)
a B (95%CI)a B (95%CI)a B(95%CI)a B(95%CI)a B(95%CI)a B(95%CI)a B(95%CI)a B(95%CI)a  B(95%CI)a 































































































































































































6.4.3 Relationship of infant conditional growth with maternal glycemia 
 
Table 6.3 highlights the conditional gain in weight, length and BMI 
SDS of offspring during the first three years of life, according to FPG 
quartiles. Offspring born to mothers in highest FPG quartile showed 
significantly lower conditional gain in weight SDS between 3 weeks to 3 
months of life [B(95%C.I)= -0.23(-0.42,-0.04)], but higher conditional gain in 
length SDS at 0-3 weeks of life [B(95%C.I) = 0.28(0.10,0.47)], BMI SDS at 
9-15 months of life [B(95%C.I)= 0.23(0.01,0.46)] compared to those in the 
lowest FPG quartile. Offspring born to mothers in the second highest or 3
rd
 
FPG quartile also showed significantly higher conditional gain in weight SDS 
[B(95%C.I)= 0.26(0.05,0.48)] and BMI SDS [B(95%C.I)= 0.26(0.05,0.47)] at 
9-15 months of life, compared to those in the lowest FPG quartile. Offspring 
born to mothers in 2
nd
 FPG quartile demonstrated decelerated length gain at 9-
15 months of life [B(95%CI) =-0.33(-0.55,-0.11)] and accelerated gain in BMI 
SDS [B(S.E) = 0.23(0.005,0.45)] compared to those in the lowest FPG 
quartile. For 2h-PG, the pattern of conditional weight SDS growth for 
offspring born to mothers in the highest 2h-PG quartile in the first three 
months of life showed no significant differences when compared with the 
lowest 2h-PG quartile. Offspring born to mothers in the second highest or 3
rd
 
2h-PG quartile showed significantly higher conditional gain in weight SDS at 
15-24 months of life [B(95%CI)=0.32(0.09,0.56)], compared to compared to 
those in the lowest 2h-PG quartile. No significant changes were observed at 
other time periods across all 2h-PG quartiles, and a similar observation was 




Table 6.3: Conditional growth of offspring weight, length and BMI SDS at 0-3 weeks, 3weeks to 3 months, 3-9, 9-15, 15-24 and 24-36 
months as the response variables and maternal FPG categories as the explanatory variable 
*,# Adjusted for parity, ethnicity, maternal education, glucose management, maternal age, maternal BMI SDS at 26-28 week gestation, maternal height and breastfeeding duration 
+ Adjusted for parity, ethnicity, maternal education, glucose management, maternal age, maternal BMI SDS at 26-28 week gestation and breastfeeding duration 
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 Table 6.4: Conditional growth of offspring weight, length and BMI SDS at 0-3 weeks, 3weeks to 3 months, 3-9, 9-15, 15-24 and 24-36 
months as the response variables and maternal 2h-PG categories as the explanatory variable. 
*,# Adjusted for parity, ethnicity, maternal education, glucose management, maternal age, maternal BMI SDS at 26-28 week gestation, maternal height and breastfeeding duration 
+ Adjusted for parity, ethnicity, maternal education, glucose management, maternal age, maternal BMI SDS at 26-28 week gestation and breastfeeding duration 
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The relationships between maternal glycemia with offspring weight, 
length and BMI were also highlighted graphically by subdividing the offspring 
according to FPG quartiles (Figures 6.1 A-C). We noted that offspring born to 
mothers of highest FPG quartile have significantly higher weight SDS at birth 
(Fig. 6.1A), higher length SDS at week 3 (Fig. 6.1B) and higher BMI SDS at 
birth (Fig. 6.1C), compared to infants born to mothers of lowest FPG quartile.  
Figure 6.1: Offspring weight SDS (A), length SDS (B) and BMI SDS (C) 
trajectory in the first 3 years of life, shown according to categories of maternal 













































Data are shown as mean SDS ± 1 S.E, corrected for gender (at all timepoints), 
gestation (birth only), and postnatal age. Differences between categories were 
assessed at each time point using ANOVA. For fasting glucose: 1st quartile (< 
4.1mmol/l), 2nd quartile (4.1 - <4.3), 3rd quartile (4.3 - <4.6), 4th quartile (≥ 4.6). 
**p<0.01 for 4th quartile compared with 1st quartile, *p<0.05 for 4th quartile 







6.4.4 Effect of maternal obesity status, parity and ethnicity on 
relationship between maternal glycemia with early infant anthropometry 
and overweight status 
We noted that the interaction between pregnancy obesity and maternal 
FPG SDS was significant only at birth for the outcome of weight SDS [β(S.E) 
= 0.19(0.07), p = 0.007] and length SDS [β(S.E) = 0.16(0.07), p = 0.024], and 
for the outcome of BMI SDS only at two years of age conditional upon birth 
[β(S.E) = -0.23(0.09), p = 0.010]. This implies that offspring of obese mothers 
with higher maternal FPG SDS have larger birth size and yet have lower BMI 
at two years of age, as compared to offspring of non-obese mothers of 
similarly elevated FPG. Parity and ethnicity (Malay compared with Chinese) 
were also observed to have significant interactions with FPG SDS on the 
outcome of BMI SDS only at two years of age conditional upon birth [β(S.E) 
= 0.20(0.08), p = 0.014 for parity; β(S.E) = -0.25(0.09), p = 0.007 for 
ethnicity]. As illustrated in Table 6.5, upon stratifying by ethnicity, obesity and 
parity, the effect of increased maternal FPG SDS on higher offspring BMI 
SDS at two years of age was observed to be significant amongst Chinese 
[β(S.E) = 0.15(0.06), p = 0.016], non-obese [β(S.E) = 0.11 (0.05), p = 0.026] 
and multiparous women [β(S.E) = 0.12(0.06), p = 0.036]. No significant 
interactions were observed for 2h-PG with maternal obesity, ethnicity and 
parity. No significant interactions were also observed for maternal FPG with 
maternal obesity, ethnicity and parity for the outcome of weight and BMI SDS 
at three years of age. 
Furthermore, we noted that ethnicity and maternal obesity showed 
significant interactions with maternal FPG SDS on the outcome of overweight 
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status at two-years of age only. Chinese infants with higher maternal FPG had 
increased odds of being overweight at two-years of age [OR(95% CI): 
3.70(1.49-9.20)] compared to Malay infants. Similarly, offspring of non-obese 
mothers with higher maternal FPG SDS were more likely to be overweight at 
two years of age [OR(95% CI): 3.19(1.27-7.97)] compared to offspring of 
obese mothers. The effect of maternal obesity on the relationship between 
maternal FPG and overweight status is further illustrated in Figures 6.2A-B. 
The association of increasing maternal FPG with higher proportion of 
offspring overweight is present only amongst non-obese women but only at 
two years, and disappears at three years. In obese mothers, the relationship 
between increasing maternal FPG and child overweight status is a reverse tick 
pattern, and unexpectedly the risk of child being overweight is highest in those 
born to mothers who are obese and in the lowest fasting glucose category. 
 
Table 6.5: Effect of maternal FPG SDS at 26-28 weeks gestation on BMI 
SDS at 2-years of age conditional upon birth BMI, stratified by ethnicity, 
parity and maternal obesity 
 
Maternal FPG SDS and BMI SDS at 2-yr conditional upon birth 
  
β S.E p value 




   
0.007 
 
Chinese 0.15 0.06 0.016 
 
 
Malay  -0.10 0.08 0.235 
 
 
Indian 0.02 0.11 0.825 
 
Parity 
   
0.014 
 
Primiparous -0.11 0.07 0.11 
 
 
Multiparous 0.12 0.06 0.036 
 
Maternal Obesity 
   
0.010 
 
Non-obese 0.11 0.05 0.026 
 
 
Obese -0.18 0.09 0.05 
 
FPG: Fasting plasma glucose, S.E: Standard error 
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Figure 6.2: Association between offspring overweight status at two- (A) 
























 This study on maternal gestational glycemia in a multi-ethnic Asian 
population showed the effect of maternal glycemia on fetal growth, which 
persisted for only a relatively short period postnatally after birth. Firstly, 
consistent with earlier studies done by Scholl et al(214) and Catalano et 
al(215), we showed that maternal FPG was associated with anthropometric 
parameters at birth, including weight and BMI, and this observed effect is 
most pronounced amongst mothers with higher FPG. In contrast, 2h-PG has 
little impact on postnatal growth, except at birth. Secondly, we also 
demonstrated that the association of maternal glycemia on postnatal weight 
and BMI showed no demonstrable difference by three months of age, in line 
with the findings of previous studies(79, 216). Thirdly, we have shown that 
offspring of mothers with higher FPG have a markedly different pattern of 
growth from their peers in early life. Whilst they have higher age-adjusted 
weight SDS at 3 weeks, there was a period of significant downward centile 
crossing for weight, but not length and BMI, between 3 weeks to 3 months 
after birth, followed by accelerated weight and BMI gain between 9-15 
months of life when compared to those in the lowest FPG quartile. The 
novelty of this study is that we demonstrated the period of decelerated growth 
actually occurs over a shorter period earlier in life, which is possible due to the 
multiple follow-up anthropometric measurements at close 3-monthly intervals 
over the first three years of life, allowing us to demonstrate that the effect of 
maternal glycemia with greater granularity on postnatal weight, which persists 
up till the first 3 weeks of life only. 
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Our data are in line with a recent study by Crume et al(81), which 
highlighted that the growth of offspring exposed to diabetes in-utero 
demonstrated a slower rate of BMI gain [β(S.E) = -0.51(0.33)] over the first 
nine months of life, followed by a period of faster rate of BMI gain between 9-
12 months, compared to offspring of non-diabetic pregnancies. A recent study 
by Liu et al also reported similar periods of rapid growth between 9-12 months 
of age amongst offspring of GDM mothers(217). We did note that increasing 
quartiles of maternal glycemia during pregnancy showed no significant 
associations with weight SDS, BMI SDS and overweight status at two- and 
three-years of age. However, earlier studies have documented the age-
associated disappearance of the association between increasing maternal 
glycemia with higher child weight status at early ages, and its re-emergence at 
only at school-going age(22, 218, 219). Hence it is plausible that the observed 
accelerated weight and BMI gain between 9-15 months amongst offspring of 
mothers with high FPG might reflect the start of subsequent higher BMI 
beyond three years of age.   
 Our data also reaffirmed the association between maternal BMI during 
pregnancy with the offspring’s weight and BMI, which persisted throughout 
the first three years of life, but no persistent association with length was 
documented. These findings, which included adjustment of maternal height, 
are in keeping with the work of Knight et al(79), who documented that the 
increase in offspring weight with maternal BMI persisted in the first two years 
of life and reflected an increase in BMI and not length. Our results are 
suggestive that maternal BMI during pregnancy has a greater influence on the 
childhood adiposity, and supports maternal adiposity as a strong determinant 
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of childhood growth compared to maternal glycemia in Asian mothers and 
offspring. 
 Interestingly, we noted in our cohort statistically significant interaction 
between maternal obesity with FPG for the outcome of size-at-birth, which 
implied that the combination of maternal obesity with raised glucose levels 
had greater influence on birth size than either factor acting alone. This finding 
is consistent with a recent study by Catalano et al(220), who documented that 
combination of gestational diabetes (GDM) with maternal obesity had far 
greater impact on neonatal size and adiposity than just GDM or maternal 
obesity alone. We also noted that the positive association of maternal FPG on 
BMI and overweight status at two-years of age was more pronounced for 
offspring of non-obese women. Similar findings were reported by Ehrlich et al 
on a cohort of Mexican-American women, where associations between 
increased levels of pregnancy plasma glucose with increased offspring BMI z-
scores from 2-7 years of age were observed amongst non-obese women(221). 
It is plausible that the effects of maternal glycemia during pregnancy would be 
easier to detect in offspring of non-obese women, who are unexposed to 
excessive fuel substrates arising from maternal obesity. It is also interesting to 
note in this study that in obese women, the proportion of overweight children 
was highest for those in the lowest FPG quartile. We postulate that these obese 
women may exhibit compensatory hyperinsulinemia, as illustrated by 
Polonsky K who showed that insulin secretion rates were substantially higher 
in obese compared to normal weight subjects(222). There is evidence 
suggesting that relative hyperinsulinemia from mothers might predispose 
offspring to childhood obesity(223), which may explain the observation of 
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highest proportion of overweight children amongst obese mothers in the 
lowest FPG quartile.  
We also noted that the positive association of maternal FPG on 
postnatal BMI at two years of age was present only amongst offspring of 
Chinese and multiparous women. Whilst the mechanism for this ethnicity-
associated relationship between raised maternal glycemia and increased 
offspring weight status is unknown, we have previously shown in Chapter 5 
that influence of raised maternal FPG on neonatal adiposity (as measured by 
ΣSFT) was more pronounced for Chinese mothers, indicating the possibility 
that this observation might extend into the postnatal period and later life. A 
recent study by Peters et al also highlighted that the effect of maternal 
glycemia on infant weight at two-years was found only amongst multiparous 
women, although the reported effect was small and in the negative direction 
(i.e. higher blood glucose levels were associated with lower weight at two-
years). It is important to note that their observations were unadjusted 
correlations, which may have explained the inconsistency with our findings. 
Our findings have also been corrected for glucose management, highlighting 
that it may not have confounded our observations.  
 The prospective design of our cohort presents a clear strength in our 
study, as it is crucial for examining the effect of any in-utero exposure on the 
outcome of postnatal growth. To date, there are few published studies relating 
maternal metabolic factors with early postnatal growth in a multi-ethnic Asian 
cohort; thus our study provides useful, informative data on this relationship. 
Another strength of our study is the analysis of the growth data in a 
conditional manner. This method of analysis is important in growth, where 
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anthropometric measures are often related to the previous measures at earlier 
timepoints. The conditional SDS of growth are mutually uncorrelated, hence 
allowing the effects of growth to be distinguished from any statistical artifact 
attributable to regression to the mean. There are however, limitations to 
consider; glucose data was collected only at fasting and 2-hour post-challenge, 
but not at 1-hour post-challenge. Data on 1-hour glucose would have allowed 
us to better address the role of maternal glycemia with postnatal growth. This 
study also lacked measures of plasma insulin, insulin growth factor (IGFs), 
ghrelin, leptin and adiponectin, which would have been useful to 
mechanistically explain the observed associations between gestational 
glycemia with offspring weight and BMI. 
 In conclusion, we have demonstrated the association of maternal 
glycemia on postnatal growth as seen in our cohort is mainly limited to the 
first 3 weeks to 3 months (of the first three years of life) followed by transient 
growth acceleration between 9-15 months, with the exception for a subgroup 
of children born to non-obese, multiparous Chinese mothers only at two years 
of age, as compared to the association of maternal BMI on offspring weight 
and BMI, which persists into early childhood. It remains to be seen if our 
observation of maternal glycemia and postnatal growth have independent 
long-term effects on increasing the risk of subsequent obesity and impaired 





Chapter 7: Effect of infant milk feeding on early postnatal growth of 
offspring exposed to gestational diabetes in-utero 
7.1 Summary 
Background: Infants on prolonged breastfeeding are known to grow slower 
during the first year of life. It is still unclear if such effects are similar in 
offspring exposed to gestational diabetes (GDM) in-utero. We examined the 
effect of infant milk feeding on postnatal growth in the first three years of life 
amongst offspring exposed and unexposed to GDM. 
Methods: In a prospective mother-offspring birth cohort, pregnant mothers 
took 75g 2-hour oral glucose tolerance tests at 26-28 weeks gestation. In 1152 
singleton offspring, measurements included weight and length at birth, 3 
weeks, and 3,6,9,12,15,18,24 and 36 months of age. Interviewer-administered 
questionnaires were used to ascertain the duration of breastfeeding. 
Conditional standard deviation score (SDS) growth models were used to 
assess the effect of breastmilk intake on early postnatal growth stratified by 
GDM status.  
Results: Correcting for potential confounders, in offspring of mothers without 
GDM, greater breastmilk intake (≥ 4 milk-months) was associated with lower 
conditional weight [B(95%CI): -0.31(-0.49,-0.13)], length [-0.22(-0.40,-0.04)] 
and BMI [-0.22(-0.40,-0.04)] SDS gains in the first year of life. In contrast, in 
offspring of mothers with GDM, greater breastmilk intake was associated with 
greater conditional weight [0.45(0.07,0.83)] and BMI SDS gains 
[0.46(0.08,0.84)] during the first six months of life.  
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Conclusions: Infants of GDM mothers who had reduced breastmilk and more 
formula milk intake did not exhibit accelerated adiposity gain. 
 
7.2 Introduction 
 The gestational and early postnatal periods have been identified as 
critical windows for risk of metabolic disorders later in life. Developmental 
influence on metabolic disease risk originating from the maternal intrauterine 
environment has been put forth as one of the mechanisms which confer 
susceptibility to excessive adiposity(203). Recent studies, including our 
findings as described in Chapter 5, have established that maternal 
hyperglycemia during pregnancy is associated with increased birth size and 
excessive neonatal adiposity(73, 74), and it is believed that prenatal exposure 
to increased fuel from the mother, namely glucose, may contribute to 
excessive weight gain of offspring born to diabetic mothers(210), thereby 
increasing the risk of overweight and obesity during childhood and 
adolescence(218).  
 In addition, infant nutrition during the early postnatal period has been 
identified as a critical window for later obesity risk(224). Many studies have 
extensively looked at the relationship between breastfeeding and long-term 
obesity risk, highlighting that periods of long and exclusive breastfeeding may 
have a protective effect on development of obesity later in life(225-228). 
Thus, breastfeeding has been recommended as a plausible solution to protect 
the offspring from the consequences of exposure to an adverse intrauterine 
environment, such as maternal diabetes(229, 230). Unfortunately, our current 
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understanding on how exposure to gestational diabetes (GDM) may influence 
the relationship between breastfeeding and postnatal infant growth is cluttered 
by the practice of combining variations of diabetes (Type I, Type II, GDM) 
into a single risk category(231, 232), despite the known differences in 
etiologies and pathophysiology of these variations of diabetic disease(202). 
Thus, it would be of particular interest to explore the effects of breastfeeding 
on growth amongst offspring who were exposed only to GDM in-utero. 
Emerging experimental evidence has also shown that exposure to over-
nutrition in-utero (excessive maternal fat and glycemia) would lead to 
offspring that are hyperphagic(233, 234), suggesting that offspring of GDM 
mothers may have altered appetitive traits that might influence later postnatal 
growth.  Additionally, few studies have looked if such effects exist in a multi-
ethnic Asian population, where the Asian phenotype and susceptibility 
towards metabolic disease differs from Caucasians(115), and where different 
ethnic groups within the Asian population exhibit physiological differences in 
susceptibility to future metabolic risk. Thus in this study, we examined the 
effect of breastmilk intake on postnatal growth of offspring exposed and 
unexposed to GDM in-utero and hypothesized that reduced breastmilk intake 
may result in accelerated adiposity gain in infants of GDM mothers, and if 







7.3 Materials and Methods 
7.3.1. Study population and assessment of gestational age 
 Details on the study population and assessment of gestational age have 
been described in Section 2.1 and Section 2.3.1.3. 
7.3.2 Oral glucose tolerance testing and anthropometry measurements 
 Details regarding oral glucose tolerance testing and measurement of 
anthropometry in the first 3 years of life have been described in Section 
2.3.1.2 and Section 2.3.2.1.  
7.3.3 Infant feeding assessment 
Details regarding infant feeding assessment has been described in 
Section 2.3.2.2.  
Breastfeeding exclusivity weights were assigned to each feeding 
practice using weights from 0 and 1, with exclusive breastfeeding having a 
weight of 1 and exclusive formula feeding having a weight of 0. Infants who 
were on predominant breastfeeding were given a weight of 0.75, and infants 
who were on partial breastfeeding were given a weight of 0.5(81). The sum of 
months of exclusive breastfeeding and the weighted months of predominant 
and partial breastfeeding [duration of exclusive breastfeeding (months) + 
duration of predominant breastfeeding (months)*exclusivity weight + duration 
of partial breastfeeding (months)*exclusivity weight] was then calculated to 
estimate breastmilk intake received over a 12-month period as a breastmilk-
month measure, divided into 2 categories (< 4 milk-months and ≥ 4 milk-
months). We also calculated the sum of months of exclusive breastfeeding and 
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the weighted months of predominant breastfeeding [duration of exclusive 
breastfeeding (months) + duration of predominant breastfeeding 
(months)*exclusivity weight] to estimate breastmilk intake by only 
exclusive/predominant breastfeeding in a 12-month period as a milk-month 
measure, divided into 3 categories (< 4 milk-months, ≥ 4 milk-months, no 
exclusive/predominant breastfeeding). 
7.3.3 Appetitive traits 
Appetitive traits were measured using the self-administered Baby 
Eating Behavior Questionnaire (BEBQ) questionnaires(235). The BEBQ was 
handed out to the parents during the 3-month post-partum home visit and 
collected at the end of the visit. Questionnaires distributed were in English 
unless a preferred language of Mandarin, Malay or Tamil was requested.  In 
this case, translated versions of the questionnaires were handed out.  
The BEBQ relates to a period of exclusive milk feeding. Each item on 
the questionnaire was answered using a five-point Likert frequency scale 
(1=never, 2=rarely, 3=sometimes, 4=often and 5=always). The 18-item BEBQ 
in this study measured three appetitive trait subscales, food responsiveness, 
slowness in eating and enjoyment of food and each subscale measures an 
infant’s response to exclusive milk feeding at 3 months of age. Satiety 
responsiveness and slowness in eating were combined under one subscale as 
slowness in eating as the items have been shown to have loaded into the same 
factor. Examples of items in the BEBQ are “My baby is always demanding a 
feed” (food responsiveness), “My baby finishing feeding quickly” (slowness 
in eating) and “My baby loves milk” (enjoyment of food). 
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7.3.4 Statistical analysis 
Descriptive statistics were reported as means and standard deviations 
for continuous variables and percents for categorical variables. Age- and 
gender-specific standard deviation scores (SDS) were calculated for weight, 
length and body mass index (BMI) for infants at all timepoints, referencing 
WHO Child Growth Standards(212). Conditional growth models for weight, 
length and BMI SDS were built using linear regression analysis. Here, weight 
SDS is used as an example: conditional growth in weight SDS from birth to 6 
months is equivalent to the standardised residuals resulting from the linear 
regression model of weight SDS at 6 months on weight SDS at birth. 
Accordingly, the conditional growth in weight SDS from 6 to 12 months is 
given as the standardised residuals obtained from regressing weight SDS at 12 
months on weight SDS at 0, 3 and 6 months simultaneously. This process is 
continued for each subsequent time point, resulting in measures of growth that 
are uncorrelated. Multiple linear regression analyses were used to assess the 
association between estimated breastmilk intake with offspring weight, length 
and BMI conditional gain during the first 3 years of life, in all cases adjusting 
for ethnicity, parity, maternal age, maternal education, maternal BMI at 26-28 
weeks gestation and gestational age at delivery. Associations between BEBQ 
scores with GDM status and estimated breastmilk intake were also tested 
using linear regression analysis. All analysis was performed using SPSS 






7.4.1 Demographic and clinical characteristics 
 Of the 1247 eligible pregnant mothers who were recruited to the study, 
1152 subjects had naturally-conceived singleton pregnancies. Data on glucose 
levels were available for 1016 subjects, out of which 181 subjects (17.8%) 
were diagnosed with GDM at 26-28 weeks of gestation. Characteristics of the 
study participants were described in Table 7.1. There was a significant 
difference in the distribution of GDM across all 3 ethnicities, with more 
Chinese and Indians having GDM compared to Malays. Subjects with GDM 
were observed to be slightly older (32.3 vs. 30.0 years), more educated (70.2% 
vs. 55.5%), had higher BMI at 26-28 weeks of gestation (27.1 vs 25.9 kg m
-2
) 
and shorter gestational age at delivery (38.0 vs 38.3 weeks) compared to their 
non-GDM counterparts (all p < 0.05). No significant differences in birth 
weight, length and BMI SDS, as well as breastmilk intake were observed for 





















Table 7.1: Clinical characteristics and demographics of study subjects 
#
p value by chi-square analysis (categorical) or two-sample t-test (continuous) 
Exc/pred BF = exclusive/predominant breastfeeding; BMI = body mass index; SDS = 










(n = 181) 
 
No GDM 








Maternal age 181 32.3(4.8) 
 
835 30.0(5.1) <0.001 
Maternal education 
     
<0.001 
< 12 years 54 29.8  366 44.5  
≥ 12 years 127 70.2  456 55.5  
Ethnicity 
     
0.001 
Chinese 113 62.4  448 53.7  
Malay 28 15.5  246 29.5  
Indian 40 22.1  141 16.9  
Parity 
     
0.101 
Primiparous 68 38.0  366 44.7  
Multiparous 111 62.0  453 55.3  
Maternal BMI  178 27.1(4.3) 
 
815 25.9(4.5) <0.001 




824 38.3(1.4) 0.013 
Infant Characteristics 
      
Birth weight SDS 181 -0.50(1.17) 
 
824 -0.48(0.95) 0.886 
Birth length SDS 181 -0.39(1.37) 
 
821 -0.52(1.14) 0.229 
Birth BMI SDS 181 -0.47(1.20) 
 
821 -0.31(1.08) 0.090 
Breastmilk  intake 
     
0.141 
< 4 milk-months 107 64.1  534 69.9  
≥ 4 milk-months 60 35.9  230 30.1  
Breastmilk intake by 
exclusive/predominant 
BF only 
     
0.061 
No exc/pred BF 99 59.3  511 66.9  
 < 4 milk-months 26 15.6  120 15.7  
 ≥ 4 milk-months 42 25.1  133 17.4  
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7.4.2 Effect of breastmilk intake on conditional growth in offspring 
exposed and unexposed to GDM in-utero 
Table 7.2 describes the association of estimated breastmilk intake with 
the offspring conditional growth outcomes during the first three years of life. 
Amongst offspring of non-GDM mothers, those who had greater breastmilk 
intake (≥ 4 milk-months) had significantly decelerated conditional gain in 
weight SDS [B(95%CI) = -0.31(-0.49,-0.13)], length SDS [B(95%CI) = -
0.22(-0.40,-0.04)] and BMI SDS [B(95%CI) = -0.22(-0.40,-0.04)] by the first 
year of life, compared to those who had reduced breastmilk intake (< 4 milk-
months). Amongst offspring of GDM mothers however, we noted that those 
who had greater breastmilk intake showed significantly accelerated 
conditional gain in weight [B(95%CI) = 0.45(0.07,0.83)] and BMI SDS 
[B(95%CI) = 0.46(0.08,0.84)] in the first six months of life compared to those 






Table 7.2: Association between estimated breastmilk intake (< 4 and ≥ 4 milk-months) and conditional growth of offspring in the first 
three years of life for offspring exposed and not exposed to maternal gestational diabetes in-utero 
  Conditional SDS gain 
B(95%CI) 
 Unexposed to GDM 
 
Exposed to GDM 
0-6 mth 6-12 mth 12-18 mth 18-24 mth 24-36mth 
 
0-6 mth 6-12 mth 12-18 mth 18-24 mth 24-36mth 
Weight SDS       
< 4 milk-mths ref 
 
ref 























   
< 4 milk-mths ref 
 
ref 























   
 < 4 milk-mths ref 
 
ref 






















Adjusted for maternal age, ethnicity, maternal education, parity, maternal BMI at 26-28 weeks gestation, gestational age at delivery 





7.4.3 Effect of breastmilk intake by only exclusive/predominant 
breastfeeding on conditional growth of offspring exposed and unexposed 
to GDM in-utero 
We also assessed the association between estimated breastmilk intake 
by only exclusive/predominant breastfeeding with offspring conditional 
growth in the first three years of life (Table 7.3). Amongst offspring of non-
GDM mothers, we observed that those with greater breastmilk intake by 
exclusive/predominant breastfeeding (≥ 4 milk-months) showed significantly 
decelerated conditional gain in weight SDS [B(95%CI) = -0.42(-0.64,-0.20)] 
and length SDS [B(95%CI) = -0.35(-0.57,-0.13)] by the first year of life, 
compared to those who were not on exclusive/predominant breastfeeding. 
Amongst offspring of GDM mothers however, those with greater breastmilk 
intake by exclusive/predominant breastfeeding showed significantly 
accelerated conditional gain in weight SDS [B(95%CI) = 0.52(0.08,0.96)] and 
BMI SDS [B(95%CI) = 0.73(0.29,1.17)] in the first six months of life, 
compared to those who were not on exclusive/predominant breastfeeding. No 
significant associations were observed between those who received breastmilk 
for less than 4 months by exclusive/predominant breastfeeding with growth 
outcomes during the first three years of life. 
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Table 7.3: Association between breastmilk intake by only exclusive/predominant (No exclusive/predominant breastfeeding, < 4 and  ≥ 4 
milk-months) and conditional growth of offspring in the first three years of life for offspring exposed and not exposed to maternal 
gestational diabetes in-utero 
 
Conditional SDS gain 
B(95%CI) 
 
Unexposed to GDM 
 
Exposed to GDM 
0-6 mth 6-12 mth 12-18 mth 18-24 mth 24-36 mth 
 
0-6 mth 6-12 mth 12-18 mth 18-24 mth 24-36 mth 
Weight SDS 
   
No exc/pred BF ref 
 
ref 













































   
No exc/pred BF ref 
 
ref 













































   
No exc/pred BF ref 
 
ref 












































Exc/pred BF: exclusive/predominant breastfeeding 
Adjusted for maternal age, ethnicity, maternal education, parity, maternal BMI at 26-28 weeks gestation, gestational age at delivery 
Figures in bold indicate p < 0.05 
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7.4.4 Differences in feeding behavior amongst GDM and non-GDM 
exposed infants  
To evaluate if the observations of accelerated weight and BMI SDS 
gain amongst GDM-exposed infants who had greater breastmilk intake were 
driven by infant appetitve traits, we compared the infant BEBQ scores 
between GDM and non-GDM exposed infants who had greater estimated 
breastmilk intake. We noted that GDM-exposed infants who were on 
prolonged and exclusive breastmilk feeding exhibited lower food 
responsiveness and slowness in eating scores, and higher enjoyment of food 
scores (Table 7.4), although these differences are not statistically significant, 
indicating no observable relationship between infant appetitive traits with 
GDM status and breastmilk duration and exclusivity. 
 Table 7.4: Means and standard error for each subscale of BEBQ 
according to GDM and feeding type 
Means adjusted for maternal age, ethnicity, education, BMI at 26-28 weeks gestation, 
gestational age at delivery and infant size at 3 months of age 
 
 
 BEBQ appetitive traits [mean(SE)] 
Food responsiveness Slowness in eating Enjoyment of food 
GDM + breastmilk intake 
 
  
Non-GDM + ≥ 4 milk-mths (n = 134) 0.24 (0.09) 0.18 (0.09) 0.17 (0.09) 
GDM + ≥ 4 milk-mths (n = 26) -0.09 (0.19) -0.06 (0.20) 0.21 (0.20) 
P value* 0.687 0.271 0.855 
GDM + breastmilk intake by only 
exclusive/predominant BF 
   
Non-GDM + ≥ 4 milk-mths  (n = 82) 0.24 (0.11) 0.13 (0.12) 0.14 (0.11) 
GDM + ≥ 4 milk-mths  (n = 18) -0.23 (0.23) -0.04 (0.24) 0.30 (0.24) 




 In this prospective Asian birth cohort study, we have demonstrated the 
varied effects of neonatal breastmilk intake on early postnatal growth in 
offspring who were exposed and unexposed to GDM in-utero. We noted that 
offspring of mothers without GDM who had greater breastmilk intake (i.e. ≥ 4 
months) exhibited significantly decelerated growth within the first year of life. 
However, offspring of GDM mothers who were on reduced breastmilk intake 
(and more formula feeding) did not exhibit the hypothesized accelerated 
growth during this early postnatal period. 
The findings amongst offspring of non-GDM mothers are consistent 
with that of the current literature. Griffiths et al reported that infants who did 
not receive breast milk grew faster than those whose mothers initiated 
breastfeeding, as did those who breastfed for 4 months or longer(87). A cohort 
study of randomly selected healthy newborns in Denmark and Iceland showed 
that exclusive breastfeeding beyond 2 months of age was related to lower 
weight gain from 2 to 6 months as well as from 6 to 12 months(236). A recent 
study on the Gemini cohort of 4680 infants also showed that infants breastfed 
for longer periods (>4 months) was independently associated with lower 
growth velocity by 6.8%(237). Not all studies have reported such similar 
results; a cluster randomized trial of a breastfeeding promotion intervention 
modelled on the WHO-UNICEF Baby-Friendly Hospital Initiative showed 
that prolonged and exclusive breastfeeding accelerated weight and length gain 




Our findings amongst offspring of mothers with GDM are consistent 
with earlier animal studies which have suggested that milk derived from 
mothers with GDM may impart metabolic consequences to their offspring. It 
has been reported that control offspring who were fed milk from dams with 
GDM showed complex “malprogramming” of hypothalamic neural circuits 
that are critically involved in the regulation of food intake, body weight, and 
metabolism(239). Longitudinal studies in humans also echoed similar 
observations, where milk intake from diabetic mothers during the first week of 
life was associated with greater relative weight and risk of overweight at two 
years of age, compared to offspring of diabetic mothers who were fed banked 
donor breastmilk(229, 230). Other studies however, such as that by Crume et 
al(231), have reported contrasting findings where it was shown that adequate 
breastfeeding (≥ 6 breast milk-months) reduces the overall body size and BMI 
growth velocity in the first nine months of life amongst offspring of diabetic 
pregnancies. Another study also reported that breastfeeding conferred similar 
protective effects against overweight at 9-14 years of age in offspring of both 
non-diabetic and diabetic women(232). It is important to note however, that 
these studies classified Type I diabetes as well as GDM into a single category, 
which may have explained the inconsistency in findings with our study due to 
the differences in etiologies of both diabetic sub-types. Our findings thus 
provides critical insights into this area of research, given the lack of 
understanding of the biochemical impact of breastmilk from GDM-only 
mothers on infant growth.  
The mechanisms underlying the varied effects of neonatal breastmilk 
intake on early postnatal growth in offspring who were exposed and 
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unexposed to GDM in-utero are likely multiple. Researchers have postulated 
that there may be differences in breast milk constituents of diabetic and non-
diabetic mothers, such as increased glucose or insulin concentrations in breast 
milk of diabetic mothers which may contribute to increased growth rates 
during early infancy. Concentration of ghrelins in milk of GDM-lactating 
women have also been reported to be lower when compared to non-diabetic 
control samples(240). Given the documented negative association between 
level of serum active ghrelin levels and BMI of infants(241), lower ghrelin 
concentrations in milk of GDM mothers might influence faster postnatal 
growth in their offspring. Milk from diabetic mothers may also contain more 
inflammatory cytokines (e.g. TNF-α, IL-6) which mimic signaling pathways 
characteristic of dysfunctional adipocytes of metabolic syndrome(242). 
Moreover, Kjos et al had earlier demonstrated that abnormal glucose 
metabolism still persists postpartum amongst women with GDM(243), further 
suggesting that continued exposure to altered fuels through breastmilk may 
bring about consequences to offspring growth. Plagemann et al had also 
proposed that milk originating from diabetic mothers may have an early 
obesogenic effect on infant weight gain that decreases with time, thus the 
positive effects of breastfeeding on reducing later adiposity may only be 
observed if breastfeeding is continued beyond a certain period where breast 
milk composition would have normalized over time(244). This begets the 
question whether proactive intervention to achieve better glycemic control in 
the early postpartum period of GDM mothers would help to accelerate the 
normalization of the breast milk and reduce the obesogenic effect, which poses 
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an interesting hypothesis that should be examined properly in an interventional 
trial. 
Another potential mechanism could be that offspring of GDM mothers 
may have greater energy intake driven by intrauterine “metabolic 
programming” as a result of GDM exposure in-utero. In our study, we 
observed that offspring of GDM mothers had greater estimated breastmilk 
intake, compared to their non-GDM counterparts. Higher intake of breast milk 
from GDM mothers and hence higher energy intake, may contribute to 
increased growth rates during early infancy. We were however, unable to 
demonstrate that GDM-exposed infants with greater breastmilk intake had 
pro-feeding behavior, when comparing BEBQ appetitive trait scores between 
GDM and non-GDM exposed infants. As approximately 50% of the 
participants answered the BEBQ, this could have led to lack of power for 
detecting significant associations given the small effect sizes observed.  
Strengths of this study include the prospective design with high follow-
up rate, along with the study of Asian ethnic groups. To date, there are few 
published studies examining the effect of breastfeeding on early postnatal 
growth among offspring exposed to GDM in-utero in a multi-ethnic Asian 
cohort. Thus this study provides useful and informative data on this 
relationship. Another strength of the study is the analysis of the growth data in 
a conditional manner. This method of analysis is important in growth, where 
anthropometric measures are often related to the previous measures at earlier 
timepoints. The conditional SDS of growth are mutually uncorrelated, hence 
allowing the effects of growth to be distinguished from any statistical artifact 
attributable to regression to the mean. This study however, is not without 
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limitations. Due to the observational nature of our study, we cannot fully rule 
out the possibility that residual confounding by parental attributes or family 
environment may affect the observed associations, as breastfeeding is a 
behavior that is self-selected and women are usually not randomized to 
breastfeed. As with most studies on breastfeeding and infant growth, it is 
largely observational and hence subject to potential confounding. Socio-
economic status presents as an important confounder, as mothers who are 
more educated tend to be more “nutrition-conscious”, more likely to 
breastfeed and less likely to feed poor quality diets post-weaning(245, 246).  
Other important potential confounding factors include maternal BMI, which is 
generally associated with shorter durations of breastfeeding(247), as well as 
maternal age, which is generally associated with greater exclusive 
breastfeeding(248). In our study, we noted that mothers with GDM were 
observed to be older, more educated and had higher BMI at 26-28 weeks of 
gestation compared to their non-GDM counterparts, which presents as a 
potential bias. The associations observed in our study findings have been 
controlled for, and are independent of these potential confounders. 
In conclusion, our study findings have demonstrated the varied effects 
of neonatal breastfeeding on early postnatal growth in offspring who were 
exposed and unexposed to GDM in-utero. Whilst offspring of mothers without 
GDM who had greater breastmilk intake exhibit decelerated weight and BMI 
gain in the first year of life, offspring of GDM mothers however, do not 
exhibit accelerated adiposity gain during the early postnatal period despite 
reduced breastmilk intake. It remains to be seen if our observations of effects 
of breastmilk on accelerated growth amongst offspring exposed to GDM in-
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Chapter 8: Identifying potential novel genetic markers of fetal growth 
and subsequent postnatal catch-up growth 
8.1 Summary 
Background: Fetal growth restriction (FGR) and accelerated postnatal catch-
up growth often predisposes offspring to increased risk of metabolic disease 
later in life. However, the molecular mechanisms which entails FGR and 
subsequent catch-up growth is not well understood. We examined the 
transcriptomic profiles of umbilical cords of infants to identify potential novel 
genetic markers that are associated with fetal growth and subsequent postnatal 
growth. 
Methods: The gene expression patterns of 80 umbilical cords from 
Singaporean newborns of Chinese ethnicity, who experienced poor fetal 
growth [with postnatal catch-up growth (n=20), without catch-up growth 
(n=20)], normal (n=20) and excessive fetal growth (n=20) were determined. 
Results:  The gene expression microarray data uncovered 19 genes which had 
expression levels significantly associated with fetal growth change between 
the 2
nd
 (19-21 weeks of gestation) and 3
rd
 trimester (32-34 weeks), and 29 
genes that had significantly different expression levels between the catch-up 
and non-catch up growth groups, and all 48 genes were found to be 
significantly enriched in pathways related to immune response, apoptosis, 
nucleotide metabolism, DNA damage repair and angiopoietin signalling. 
Further validation of the array expression data using quantitative real-time 
PCR identified a total of 15 out of the 48 genes showing expression level 
differences similar to that observed in the microarray data, and were 
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associated with a variety of growth measures (fetal growth, birth weight, birth 
length and conditional postnatal growth). 
Conclusion: This study has managed to uncover gene expression changes 
significant for fetal growth and subsequent postnatal growth, and provided 
insights into the transcriptomic profile of babies with differing fetal growth 
types. This may allow for the development of prognostic markers to predict 
FGR. 
8.2 Introduction 
 Normal fetal growth represents a critical component of a healthy 
pregnancy and influences the long-term health of the offspring. In this aspect, 
fetal growth restriction (FGR) constitutes a major and important clinical 
problem, both in developed and developing countries. FGR often predisposes 
the offspring to increased risk of perinatal death, birth hypoxia, neonatal 
complications and impaired neurodevelopment(249-251). Additionally, an 
increasing body of evidence has shown that common adult diseases such as 
type 2 diabetes, coronary heart disease, hypertension and other manifestations 
of the metabolic syndrome are linked to abnormal fetal growth, particularly 
FGR(252). Hence, being able to predict a poor growing fetus in-utero would 
prove to be clinically valuable both in the short- and long-term because: (i) 
clinicians would be able to readily identify fetuses that require early referral to 
secondary care and closer surveillance, (ii) it would allow specific 
interventions to be tested on at-risk fetuses, and avoid the use of unnecessary 
interventions on low-risk fetuses, (iii) studying predictors of fetal growth 
would improve the understanding of biological and pathological mechanisms 
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of FGR, and (iv) accurate prediction of poor fetal growth at an early stage 
would play an important role in avoiding the adult consequences of FGR later 
in life(253).  
 Currently, the molecular mechanisms that underlie the pathology of 
FGR are not well-understood. Several biochemical markers for predicting 
FGR have been proposed in recent years(254-259), however none have been 
sufficiently accurate to recommend their use as predictors of FGR in routine 
clinical practice. With recent advances in genetic epidemiology such as high-
throughput gene expression and genome-wide methylation microarrays, 
several groups have reported the association of transcriptomic and epigenetic 
marks, derived from umbilical cord tissue with adverse intrauterine 
experience(260-263). These studies however, use the common approach of 
defining FGR and small-for-gestational age (SGA) interchangeably (i.e. 
birthweight-for-gestational age < 10
th
 percentile). This is problematic, as SGA 
fetuses are not necessarily growth-restricted; they may be constitutionally 
small but healthy. Conversely, fetuses with weight above the 10
th
 percentile 
may not necessarily denote normal fetal growth.  The birthweight of the 
newborn represents size-at-birth but does not necessarily reflect the actual 
growth of the fetus in-utero. The fetal growth rate may undergo a pathological 
decline during late gestation which incurs a risk of perinatal morbidity or 
mortality, even though the birthweight is still above the 10
th
 percentile(141). 
To overcome this, serial ultrasound measurements for the same fetus taken at 
different gestational periods, alongside birth anthropometric data may give a 
better indication of fetal growth velocity. Additionally, it may allow for a 
more direct examination of fetal growth by studying growth conditional on 
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earlier size, which enables growth at different gestational periods to be studied 
independently of earlier size and growth. This would identify if infants had 
consistently reduced fetal growth rates over the course of gestation, hence a 
better indication of FGR. 
 Majority (~two-thirds) of infants with FGR will tend to show catch-up 
growth, defined as height or weight growth above the statistical limits of 
normality for age(264, 265), in the first two to three years of life(266). This 
period of accelerated postnatal growth following FGR has been shown to be 
crucial in the programming of later metabolic disease risk(32, 264). However, 
a significant proportion (~20-30%) may still persist to remain small and failed 
to catch-up in their height and weight compared to their peers. Therefore 
identifying molecular signatures which are predictive of successful or failed 
catch-up growth following FGR will have potential clinical applications, such 
as determining which children should be considered for early growth hormone 
therapy, and also unravel biological pathways which determine catch-up 
growth. These molecular signatures would also be useful in understanding the 
associations between fetal growth, birth size and disease risk in later life. Thus 
in this study, we sought to examine the relationship between fetal growth (as 
measured by serial ultrasound measurements) with transcriptomic profiles of 
umbilical cords of GUSTO infants to identify potential novel genetic markers 
that are associated with fetal growth restriction and subsequent postnatal 
growth, and hypothesized that offspring with poor growth in-utero and 
subsequent catch-up growth have a unique gene expression profile which is 




8.3 Materials and Methods 
8.3.1 Study population, assessment of fetal biometry and gestational age 
 Details on the study population and assessment of fetal biometry and 
gestational age have been described in Section 2.1 and Section 2.3.1.3. 
8.3.2 Criteria for the evaluation of fetal growth 
All fetal growth characteristics for each subject, were converted to 
standard deviation scores (SDS) using internally derived gestational age-
specific means and standard deviations. 
SDS = (measurement – cohort mean)/cohort standard deviation).  
Fetal growth was examined by calculating a change in SDS between 
the second trimester (19-21 weeks) and the third trimester (32-34 weeks) for 
biparietal diameter (BPD), femur length (FL) and abdominal circumference 
(AC). Fetal growth patterns was categorized by a change of more than 0.67 
SDS, a well-recognized threshold value in studies on growth(267). "Poor fetal 
growth" infants were selected from those whose change in SDS was more than 
-0.67 SDS between the 2nd and 3rd trimester for AC, and in addition, either 
BPD or FL (which is, two criteria).  Similarly, "excessive fetal growth” were 
selected from those whose change in SDS was more than +0.67 SDS between 
the 2nd and 3rd trimester for AC and either BPD or FL. Infant subjects whose 
change in SDS were between -0.67 or +0.67 SDS were classified as being 





8.3.3 Biospecimens –  selection of umbilical cord samples 
The microarray analysis sample set consisted of a total of 80 umbilical 
cords from babies of Chinese ethnicity. It was designed to include 20 
"exceeding fetal growth", 20 "steady fetal growth" and 40 "poor fetal growth", 
of which 20 exhibited postnatal “catch-up growth” and the remaining 20 failed 
to exhibit catch-up growth. The samples were matched for gender and 
gestational age at delivery. Gestational ages were restricted to between 37-40 
completed weeks. Mothers with underlying pregnancy complications with 
potential effects on fetal growth (gestational diabetes, hypertension, pre-
eclampsia, anaemia) were excluded from this study. Mothers who smoked 
during the course of their pregnancy were also excluded in this study.  
8.3.4 Infant anthropometry 
Details regarding measurement of infant anthropometry have been 
described in Section 2.3.2.1.  
8.3.5 Analysis of biospecimens and extraction of RNA 
Details regarding biospecimen analysis and RNA extraction from 
umbilical cords have been described in detail in Section 2.4.1 and Section 
2.4.2 
8.3.6 Gene-expression microarray 
HumanHT-12 v4 Expression BeadChips (cat#BD-103-0204, Illumina) 
with 47,231 transcript probes were used for gene expression analysis. Briefly, 
500ng of total RNA was used for complementary RNA (cRNA) synthesis 
using Illumina® TotalPrep™-96 RNA Amplification Kit (cat# 4393543, Life 
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Technologies) according to manufacturer’s instructions and recommendations. 
750ng of cRNA was hybridized onto the array for 18 hours at 58°C. The 
arrays were scanned on Illumina iScan, and data was extracted by the Illumina 
Genome Bead Studio™ Software for further analysis. Background subtraction 
was performed on the extracted data, and probes with at least 3 beads (NBEADS 
≥ 3) with significant detection value (p < 0.05) were selected.  The data were 
then loaded into Arraystudio (Omicsoft), and all expression values were log 
transformed and normalised amongst samples using quantile normalisation, a 
technique for transforming data to have a common distribution of expression 
intensities across all samples(268), thus allowing the expression intensities to 
be compared between samples.   
8.3.7 Pathway analysis 
All genes that were significantly expressed were subjected to pathway 
enrichment and de novo network analysis. Pathway analysis was performed in 
GeneGo MetaCore™. 
8.3.8 Quantitative Real Time-PCR (qRT-PCR) 
To validate the gene expression levels observed from the microarray, 
qRT-PCR was performed. Total RNA (4ug) was reverse transcribed using a 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems Inc, 
ABI, CA, USA). PCR reactions were prepared using 10ul of Power SyBr 
Green PCR 2X Master mix (Applied Biosystems Inc, ABI, Foster City, CA, 
USA), 1ul of each primer (2uM), and 20ng of cDNA in a total reaction volume 
of 20ul. PCR for each sample was done in triplicates in 384-well plates using 
the ABI 7900 HT Sequence Detection System. Cycle parameters used were 10 
min at 95°C (1 cycle), then 15 s at 95˚C and 1 min at 60°C (40 cycles). 
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Targets genes and three endogenous control genes (RPL18, RPL19 and 
HSP90AB1) were analyzed.  The threshold cycles (Ct) of samples provided 
from the equipment software were normalized by the average Ct of controls 
using Higher ∆Ct value indicates lower 
gene expression level.  
8.3.9 Statistical analysis 
Descriptive statistics were reported as means and standard deviations 
for continuous variables and percents for categorical variables. As a measure 
of quality control for gene expression data, median absolute deviation (MAD) 
scores were calculated for the sample sets. MAD measures the variability in a 
univariate dataset and is a robust measure of statistical dispersion, defined as 
the median of absolute deviations from the data’s median: 
MAD = Mediani(|Xi - Medianj(Xj)|)  
For each data point (Xi), individual deviations from the median of all data 
points (Median Xj) are first calculated [given by the formula Xi -Medianj(Xj)]. 
The absolute values of the individual deviations are taken [i.e. |Xi - 
Medianj(Xj)|]. The MAD would thus be the median of these absolute values. 
The MAD score would then be calculated using the following formula: 
 
All samples with MAD scores < -5 were removed from the 
analysis(269). Principal component analysis and hierarchical clustering were 
performed to observe the clustering of technical replicates and discernible 
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batch effects. To identify probes that had significantly different expression 
levels, one-way ANOVAs (multiple testing correction: Benjamin- Hochberg) 
were performed. Linear regression analysis was applied on the delta Ct values 
of target genes against a variety of intrauterine, birth and postnatal growth 
measures in the first 2-years of life. 
8.4 Results 
8.4.1 Demographic and clinical characteristics 
Baseline demographic characteristics of the study subjects were 
described in Table 8.1. No significant differences across the 3 fetal growth 
groups were observed for maternal education, housing type, parity, maternal 
age and BMI at 26-28 weeks gestation. Males and females were also equally 
distributed across the 3 fetal growth groups. Infants from the “poor fetal 
growth” group exhibited significantly lowest birth weight [mean(SD): 
2.82(0.22) vs. 3.21(0.23) vs. 3.52(0.31)] and birth length [mean(SD): 48.1(2.2) 





















Table 8.1: Comparison of baseline characteristics between “poor fetal growth”, 
“normal fetal growth” and “excessive fetal growth”.  
#
p value across 3 groups, by Chi-square analysis (categorical) or one-way ANOVA 
(continuous) 
8.4.2 Microarray analysis and quality control  
All samples were subjected to expression microarray analysis and the 
expression values were log transformed. Of the 47221 probes that are present 
on the microarray chip, 14281 probes were found to have at least 3 beads with 
significant detection p value < 0.05. After probe quality control and inter-
sample quantile normalisation of the 80 RNA samples interrogated on the 
array, the data for one sample failed quality control (MAD scores < -5); this 
sample was a technical replicate and was subsequently removed from analysis 
(Fig 8.1). Sixteen series of technical replicates were included in the 
experiment, of which they clustered together in 15 out of 16 cases, 
highlighting that intra-sample variation was lower than the inter-sample 
variation. Hence the data was deemed of acceptable quality and the technical 




N = 40 
“Normal 
growth” 
N = 20 
“Excessive 
growth” 
N = 20 
Total 
N = 80 P value
#
 
Maternal education(%)         0.094 
 < 12 years 28.9 10.0 40.0 26.9  
 ≥ 12 years 71.1 90.0 60.0 73.1   
Type of housing (%)  
    
0.895  
 Government  84.2 80.0 85.0 83.3   
 Private 15.8 20.0 15.0 16.7   
Parity (%) 
    
0.419 
 Primiparious 62.5 70.0 50.0 61.3   
 Multiparous 37.5 30.0 50.0 38.8   
Body Mass Index (kg/m
2 
)  24.1 ± 3.2 23.9 ± 2.5 25.0 ± 3.5 24.3 ± 3.1 0.452  
Age (years) 31.1± 5.0 30.1 ± 4.1 31.4 ± 4.5 30.9 ± 4.7 0.621  
Offspring      
Gender (%)     0.759 
 Male 55.0 45.0 50.0 51.2  
 Female 45.0 55.0 50.0 48.8  
Gestational age (wks) 38.4 ± 0.9 38.7 ± 1.0 38.6 ± 1.0 38.5 ± 1.0 0.513  
Birth weight (kg) 2.82 ± 0.22 3.21 ± 0.23 3.52 ± 0.31 3.10 ± 0.38 <0.001  
Birth length (cm) 48.1 ± 2.2 49.4 ± 1.9 50.1 ± 1.8 48.9 ± 2.2 0.002 
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Figure 8.1: Plot of MAD scores for each sample ID 
Each point represents MAD score for 1 sample 
 
Fig 8.2 Plot of MAD scores for each sample ID highlighting clustering of sample 
replicates 
Each point represents MAD score for 1 sample. Green points represent non-replicates, purple 
points represent technical replicates within each microarray chip. Red circles indicate 










8.4.3 Identifying potential underlying associations between individual 
transcriptomes and fetal growth 
Figure 8.3 illustrates the pattern of relatedness between individual 
transcriptomes and potential underlying associations with fetal growth using 
principal components analysis. No significant relationship with fetal growth 
type (i.e. poor vs. normal vs. excessive growth) was observed and the samples 
did not appear to separate according to the fetal growth type. This may be 
indicative that the fetal growth type may not be a strong driver of umbilical 
cord transcriptomes.  
Fig 8.3: Prinicipal component analysis using the RNA expression microarray 
data across fetal growth type 
Samples are classified as excessive (blue), normal (green) and poor fetal growth (purple). 




We performed 2-sample group tests to identify genes for which 
transcript levels were differential for fetal growth type, by comparing poor vs. 
normal, poor vs. excessive and normal vs. excessive fetal growth. Figure 8.4 
illustrates the p-value distribution of all the genes for the 3 group tests. The 
distribution is relatively uniform and there are no more p-values < 0.05 than 
would be expected by chance, indicating that there is possibly no association 
between the gene expression level with the fetal growth type.    
Fig 8.4: The distribution of p-values for mean transcript level differences between 




In addition to this, linear regression analysis was performed to identify which 





 trimester (i.e. ∆AC, ∆BP, ∆FL between 2nd and 3rd 
trimester). The distribution of p-values obtained for the regression coefficients 
is shown in Fig 8.5. There were more p values < 0.05 than would be expected 
by chance for the outcome of change in AC and FL, which suggests that some 





 trimester. A total of 104 common genes were found to be 
significantly associated with change in AC, BP and FL, and 87 common genes 
were significantly associated with change in AC and FL. 
Fig 8.5: The distribution of p-values for regression coefficients of association between 
transcript levels with ∆AC (top left), ∆BP (top right) and ∆FL (bottom left) between 2nd 







Pathway analysis was then performed on the 87 genes which had 
significant associations with ∆AC, ∆BP and ∆FL between 2nd and 3rd 
trimester. The most enriched pathways were related to immune response 
(Table 8.2); Immune response IFN alpha/beta signaling pathway (p = 6.87 x 
10-10, FDR = 4.26 x 10-8) and Immune response antiviral actions of 
interferons (p = 2.02 x 10-7, FDR = 6.28 x 10-6), with 11 out of the 87 genes 
related to the aforementioned pathways (AVP, STAT1, IRF9, ISG15, IFI6, 
IFIT2, OAS1, OAS2, MX1, MX2). An additional 8 probes (DHX58, IFIH1, 
SET, HMGB2, XPC, RAD1, LAP3, PREB) were found to be enriched in other 
pathways with a p-value < 0.05. 
Table 8.2: Pathway enrichment analysis of genes significantly associated with 
fetal growth 




# Maps pValue FDR Genes 
1 
Immune response_IFN alpha/beta signaling 
pathway 
6.870E-10 4.259E-08 
AVP, STAT1, IRF9, ISG15, 
IFI6, IFIT2 
2 
Immune response_Antiviral actions of 
Interferons 
2.024E-07 0.0000063 
AVP, OAS1, OAS2, STAT1, 
IRF9, MX1, MX2 
3 Development_Angiotensin signaling via STATs 3.670E-03 0.07584 STAT1, IRF9 
4 
Immune response_Innate immune response to 
RNA viral infection 
6.916E-03 0.09184 DHX58, IFIH1 
5 Apoptosis and survival_Granzyme A signaling 7.548E-03 0.09184 SET, HMGB2 
6 DNA damage_Nucleotide excision repair 8.888E-03 0.09184 XPC, RAD1 
7 DNA damage_Brca1 as a transcription regulator 1.266E-02 0.1122 STAT1, XPC 
8 Development_G-CSF signaling 1.702E-02 0.1237 STAT1, LAP3 
9 
Immune response _IFN gamma signaling 
pathway 
1.796E-02 0.1237 STAT1, IRF9 
10 
Development_c-Kit ligand signaling pathway 
during hemopoiesis 
2.403E-02 0.1416 STAT1, LAP3 
11 Development_Prolactin receptor signaling 2.512E-02 0.1416 STAT1, OAS1 
12 Delta508-CFTR traffic / ER-to-Golgi in CF 3.990E-02 0.1903 PREB 
13 Normal wtCFTR traffic / ER-to-Golgi 3.990E-02 0.1903 PREB 
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8.4.4 Identifying potential underlying associations between individual 
transcriptomes with postnatal and catch-up growth 
Figure 8.6 illustrates the postnatal growth trajectory in the first two 
years of life of the 80 infants from the three fetal growth types. We noted that 
amongst the “poor fetal growth” infants, there was a subgroup (n=20) who 
exhibited catch-up growth, and another subgroup that remained consistently 
small (i.e. non catch-up, n=20) during the first two years of life. We also 
performed 2-sample group tests to identify the genes for which transcript 
levels were differential between catch-up and non catch-up groups. A total of 
208 genes were observed to have significantly different expression levels 
between the catch-up and non catch-up group. Pathway enrichment was also 
performed for the 208 genes identified to have significantly different 
expression levels between catch-up and non catch-up group. The most 
enriched pathways were related to dATP metabolism (p = 0.00288) and NFAT 
immune response (p = 0.00336). A total of 29 out of the 208 genes were found 
to be enriched in pathways with a p-value < 0.05. 
Figure 8.6: Weight trajectory of poor, normal and excessive fetal growth infants during 





















8.4.5 Experimental validation of identified genes associated with fetal and 
postnatal growth 
Given that microarray data is inherently “noisy” and to rule out any 
artefacts of false positive results, we performed an experimental validation by 
assaying the expression levels of the 48 genes that were significantly enriched 
in pathway analysis using quantitative real-time PCR (qPCR). A total of 15 
out of 48 genes (AVP, IFI6, SET, HMGB2, RAD1, AIFM1, APAF1, CALM2, 
NUDT1, IKBKG, CCNL1, LIG1, PITX, TNIP2, RBP) were validated to have 
the expression level differences similar to that observed in the microarray data, 
between the fetal growth types and the catch-up vs. non catch-up group.  
We next enhanced the number of umbilical cord samples (n=200) to 
ascertain whether the expression levels of the 15 experimentally-validated 
genes identified above were associated with fetal growth characteristics, birth 
outcomes as well as postnatal growth characteristics of the GUSTO infant 
subjects. First, we conducted qRT-PCR experiments using umbilical cord 
specimens from the 200 individuals. Linear regression analysis was then 
applied on the delta Ct values of target genes against the variety of clinical 
measures. We noted that AIFM1 expression levels had a positive significant 
association with fetal AC SDS [B(95%CI) = 0.18(0.03,0.33)] and BPD SDS at 
26-28 weeks gestation [0.13(0.006,0.25)]. TNIP2 expression levels also 
showed a positive significant association with fetal AC SDS at 26-28 weeks 
[0.53(0.23,0.83)], and with FL SDS at 19-21 weeks [0.42(0.13,0.71)], 26-28 
weeks [0.41(0.11,0.70)] and 32-34 weeks gestation [0.35(0.03,0.67)]. For birth 
outcome characteristics, AIFM1 and CCNL1 showed a positive significant 
association with birth weight SDS [0.24(0.03,0.46) and 0.14(0.02,0.27) 
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respectively]. APAF1 and CCNL1 expression levels also showed positive 
significant association with birth length SDS [0.24(0.05,0.42) and 
0.36(0.14,0.58) respectively]. For postnatal growth characteristics, only 
AIFM1 expression levels showed a positive association with conditional 




















 A period of sub-optimal fetal growth carries an increased susceptibility 
for a range of diseases later in life, although this may vary from one individual 
to another. Prognostic markers, such as gene expression levels, may be able to 
predict individuals who are on the trajectory of increased risk of disease. In 
this study, we were able to assess the gene expression patterns of umbilical 





 trimester of pregnancy using birth tissue specimens collected by 
GUSTO cohort study, and associate the expression levels with birth as well as 
postnatal growth outcomes. 
 Our study was designed to examine the molecular correlates of fetal 
growth during pregnancy across three groups, namely poor, normal and 
excessive fetal growth, with very little emphasis on birthweight. One of the 
stumbling blocks in other studies is the problematic approach of defining FGR 
and SGA interchangeably. Such a definition does not clearly distinguish those 
who are pathologically growth-restricted from those who are constitutionally 
small and healthy. The novelty of this study was the use of serial ultrasound 
measurements for the same fetus taken at different gestational periods to give 
a better indication and definition of fetal growth velocity. To our knowledge, 
few studies have utilized such a measure when examining molecular correlates 
of FGR. Our minimal emphasis on birthweight is also in-line with recent 
evidence that birthweight is not a crucial factor in driving the transcriptome. 
An earlier study conducted by Stunkel W et al on the GUSTO cohort 
highlighted that gestational age rather than birthweight, even at extremes, was 
the important factor in driving the transcriptome(269), a finding that was also 
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supported by the work of Cohen et al(270). Another study utilizing umbilical 
cord blood from Caucasian and African-American mothers in the Conditions 
affecting Neurocognitive Development and Learning in Early Childhood 
(CANDLE) cohort also failed to find significant relationships with birth 
weight at the transcript level(113). Given these findings, birth measurements 
may not be entirely useful when studying molecular correlates of fetal growth.  
 The gene expression microarray data obtained after comparison 
between subjects of differing fetal growth types revealed a putative list of 15 
genes that were differentially expressed. These genes were also observed to be 
significantly enriched in pathways related to immune response (AVP, IFI6, 
CALM2, IKBKG), apoptosis and survival (AIFM1, APAF1, SET, HMGB2). 
Immune response is known to be modulated in FGR infants. Mukhopadhyay D 
et al documented that FGR is correlated with fewer circulating as well as 
decreased functioning of T-regulatory cells compared to normal infants(271). 
Troger B et al also reported significantly lower white blood cell and platelet 
count amongst SGA infants compared to normal infants(272), highlighting 
how immune response may be modulated by intrauterine growth. FGR has 
also been reported to be associated with increased incidence of apoptosis; 
Murthi P et al documented increased apoptosis in FGR-affected fetal 
membranes, with the apoptotic cells restricted primarily to the chorionic 
trophoblast layer of the fetal membranes, which can impair normal fetal 
development and growth(273). Similarly, Whitehead CL et al reported an 
increased expression of genes regulating intrinsic apoptosis amongst FGR 
infants(274), though this was observed in the placenta rather than the 
umbilical cord. With the knowledge that FGR may play a role in modulating 
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genes in immune response and apoptotic pathways, these genes may serve to 
be useful prognostic markers to predict FGR individuals.  
 In addition, we observed differential expression for genes enriched in 
pathways related to nucleotide metabolism (NUDT1), DNA damage repair 
(RAD1), and angiopoietin signalling (TNIP2). NUDT1 is a deoxyinosine 
diphosphatase, and studies have shown that its deficiency induces 
accumulation of single-strand breaks in nuclear DNA, which can lead to 
growth arrest. RAD1 is a gene that encodes a component of a heterotrimeric 
cell cycle checkpoint complex, known as the 9-1-1 complex, which stops cell 
cycle progression in response to DNA damage or incomplete DNA 
replication(275, 276). In our expression microarray and qRT-PCR data, we 
noted lower expression levels for these two genes in the poor fetal growth 
group and also in the subgroup that exhibits non catch-up growth in the first 2 
years of life. Reduced expression of these 2 genes might lead to growth arrest 
due to accumulation of DNA single-strand breaks and reduced ability to repair 
the damaged DNA. TNIP2 is a protein-encoding gene which inhibits 
activation of NF-κB in the angiopoeitin signalling pathway. This signalling 
pathway is crucial for angiogenesis and vascular maintenance(277), and 
inhibition of NF-κB activity in this pathway is known have anti-apoptotic 
action(278). We also noted reduced expression of TNIP2 in the poor fetal 
growth subgroup that exhibits non catch-up growth, hinting increased 
apoptotic activity, which is in line with existing evidence of increased 
apoptotic activity amongst FGR infants. Again, these genes may serve to be 
useful prognostic markers to predict FGR individuals 
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This study is not without limitations; we assayed the genomics of 
umbilical cord tissue as the only available somatic tissue. While the umbilical 
cord may represent a suitable “snapshot” of the gene expression patterns 
associated with fetal growth, such patterns may not be truly reflective of 
differences in expression levels in true target tissues that give rise to diseases 
with developmental origins (e.g. liver, pancreas or other endocrine tissues), 
and thus it would be difficult to extrapolate the molecular patterns observed in 
umbilical cord to later disease risk. Our approach is built on the premise that 
gene expression differences in the true target tissues might be reflected in the 
umbilical cord, although any observed strength of association may be much 
weaker. Given that we could only at best detect indirect associations, there 
might be some merit to more closely examining the top ranked associations in 
our data set. 
 In conclusion, our study has managed to uncover gene expression 
changes significant for fetal growth and subsequent postnatal growth. Previous 
studies have examined the association between retarded fetal growth with gene 
expression patterns in a variety of pathological states (e.g. Beckwith-
Wiedemann or Russell-Silver Syndromes)(112, 279, 280). By contrast, our 
study is one of the few to determine if variation in gene expression is 
associated with fetal growth as measured by ultrasound among a set of 
newborns of from low-risk pregnancies. Our results may have provided 
insights into the transcriptomic profile of babies with differing fetal growth 
types. This may allow for the development of prognostic markers to predict 
FGR. Future research should focus on the functional characterization of these 
genes to explore if the expression differences are associated with 
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characteristics related to metabolic disease (e.g. insulin sensitivity and 
































Chapter 9: The contrasting effects of melanocortin-3-receptor (MC3R) 
and fat-mass and obesity associated gene (FTO) polymorphisms on 
adiposity in early childhood 
9.1 Summary 
Background: Polymorphic variants within the melanocortin-3 receptor gene 
(MC3R) and the fat-mass and obesity-associated gene (FTO) have been 
associated with adult obesity. However, their influence on early childhood 
adiposity is unclear. We assessed the association between genotype at 
polymorphic sites within the MC3R and FTO genes with overweight status 
during early childhood, and determined if this was mediated by early 
childhood feeding behaviour. 
Methods: One thousand and ninety singleton offspring in a prospective birth 
cohort genotyped for MC3R (rs3746619, rs3827103) and FTO (rs9939973, 
rs1421085, rs1121980, rs9939609, rs17817449, rs8050136) variants were 
studied, as well as in a subgroup (n=422) with completed childhood appetitive 
trait scores at 1-year of age. Overweight status at 1-, 2- and 3-years of age was 
defined as having a body mass index z-score more than 2, following the World 
Health Organization 2006 Child Growth Standards. Associations between 
MC3R and FTO genotype with overweight status was assessed using 
multivariable logistic regression. 
Results: Independent of potential confounders, each additional MC3R variant 
minor allele was associated with a linear increase in the proportion of 
overweight children at 2- and 3-years of age, but not at 1-year of age, and with 
an increased odds of overweight at ages 2- and 3-years. In contrast, no 
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significant associations were observed between FTO variants and overweight 
at 1-, 2- and 3-years of age. Children homozygous for the minor allele in 
MC3R variants had the highest scores for “slowness in eating” appetitive trait. 
Conclusion: The findings suggest that MC3R, but not FTO genetic variants 
are associated with early childhood adiposity, and this relationship might be 
mediated by childhood appetitive traits at 1-year. The relative effects of 
various susceptibility genetic variants may differ at different ages and stages 
of life.   
9.2 Introduction 
 Overweight and obesity are commonly associated with increased risk 
of chronic diseases including type 2 diabetes and cardiovascular disease, and 
present a massive public health challenge as they rapidly become a worldwide 
epidemic(1, 281). Non-syndromic or common obesity is often viewed as a 
complex and multifactorial condition, where exposure to an “obesogenic” 
environment, coupled with an underlying genetic susceptibility to excessive 
weight gain causes an obese phenotype (282, 283). In recent years, genome-
wide association studies (GWAS) have succeeded in identifying genetic 
variants that were associated with body mass index (BMI) and risk of obesity. 
An example is the fat-mass and obesity-associated gene (FTO)(284-286). The 
association between FTO variants with BMI and obesity risk has been 
confirmed in many populations (287-290), though the effect is modest, with 
the minor (risk) allele increasing BMI by 0.39 kg/m
2
 (or ~1 kg in body 
weight) and increasing obesity risk by 1.2 fold (291). A recent study 
conducted on 4,298 multi-ethnic Singaporean adults highlighted nine FTO 
variants commonly reported in such studies of European populations were also 
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associated with increased BMI amongst ethnic Chinese and Malays in 
Singapore, and also contributed to increased risk of type 2 diabetes amongst 
Malays (292). 
Linkage studies by Fox et al (293) and Lembertas et al (294) reported 
that a polymorphism within the melanocortin-3-receptor (MC3R) locus is 
associated with susceptibility for obesity. Mice models with genetic alterations 
which disrupt MC3R exhibited hypophagia, higher energy efficiency, reduced 
locomotor activity, hyperleptinemia and reduced linear growth accompanied 
by higher percentage of body fat without increased body weight, compared 
with the wildtype mice (295, 296). Furthermore, two case-control studies have 
independently demonstrated two missense MC3R variants, Thr6Lys 
(rs3746619) and Val81Ile (rs3827103) which are in near complete linkage 
disequilibrium, were significantly associated with increased adiposity in 
childhood, and exhibited reduced in-vitro activity compared to wild-type 
MC3R (297, 298). It has been previously described that Singaporean obese 
children with the Thr6Lys/Val81Ile variants exhibited significantly higher 
leptin levels, percentage body fat and insulin sensitivity (298). Thus, the 
published evidence supports the role of MC3R as well as FTO in human 
weight regulation, and the effects of MC3R and FTO variants on childhood 
adiposity are mediated by increased energy intake and possibly altered 
sensitivity to satiety (299-302). Data on the influence of MC3R and FTO 
variants on adiposity during the first few years of life is fragmentary, and it is 
unclear when and at what age do such susceptibility variants start to exert 
effects on phenotype. Thus in this study, we assessed the association between 
genetic variants within the MC3R and FTO loci with overweight status at early 
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childhood, and hypothesized that offspring with polymorphic variants of 
known adiposity-associated genes (MC3R and FTO) would be predisposed to 
overweight during early childhood, and determined if these effects were 
mediated by childhood appetitive traits. 
9.3 Materials and Methods 
9.3.1 Study population, antenatal and infant anthropometry 
measurements 
Details on the study population, antenatal and infant anthropometry 
measurements have been described in Section 2.1, Section 2.3.1 and Section 
2.3.2.1 
9.3.2 Illumina Omniexpress + exome genotyping  
Genotyping was performed on DNA extracted from frozen umbilical 
cords using the Illumina omniexpress + exome array platform. These arrays 
genotype the most frequent SNPs genome wide (omniexpress) and those 
discovered within exons (exome). DNA hybridization to arrays and scanning 
was performed by the service provider Expression Analysis Inc. Data was 
processed in GenomeStudio Genotyping Module
™
. Genotyping calls were 
made by the GenCall software which incorporates a clustering algorithm 
(GenTrain) and a calling algorithm (Bayesian model). GenCall score of each 
SNP probe and call rate of each sample are generated. Genotypes with a 
GenCall score less than 0.15 were considered missing. There were no poorly 
performing samples as defined by low sample call rates or low GC Scores. 
Nine variants within the MC3R gene (rs3746619, rs3827103, exm1551534, 
exm1969518, exm1551535, exm1969522, exm1551559, exm1551560, 
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exm1551565) were genotyped on the arrays. However, only two variants 
(rs3746619, rs3827103) were polymorphic in our study population. The minor 
alleles of these two variants represented missense polymorphisms 17C > A 
(Thr6Lys) and 241 G >A (Val81Ile) respectively. Nine FTO variants were 
previously reported to show significant association with obesity in ethnic 
Chinese and Malay adults in Singapore Nine FTO variants were previously 
reported to show significant association with obesity in ethnic Chinese and 
Malay adults in Singapore (292). Of those nine variants, six were genotyped 
on the arrays and analyzed in this report (rs9939973, rs1421085, rs1121980, 
rs9939609, rs17817749, rs8050136).  
9.3.3 Infant feeding and appetitive traits 
Details regarding infant feeding assessment has been described in 
Section 2.3.2.2.  
Early childhood appetitive traits were measured using the Child Eating 
Behaviour Questionnaire (CEBQ) completed by the mothers. The CEBQ was 
sent by postal service to the participants home prior to the 1-year visit and 
collected during the 1-year home visit. Questionnaires distributed were in 
English unless a preference for another language (Mandarin, Malay or Tamil) 
was expressed.  For these cases, translated versions of the questionnaires were 
distributed. The CEBQ relates to a period in which the child was predominatly 
fed solid food. Each item on the questionnaire was answered using a five-point 
Likert frequency scale (1=never, 2=rarely, 3=sometimes, 4=often and 5 
=always). Principal component analysis (PCA) was performed to reduce the 
appetitive trait items into robust components, with Varimax normalized 
rotation applied on all items of the CEBQ. Questions with reverse scales were 
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first reverse scored, and a factor loading cut-off of 0.5 was applied before 
running the analysis. The 35-item CEBQ in this study was reduced to seven 
components, four of which measured food approach appetitive traits: food 
esponsiveness, enjoyment of food, emotional over eating and desire to drink. 
Food fussiness and enjoyment of food were combined as one subscale under 
enjoyment of food as they have been shown to load into the same factor.  
Examples of items that fall under the category of food approach behavior are 
“My child is always asking for food” (food responsiveness), “My child loves 
food” (enjoyment of food), “My child eats more when worried” (emotional 
over eating), “My child is always asking for a drink” (desire to drink). The 
three other subscales of the CEBQ measure food avoidant behaviors: 
Emotional under eating, satiety responsiveness and slowness in eating. 
Examples of items that fall under the category of food avoidant appetitive 
traits are “My child eats less when angry” (emotional under eating), “My child 
gets full up easily” (satiety responsiveness) and “My child eat slowly” 
(slowness in eating).  
9.3.4 Statistical analyses 
 Descriptive statistics were reported as means and standard deviations 
for continuous variables and percentages for categorical variables. Infant BMI 
was calculated as infant weight/(infant height)
2
. Age- and gender-specific 
standardized z-scores were calculated for BMI, referencing the WHO Child 
Growth Standards (212). Overweight status at 1-, 2- and 3-years of age was 
defined as having a BMI z-score of more than 2 as defined by WHO (212). 
Linkage disequilibrium (LD), in the form of r
2
, for the two MC3R and six FTO 
variants respectively were estimated using Haploview (303). For analyses of 
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associations of MC3R and FTO variants with overweight status at 1, 2- and 3-
years of age, each variant was considered as a continuous variable. Individuals 
were assigned as 0, 1, or 2 according to their number of minor alleles. Logistic 
regression models were used to calculate odds ratios for each variant, higher 
by one minor allele, with Model I adjusting for ethnicity, Model II including 
additional adjustment of birth factor i.e.birthweight-for-gestational age and 
Model III including additional adjustment for postnatal factor i.e. 
breastfeeding duration. To test the hypothesis that appetitive traits may 
mediate the relationship between MC3R or FTO variants and overweight 
status, we analysed the association between MC3R or FTO variants with 
CEBQ scores at 1-year of age using multivariate linear regression. All 















9.4.1 Demographics and clinical characteristics 
 Complete genotype data for the two and six polymorphic variants 
within MC3R and FTO loci respectively, were available for 1090 study 
participants. Demographic and clinical characteristics, stratified by MC3R 
genotype, are shown in Table 9.1. No significant differences were observed in 
maternal characteristics (education, BMI at 26-28 weeks gestation, parity, 
gestational diabetes) and offspring characteristics (gender, gestational age at 
delivery, breastfeeding duration, birth weight, length, BMI) across the MC3R 
genotypes. Indian infants were more likely to carry two copies of the minor 
allele compared to Chinese and Malay infants, although this difference is not 
statistically significant. No significant differences in parity, gestational 
diabetes, infant gender, gestational age, birth weight, length and BMI were 
observed across the FTO genotypes (Tables 9.2-9.4). Infants who carried the 
minor allele had higher maternal BMI at 26-28 weeks gestation (p<0.001 for 
all six FTO variants), were more likely to be of Indian ethnicity (p<0.001 for 
all six FTO variants), tended to breastfeed for less than 6 months (p < 0.05 for 
rs9939609, rs17817449, rs8050136) and were more likely to have less than 12 
years of education (p < 0.05 for rs1421085, rs9939609, rs17817449, 
rs8050136).  Figures 9.1A-B illustrates the LD of the two MC3R and six FTO 
variants respectively. The two MC3R variants, rs3746619 and rs3827103, 
were in near perfect LD in our study population (r
2
 = 0.98). The six FTO 





Table 9.1: Demographic and clinical characteristics of study participants by MC3R genotype 
Numbers represent mean ± SD or n(%) 
#
 P value for continuous variables by One-Way ANOVA; for categorical variables by chi-square analysis 
 
 rs3746619  rs3827103 
Mothers 
CC 
N = 639 
AC 
N = 385 
AA 
N = 66 
P value
#  CC 
N = 644 
AC 
N = 380 
AA 
N = 66 
P value
# 
Education level    0.111     0.092 
 < 12 years 242 (55.4) 162 (37.1) 33 (7.6)   243 (55.6) 161 (36.8) 33 (7.6)  
 ≥ 12 years 389 (60.8) 218 (34.1) 33 (5.2)   393 (61.4) 214 (33.4) 33 (5.2)  
Ethnicity    0.069     0.137 
 Chinese 385 (62.4) 199 (32.3) 33 (5.3)   385 (62.4) 199 (32.3) 33 (5.3)  
 Malay 150 (54.3) 108 (39.1) 18 (6.5)   150 (54.3) 108 (39.1) 18 (6.5)  
 Indian 104 (52.8) 78 (39.6) 15 (7.6)   109 (55.3) 73 (37.1) 15 (7.6)  
Parity    0.755     0.661 
 Primiparous 286 (57.7) 181 (36.5) 29 (5.8)   287 (57.9) 180 (36.3) 29 (5.8)  
 Multiparous 353 (59.4) 204 (34.3) 37 (6.2)   357 (60.1) 200 (33.7) 37 (6.2)  
Body Mass Index (kg/m
2
)  
at 26-28 weeks pregnancy 
26.1 ± 4.3 26.5 ± 4.6 25.7 ± 4.7 0.305  26.2 ± 4.3 26.5 ± 4.6 25.7 ± 4.7 0.375 
Gestational diabetes    0.854     0.855 
 No 480 (58.0) 294 (35.6) 53 (6.4)   483 (58.4) 291 (35.2) 53 (6.4)  
 Yes  110 (58.5) 68 (36.2) 10 (5.3)   111 (59.0) 67 (35.6) 10 (5.3)  
Offspring   
Gestational age (weeks) 38.3 ± 1.4 38.3 ± 1.6 38.3 ±1.2 0.935  38.3 ± 1.4 38.3 ± 1.6 38.3 ± 1.2 0.909 
Gender    0.611     0.633 
 Male  308 (60.2) 175 (34.2) 29 (5.7)   310 (60.5) 173 (33.8) 29 (5.7)  
 Female 331 (57.3) 210 (36.3) 37 (6.4)   334 (57.8) 207 (35.8) 37 (6.4)  
Breastfeeding duration    0.062     0.072 
 < 6 months 277 (56.2) 182 (36.9) 34 (6.9)   280 (56.8) 179 (36.3) 34 (6.9)  
 ≥ 6 months 204 (63.9) 101 (31.7) 14 (4.4)   205 (64.3) 100 (31.3) 14 (4.4)  
Birth weight 3.1 ± 0.4 3.1 ± 0.4 3.1 ± 0.4 0.545  3.1 ± 0.4 3.1 ± 0.4 3.1 ± 0.4 0.485 
Birth length 48.7 ± 2.3 48.6 ± 2.3 48.6 ± 1.9 0.764  48.7 ± 2.3 48.6 ± 2.3 48.6 ± 1.9 0.719 
Birth BMI 13.1 ± 1.3 13.1 ± 1.4 13.0 ± 1.4 0.670  13.1 ± 1.3 13.1 ± 1.4 13.0 ± 1.4 0.615 
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Table 9.2: Demographic and clinical characteristics of study participants by FTO rs9939973 and rs1421085 genotype 
Numbers represent mean ± SD or n(%) 
#
 P value for continuous variables by One-Way ANOVA; for categorical variables by chi-square analysis 
 
 rs9939973  rs1421085 
Mothers 
GG 
N = 615 
AG 
N = 387 
AA 
N = 87 
P value
#  TT 
N = 684 
CT 
N = 346 
CC 
N = 59 
P value
# 
Education level    0.243     0.044 
 < 12 years 235 (53.9) 161 (36.9) 40 (9.2)   256 (58.7) 151 (34.6) 29 (6.7)  
 ≥ 12 years 375 (58.6) 219 (34.2) 46 (7.2)   422 (65.9) 188 (29.4) 30 (4.7)  
Ethnicity    <0.001     <0.001 
 Chinese 415 (67.4) 175 (28.4) 26 (4.2)   463 (75.2) 139 (22.6) 14 (2.3)  
 Malay 128 (46.4) 124 (44.9) 24 (8.7)   134 (48.6) 121 (43.8) 21 (7.6)  
 Indian 72 (36.5) 88 (44.7) 37 (18.8)   87 (44.2) 86 (43.7) 24 (12.2)  
Parity    0.196     0.117 
 Primiparous 289 (58.4) 174 (35.2) 32 (6.5)   325 (65.7) 149 (30.1) 21 (4.2)  
 Multiparous 326 (54.9) 213 (35.9) 55 (9.3)   359 (60.4) 197 (33.2) 38 (6.4)  
Body Mass Index (kg/m
2
)  
at 26-28 weeks pregnancy 
25.6 ± 4.0 26.9 ± 4.8 27.7 ± 4.9 <0.001  25.7 ± 4.0 27.0 ± 4.8 28.0 ± 5.2 <0.001 
Gestational diabetes    0.267     0.595 
 No 463 (56.1) 302 (36.6) 61 (7.4)   516 (62.5) 266 (32.2) 44 (5.3)  
 Yes  115 (61.2) 57 (30.3) 16 (8.5)   122 (64.9) 54 (28.7) 12 (6.4)  
Offspring   
Gestational age (weeks) 38.4 ± 1.4 38.2 ± 1.4 38.2 ± 1.9 0.246  38.4 ± 1.4 38.2 ± 1.4 38.0 ± 2.1 0.083 
Gender    0.531     0.634 
 Male  280 (54.7) 189 (36.9) 43 (8.4)   314 (61.3) 169 (33.0) 29 (5.7)  
 Female 335 (58.1) 198 (34.3) 44 (7.6)   370 (64.1) 177 (30.7) 30 (5.2)  
Breastfeeding duration    0.466     0.087 
 < 6 months 265 (53.8) 182 (36.9) 46 (9.3)   293 (59.4) 164 (33.3) 36 (7.3)  
 ≥ 6 months 182 (57.2) 113 (35.5) 23 (7.2)   208 (65.4) 97 (30.5) 13 (4.1)  
Birth weight 3.1 ± 0.4 3.1 ± 0.4 3.1 ± 0.5 0.939  3.1 ± 0.4 3.1 ± 0.4 3.1 ± 0.5 0.712 
Birth length 48.7 ± 2.2 48.6 ± 2.2 48.4 ± 3.0 0.591  48.7 ± 2.2 48.6 ± 2.2 48.2 ± 3.2 0.186 
Birth BMI 13.0 ± 1.3 13.1 ± 1.3 13.1 ± 1.4 0.568  13.0 ± 1.3 13.1 ± 1.3 13.1 ± 1.4 0.471 
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Table 9.3: Demographic and clinical characteristics of study participants by FTO rs1121980 and rs9939609 genotype 
Numbers represent mean ± SD or n(%) 
#
 P value for continuous variables by One-Way ANOVA; for categorical variables by chi-square analysis 
 
 rs1121980  rs9939609 
Mothers 
CC 
N = 623 
CT 
N = 383 
TT 
N = 83 
P value
#  TT 
N = 698 
AT 
N = 337 
AA 
N = 54 
P value
# 
Education level    0.167     0.025 
 < 12 years 236 (54.1) 162 (37.2) 38 (8.7)   261 (59.9) 147 (33.7) 28 (6.4)  
 ≥ 12 years 382 (59.7) 214 (33.4) 44 (6.9)   431 (67.3) 183 (28.6) 26 (4.1)  
Ethnicity    <0.001     <0.001 
 Chinese 421 (68.3) 172 (27.9) 23 (3.7)   466 (75.6) 138 (22.4) 12 (1.9)  
 Malay 129 (46.7) 123 (44.6) 24 (8.7)   137 (49.6) 118 (42.8) 21 (7.6)  
 Indian 73 (37.1) 88 (44.7) 36 (18.3)   95 (48.2) 81 (41.1) 21 (10.7)  
Parity    0.153     0.170 
 Primiparous 294 (59.4) 171 (34.5) 30 (6.1)   329 (66.5) 147 (29.7) 19 (3.8)  
 Multiparous 329 (55.4) 212 (35.7) 53 (8.9)   369 (62.1) 190 (32.0) 35 (5.9)  
Body Mass Index (kg/m
2
)  
at 26-28 weeks pregnancy 
25.6 ± 4.0 26.9 ± 4.8 27.6 ± 5.0 <0.001  25.7 ± 4.0 27.0 ± 4.9 27.9 ± 5.4 <0.001 
Gestational diabetes    0.324     0.841 
 No 470 (56.9) 298 (36.1) 58 (7.0)   526 (63.7) 258 (31.2) 42 (5.1)  
 Yes  116 (61.7) 57 (30.3) 15 (8.0)   124 (66.0) 55 (29.3) 9 (4.8)  
Offspring   
Gestational age (weeks) 38.4 ± 1.4 38.2 ± 1.5 38.2 ± 1.8 0.159  38.4 ± 1.4 38.1 ± 1.6 38.3 ± 1.1 0.086 
Gender    0.667      
 Male  286 (55.9) 187 (36.5) 39 (7.6)   319 (62.3) 167 (32.6) 26 (5.1)  
 Female 337 (58.4) 196 (34.0) 44 (7.6)   379 (65.7) 170 (29.5) 28 (4.9)  
Breastfeeding duration    0.332     0.034 
 < 6 months 266 (54.0) 183 (37.1) 44 (8.9)   297 (60.2) 161 (32.7) 35 (7.1)  
 ≥ 6 months 187 (58.8) 109 (34.3) 22 (6.9)   214 (67.3) 93 (29.2) 11 (3.5)  
Birth weight 3.1 ± 0.4 3.1 ± 0.4 3.1 ± 0.5 0.977  3.1 ± 0.4 3.1 ± 0.4 3.1 ± 0.4 0.964 
Birth length 48.7 ± 2.2 48.6 ± 2.2 48.4 ± 2.9 0.509  48.7 ± 2.2 48.5 ± 2.4 48.4 ± 2.5 0.408 
Birth BMI 13.0 ± 1.3 13.1 ± 1.3 13.1 ± 1.3 0.621  13.0 ± 1.3 13.1 ± 1.3 13.3 ± 1.1 0.398 
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Table 9.4: Demographic and clinical characteristics of study participants by FTO rs17817449 and rs8050136 genotype 
Numbers represent mean ± SD or n(%) 
#
 P value for continuous variables by One-Way ANOVA; for categorical variables by chi-square analysis 
 
 rs17817449  rs8050136 
Mothers 
TT 
N = 700 
GT 
N = 335 
GG 
N = 54 
P value
#  TT 
N = 700 
AT 
N = 335 
AA 
N = 54 
P value
# 
Education level    0.020     0.020 
 < 12 years 261 (59.9) 147 (33.7) 28 (6.4)   261 (59.9) 147 (33.7) 28 (6.4)  
 ≥ 12 years 433 (67.7) 181 (28.3) 26 (4.1)   433 (67.7) 181 (28.3) 26 (4.1)  
Ethnicity    <0.001     <0.001 
 Chinese 468 (76.0) 136 (22.1) 12 (1.9)   468 (76.0) 136 (22.1) 12 (1.9)  
 Malay 137 (49.6) 118 (42.8) 21 (7.6)   137 (49.6) 118 (42.8) 21 (7.6)  
 Indian 95 (48.2) 81 (41.1) 21 (10.7)   95 (48.2) 81 (41.1) 21 (10.7)  
Parity    0.144     0.144 
 Primiparous 331 (66.9) 145 (29.3) 19 (3.8)   331 (66.9) 145 (29.3) 19 (3.8)  
 Multiparous 369 (62.1) 190 (32.0) 35 (5.9)   369 (62.1) 190 (32.0) 35 (5.9)  
Body Mass Index (kg/m
2
)  
at 26-28 weeks pregnancy 
25.7 ± 4.0 27.0 ± 4.9 27.9 ± 5.4 <0.001  25.7 ± 4.0 27.0 ± 4.9 27.9 ± 5.4 <0.001 
Gestational diabetes    0.857     0.785 
 No 527 (63.8) 257 (31.1) 42 (5.1)   527 (63.8) 257 (31.1) 42 (5.1)  
 Yes  124 (66.0) 55 (29.3) 9 (4.8)   125 (66.5) 54 (28.7) 9 (4.8)  
Offspring   
Gestational age (weeks) 38.4 ± 1.4 38.1 ± 1.6 38.3 ± 1.1 0.091  38.4 ± 1.4 38.2 ± 1.6 38.3 ± 1.1 0.100 
Gender    0.583     0.583 
 Male  321 (62.7) 165 (32.2) 26 (5.1)   321 (62.7) 165 (32.2) 26 (5.1)  
 Female 379 (65.7) 170 (29.5) 28 (4.9)   379 (65.7) 170 (29.5) 28 (4.9)  
Breastfeeding duration    0.026     0.032 
 < 6 months 297 (60.2) 161 (32.7) 35 (7.1)   298 (60.4) 160 (32.5) 35 (7.1)  
 ≥ 6 months 216 (67.9) 91 (28.6 11 (3.5)   215 (67.6) 92 (28.9) 11 (3.5)  
Birth weight 3.1 ± 0.4 3.1 ± 0.5 3.1 ± 0.4 0.964  3.1 ± 0.4 3.1 ± 0.5 3.1 ± 0.4 0.965 
Birth length 48.7 ± 2.2 48.5 ± 2.4 48.4 ± 2.5 0.411  48.7 ± 2.2 48.5 ± 2.4 48.4 ± 2.5 0.411 
Birth BMI 13.0 ± 1.3 13.1 ± 1.3 13.3 ± 1.1 0.401  13.0 ± 1.3 13.1 ± 1.3 13.3 ± 1.1 0.399 
 181 
 











9.4.2 Relationship between MC3R and FTO variants with frequency of 
overweight at 1-, 2- and 3-years of age 
We next examined the association between MC3R and FTO variants 
with overweight status at 1-, 2- and 3-years of age. Due to the strong LD 
between the two genetic variants within the MC3R locus, we discuss the 
analysis results for MC3R rs3746619 and note that similar results are obtained 
for MC3R rs3827103. Likewise, we discuss results for FTO rs9939973 since 
similar conclusions are obtained for the other FTO variants. We selected 
rs3746619 and rs9939973 as representative variants to cover the MC3R and 
FTO haploblocks respectively, as these variants exhibited the highest minor 




of overweight infants at 2- and 3-years of age (1.5% to 6.0% at 2-years; 3.5% 
to 10.9% at 3-years, p<0.05 by Chi-square test for trend), but not at 1-year of 
age, for every minor allele increase for MC3R rs3746619 (Figure 9.2A), 
highlighting the positive relationship between MC3R risk variants with 
overweight status during early childhood. No obvious linear relationship with 
increasing frequency of overweight status at 1- and 2-years of age was noted 
for FTO rs9939973 (Figure 9.2B). A chi-square test revealed no significant 
linear trend for overweight status at 1- and 2-years of age for FTO rs9939973 
Our findings in Figure 9.2B also seems to suggest that there is an increase in 
risk of overweight only for the FTO heterozygote variants at 3-years of age, 
implying a plausible co-dominance genetic model for FTO and overweight 
status at 3-years of age. A sub-analysis using a co-dominant model of FTO 
(heterozygote vs. the two homozygotes) with outcome of overweight status at 
3-years however, showed no significant associations (Table 9.5). The 
proportion of overweight infants at 1-, 2- and 3-years of age according to the 




Figure 9.2: Frequency of overweight status at 1-, 2- and 3-years of age according to MC3R 
rs3746619 (A) and FTO rs9939973 (B) genotype. Dotted line = overweight at 1-year, Dashed line = 
























Figure 9.3: Frequency of overweight status at 1-, 2- and 3-years of age according to MC3R rs3827103 (A), FTO rs1421085 (B), FTO rs1121980 (C), 
FTO rs9939609 (D), FTO rs17817449 (E), FTO rs8050136 (F). Dotted line = overweight at 1-year, Dashed line = overweight at 2-years, Solid line = 





A) B) C) 
D) E) F) 
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Table 9.5: Association between FTO genetic variants with overweight status at 3-
years of age using a co-dominant genetic model 
Odds ratios represent odds of being overweight for heterozygote vs. two homozygotes 
Adjusted for ethnicity, birthweight-for-gestational age, breastfeeding duration 
 
9.4.3 Association between MC3R and FTO variants with overweight status 
at 1-, 2- and 3-years of age 
The associations of MC3R and FTO with overweight status at 1-, 2- 
and 3-years of age are given in Table 9.6, including odds ratios (OR) and 95% 
confidence intervals (CI). The minor allele for MC3R rs3746619 increased the 
risk of being overweight at 2-years (p=0.031) and 3-years of age (p=0.012), 
with a consistent albeit not statistically significant trend at 1-year. Each 
additional copy of the risk allele for MC3R rs3746619 increased the odds of 
being overweight at 2- years by 2.23 times (95% CI: 1.08-4.61), after 
adjustment for potential confounders. Similar results were noted for 
overweight status at 3-years of age (OR = 2.05, CI: 1.17-3.58). In addition, 
FTO rs9939973 variant was not significanly associated with overweight status 
at 1-, 2- and 3-years of age. The associations of the other MC3R and FTO 
variants with overweight status at 1-, 2- and 3-years of age are also illustrated 
in Table 9.6. 
Genetic 
variants 
Overweight at 3-years 
OR 95% CI 
FTO   
rs9939973 AG vs. (AA/GG) 2.09 0.97-4.50 
rs1421085 CT vs. (CC/TT) 1.71 0.79-3.70 
rs1121980 CT vs. (CC/TT) 2.08 0.97-4.47 
rs9939609 AT vs. (AA/TT) 1.82 0.84-3.91 
rs17817449 GT vs. (GG/TT) 1.82 0.84-3.92 
rs8050136 AT vs. (AA/TT) 1.82 0.84-3.92 
 186 
 
Table 9.6: Association between MC3R and FTO genetic variants with overweight status at 1-, 2- and 3-years of age.  
OR represents the odds ratios of being overweight associated with for every additional copy of minor allele 
1
 Representative variant for MC3R haploblock 
2
 Representative variant for FTO haploblock 
a 
Model 1: Adjusted for ethnicity 
b 
Model 2: Adjusted for Model 1 + birthweight-for-gestational age 
c
 Model 3: Adjusted for Model 1 + Model 2 + breastfeeding duration 
*Additionally adjusted for maternal BMI at 26-28 weeks gestation 
+






Overweight at 1-year  Overweight at 2-years 
 



















OR 95%CI OR 95%CI OR 95%CI  OR 95%CI OR 95%CI OR 95%CI  OR 95% CI OR 95% CI OR 95% CI 
MC3R                     
rs3746619
1
  1.33 0.64-2.78 1.45 0.70-3.10 1.59 0.71-3.57  2.00 1.02-3.94 2.16 1.09-4.28 2.23 1.08-4.61  1.77 1.12-2.79 1.82 1.14-2.89 2.05 1.17-3.58 
rs3827103 1.34 0.64-2.79 1.49 0.71-3.11 1.60 0.71-3.58  2.01 1.03-3.95 2.17 1.10-4.29 2.24 1.09-4.63  1.79 1.13-2.82 1.84 1.16-2.91 2.08 1.19-3.61 
FTO                     
rs9939979
2
* 0.78 0.36-1.69 0.80 0.37-1.75 0.76 0.31-1.82  1.20 0.59-2.43 1.27 0.62-2.60 1.10 0.51-2.40  1.12 0.70-1.79 1.12 0.70-1.79 0.86 0.48-1.56 
rs1421085
+ 
0.91 0.42-1.99 0.92 0.42-2.04 0.83 0.34-2.02  0.93 0.43-2.01 0.96 0.44-2.11 0.90 0.39-2.05  1.17 0.71-1.92 1.17 0.70-1.93 0.85 0.45-1.59 
rs1121980* 0.79 0.37-1.72 0.81 0.37-1.77 0.76 0.32-1.83  1.23 0.60-2.50 1.30 0.63-2.68 1.12 0.51-2.45  1.09 0.68-1.75 1.08 0.67-1.74 0.88 0.48-1.59 
rs9939609
+ 
0.95 0.44-2.06 0.95 0.43-2.08 0.85 0.35-2.05  0.98 0.45-2.11 0.99 0.45-2.18 0.94 0.41-2.13  1.19 0.72-1.96 1.16 0.70-1.92 0.89 0.48-1.67 
rs17817449
+ 
0.95 0.44-2.06 0.95 0.43-2.08 0.85 0.35-2.05  0.98 0.45-2.12 1.00 0.45-2.19 0.94 0.41-2.13  1.19 0.72-1.96 1.16 0.70-1.92 0.89 0.48-1.67 
rs8050136
+ 
0.95 0.44-2.06 0.95 0.43-2.08 0.85 0.35-2.05  0.98 0.45-2.12 1.00 0.45-2.18 0.94 0.41-2.13  1.19 0.72-1.96 1.16 0.70-1.92 0.89 0.48-1.67 
 187 
 
9.4.4 Association between MC3R and FTO variants with childhood 
appetitve traits at 1-year of age 
To test the hypothesis that appetitive traits may mediate the 
relationship between MC3R and FTO variants and overweight status at 2- and 
3-years of age, we analysed the association of each variant with each subscale 
of the CEBQ appetitive trait scores within a subgroup (n = 422) that had 
completed the CEBQ questionnaires. Characteristics of participants who 
completed the CEBQ questionnaires tended to be Chinese, had at least 12 
years of education, breastfed their infants for at least 6 months, had lower BMI 
at 26-28 weeks of gestation, had shorter duration of gestation and had higher 
birth weight, length and BMI compared to those who did not complete the 
questionnaire (Table 9.7). We observed a significant positive relationship 
between MC3R with only the “slowness in eating” subscale, (p=0.019, Table 
9.8). Those who were homozygous for the minor allele had the highest scores 
for “slowness in eating” (mean z-score ± SD: 0.53 ± 1.16 for rs3746119) 
compared to those who were homozygous for the protective allele (mean z-
score ± SD: -0.11 ± 1.00 for rs3746119). However, this finding does not pass 
strict multiple testing correction. No significant associations were observed 








Table 9.7: Characteristics of participants who completed the CEBQ 






CEBQ (n = 422) 
 
Did not complete 
CEBQ (n = 678) 
 
P value 
Maternal education     0.022 
 < 12 years 152 (36.3)  285 (43.3)   
 ≥ 12 years 267 (63.7)  373 (56.7)   
Ethnicity     <0.001 
 Chinese 268 (63.5)  349 (52.2)   
 Malay  101 (23.9)  175 (26.2)   
 Indian 53 (12.6)  144 (21.6)   
Parity     0.452 
 Primiparous 186 (44.1)  310 (46.4)   
 Multiparous 236 (55.9)  358 (53.6)   
BMI at 26-28 weeks pregnancy 25.8 ± 4.1  26.5 ± 4.6  0.011 
Gestational Diabetes     0.041 
 No 335 (84.6)  492 (79.5)   
 Yes 61 (15.4)  127 (20.5)   
Gestational age at delivery 38.6 ± 1.0  38.0 ± 1.6  <0.001 
Gender     0.879 
 Male 225 (53.3)  353 (52.8)   
 Female 197 (46.7)  315 (47.2)   
Breastfeeding duration     0.015 
 < 6 months 206 (56.1)  287 (64.5)   
 ≥ 6 months 161 (43.9)  158 (35.5)   
Birth weight (kg) 3.2 ± 0.4  3.0 ± 0.5  <0.001 
Birth length (cm) 49.0 ± 2.0  48.4 ± 2.4  <0.001 
Birth BMI (kg/m
2
) 13.3 ± 1.2  12.9 ± 1.3  <0.001 
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Table 9.8: Childhood eating behaviour (CEBQ) scores by MC3R and FTO genotypes 
 




AA (n=24) AC (n=150) CC (n=248) +P value
 
 
AA (n=27) AG (n=149) GG (n=245) +P value 
CEBQ 
         
Enjoyment of food -0.15 ± 1.26 0.07 ± 0.99 -0.02 ± 0.96 0.883  -0.01 ± 1.24 0.02 ± 1.00 -0.008 ± 0.95 0.922 
Food responsiveness 0.24 ± 0.94 -0.04 ± 0.95 -0.004 ± 1.03 0.440  -0.20 ± 0.94 -0.08 ± 1.07 0.07 ± 0.95 0.257 
Emotional under eating -0.05 ± 1.02 -0.02 ± 0.98 -0.004 ± 1.00 0.592  -0.23 ± 1.10 -0.11 ± 0.98 0.07 ± 0.99 0.525 
Slowness in eating 0.53 ± 1.16 0.10 ± 0.91 -0.11 ± 1.00 0.019  0.07 ± 1.09 -0.02 ± 0.96 0.008 ± 1.00 0.659 
Emotional over eating 0.14 ± 1.19 0.04 ± 0.98 -0.04 ± 0.98 0.120  -0.16 ± 0.97 0.08 ± 1.04 -0.04 ± 0.96 0.542 
Desire to drink -0.02 ± 0.90 0.12 ± 1.01 -0.06 ± 1.01 0.364  -0.01 ± 0.98 -0.04 ± 0.96 0.03 ± 1.04 0.598 
Satiety responsiveness -0.14 ± 0.85 0.01 ± 0.98 0.05 ± 1.02 0.123  0.06 ± 1.12 0.06 ± 1.00 -0.06 ± 0.98 0.347 
 CEBQ scores are computed as z-scores relative to the GUSTO cohort 
Numbers represent mean z-score ± S.D 
+
Adjusted for gender, ethnicity, birthweight-for-gestational age and breastfeeding duration 
Table 9.9: Childhood eating behaviour (CEBQ) scores by MC3R and FTO genotypes 
CEBQ scores are computed as z-scores relative to the GUSTO cohort 
Numbers represent mean z-score ± S.D 
+






AA (n=24) AG (n=149) GG (n=249) +P value 
 
CC (n=20) CT (n=131) TT (n=270) +P value 
CEBQ 
         
Enjoyment of food -0.15 ± 1.26 0.07 ± 1.00 -0.02 ± 0.96 0.931  -0.06 ± 1.31 0.05 ± 1.00 -0.02 ± 0.96 0.901 
Food responsiveness 0.24 ± 0.94 -0.04 ± 0.96 -0.003 ± 1.02 0.485  -0.10 ± 0.84 -0.10 ± 1.10 0.05 ± 0.96 0.529 
Emotional under eating -0.05 ± 1.02 -0.01 ± 0.98 -0.007 ± 0.94 0.557  -0.23 ± 1.26 -0.20 ± 0.92 0.09 ± 1.00 0.261 
Slowness in eating 0.53 ± 1.17 0.11 ± 0.91 -0.12 ± 1.00 0.013  0.13 ± 1.24 -0.03 ± 0.98 0.006 ± 0.99 0.485 
Emotional over eating 0.14 ± 1.19 0.05 ± 0.98 -0.04 ± 0.98 0.112  -0.15 ± 0.83 0.07 ± 1.08 -0.03 ± 0.95 0.626 
Desire to drink -0.02 ± 0.90 0.12 ± 1.01 -0.06 ± 1.01 0.366  -0.002 ± 1.02 0.0001 ± 0.94 0.007 ± 1.04 0.876 
Satiety responsiveness -0.14 ± 0.85 -0.09 ± 0.99 0.04 ± 1.01 0.133  0.19 ± 1.17 -0.03 ± 0.99 -0.02 ± 0.99 0.622 
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TT (n=26) CT (n=147) CC (n=248) +P value
 
 
AA (n=19) AT (n=129) TT (n=273) +P value 
CEBQ 
         
Enjoyment of food -0.01 ± 1.26 0.04 ± 1.00 -0.02 ± 0.96 0.814  -0.06 ± 1.35 0.06 ± 0.98 -0.02 ± 0.97 0.851 
Food responsiveness -0.23 ± 0.95 -0.08 ± 1.08 0.07 ± 0.95 0.250  -0.13 ± 0.85 -0.09 ± 1.10 0.05 ± 0.95 0.642 
Emotional under eating -0.23 ± 1.11 -0.13 ± 0.95 0.08 ± 1.01 0.425  -0.23 ± 1.30 -0.21 ± 0.89 0.10 ± 1.01 0.195 
Slowness in eating 0.09 ± 1.11 -0.006 ± 0.95 -0.008 ± 1.01 0.874  0.16 ± 1.27 -0.005 ± 0.97 -0.007 ± 0.99 0.722 
Emotional over eating -0.13 ± 0.97 0.09 ± 1.04 -0.05 ± 0.96 0.630  -0.11 ± 0.83 0.07 ± 1.08 -0.04 ± 0.95 0.747 
Desire to drink -0.03 ± 1.00 -0.04 ± 0.96 0.03 ± 1.04 0.557  -0.03 ± 1.04 -0.002 ± 0.94 0.01 ± 1.04 0.815 
Satiety responsiveness 0.05 ± 1.14 0.06 ± 1.01 -0.06 ± 0.98 0.435  0.18 ± 1.20 -0.04 ± 0.98 -0.008 ± 0.99 0.625 
CEBQ scores are computed as z-scores relative to the GUSTO cohort 
Numbers represent mean z-score ± S.D 
+
Adjusted for gender, ethnicity, birthweight-for-gestational age and breastfeeding duration 
Table 9.11: Childhood eating behaviour (CEBQ) scores by FTO genotypes 
 




GG (n=19) GT (n=129) TT (n=273) +P value
 
 
AA (n=19) AT (n=129) TT (n=273) +P value 
CEBQ 
         
Enjoyment of food -0.06 ± 1.35 0.06 ± 0.98 -0.02 ± 0.97 0.851  -0.06 ± 1.35 0.06 ± 0.98 -0.02 ± 0.97 0.851 
Food responsiveness -0.13 ± 0.85 -0.09 ± 1.10 0.05 ± 0.95 0.642  -0.13 ± 0.85 -0.09 ± 1.10 0.05 ± 0.95 0.642 
Emotional under eating -0.23 ± 1.30 -0.21 ± 0.89 0.10 ± 1.01 0.195  -0.23 ± 1.30 -0.21 ± 0.89 0.10 ± 1.01 0.195 
Slowness in eating 0.16 ± 1.27 -0.005 ± 0.97 -0.007 ± 0.99 0.722  0.16 ± 1.27 -0.005 ± 0.97 -0.007 ± 0.99 0.722 
Emotional over eating -0.11 ± 0.83 0.07 ± 1.08 -0.04 ± 0.95 0.747  -0.11 ± 0.83 0.07 ± 1.08 -0.04 ± 0.95 0.747 
Desire to drink -0.03 ± 1.04 -0.002 ± 0.94 0.01 ± 1.04 0.815  -0.03 ± 1.04 -0.002 ± 0.94 0.01 ± 1.04 0.815 
Satiety responsiveness 0.18 ± 1.20 -0.04 ± 0.98 -0.008 ± 0.99 0.625  0.18 ± 1.20 -0.04 ± 0.98 -0.008 ± 0.99 0.625 
CEBQ scores are computed as z-scores relative to the GUSTO cohort 
Numbers represent mean z-score ± S.D 
+




In this longitudinal study, we unravelled the novel associations 
between MC3R variants with early childhood adiposity and overweight status. 
To our knowledge, this is the first study to assess the relationship between 
MC3R variants and overweight status in children at such an early age. The 
effect of MC3R minor alleles on overweight status was present at both 2- and 
3-years of age, but not at 1-year, after adjusting in the regression models for 
factors which are known to influence size and adiposity during early 
childhood, suggesting that the influence of MC3R variants on childhood 
adiposity may manifest clinically from two years of age. A possible 
explanation is that the child might only start to exercise autonomy in self-
feeding between one and two years of age, while during the first year of life 
feeding is still very much dependent on what the mother provides. Earlier 
reports by Feng N et al(297), Zegers D et al(304) and Lee YS et al(298) have 
documented associations of these MC3R missense polymorphisms with 
adiposity in older obese children, in later childhood. Other studies that have 
identified significant relationships between MC3R variants and obesity were 
conducted in adult populations (305-307). Unlike the MC3R variants, the FTO 
variants showed no significant associations with overweight status at both two 
and three years of age despite its established status as the most prominent BMI 
susceptibility locus at later ages. Taken together, our findings support the role 
of MC3R minor allele variants in determining early childhood adiposity, and 
suggests effects at a much earlier ages as compared to FTO variants.  
Our findings are consistent current reports that the MC3R risk variants 
could be contributing to common obesity (283). Studies done on obese 
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children from different populations have independently described the 
association between MC3R minor allele variants with childhood adiposity. 
Feng N et al(297) showed that those who were homozygous for Thr6Lys and 
Val81Ile variants were significantly heavier, had more body fat, greater 
plasma leptin and insulin concentrations, and greater insulin resistance than 
children who were wild-type or heterozygous for MC3R variants. These 
homozygous variants were also only observed amongst children who were at 
risk of overweight (BMI ≥ 85th percentile), or who were considered 
overweight (BMI ≥ 95th percentile). Similar observations in a population of 
obese Singaporean Asian children have also been described, whereby obese 
children with the Thr6Lys and Val81Ile variants exhibited significantly higher 
leptin levels, and percentage body fat, highlighting that MC3R variants may be 
a predisposing factor for excessive body weight gain in children (298). 
However, other studies have reported null findings between MC3R risk 
variants with childhood obesity. A study by Obregón AM et al(301) on 229 
obese Chilean children found insufficient evidence of significant association 
between childhood obesity and the common MC3R variants, including the 
Val81Ile variant. Another study by Cieslak J et al(308) on a group of Polish 
children showed that the common MC3R polymorphism, Val81Ile, was widely 
distributed amongst obese and control cohorts, suggesting that the 
predisposing effect of the Val81Ile polymorphic variant to obesity may be 
rather unlikely.  
We also reported null associations between the FTO variants with 
overweight status at 1-, 2- and 3-years of age, which are in line with previous 
reports. A recent study by Mook-Kanamori et al involving 703 infants from 
 193 
 
the Generation R cohort highlighted no association between the FTO 
rs9939609 polymorphism and body composition at the age of six 
months(309). Another study involving 2732 full-term neonates of the German 
GINI-plus and LISA-plus birth cohorts also reported no evidence for BMI 
differences between genotypes of FTO variants during the first three years of 
life(310). A recent Fels Longitudinal Study involving 534 subjects also 
reported no association between FTO genotype with early growth in the first 
three years of life(311). Only one study thus far has shown that FTO gene 
polymorphism might associate with adipose tissue accumulation and weight 
gain, at least temporarily, during the neonatal period, although the authors 
noted that the genetic associations were shown without correcting for multiple 
comparisons(312). Interestingly, our findings suggested that there was an 
increase in risk of overweight only for the FTO heterozygote at three-years of 
age, implying a plausible co-dominance genetic model for FTO and 
overweight status. A sub-analysis of a co-dominant genetic model of FTO 
with the outcome of overweight at three-years of age however, showed no 
significant associations. Taken together, it seems to suggest that the effect of 
FTO genotype on adiposity does not appear to exert its influence during 
infancy and early childhood, unlike the MC3R variants in our study where the 
effect was observed as early as two-years of age. 
Mouse studies have shown that the mechanism in which MC3R 
variation leads to increased body fat was not increased food intake, but 
increased feed efficiency. These mice exhibited hypophagia compared to 
wildtype littermates, and were unusually susceptible to high fat diet-induced 
obesity, partly explained by physical inactivity(295, 296). Interestingly, our 
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study findings also reported a significant positive relationship between MC3R 
with the “slowness in eating” subscale of childhood appetitive traits at 1-year 
of age, indicating that subjects with the MC3R minor allele were perceived by 
their mothers to be eating more slowly compared to those without the risk 
allele. Although our finding does not pass strict multiple testing correction, it 
is strikingly similar with an earlier study conducted on a Chilean cohort, 
where obese boys carrying the minor allele for rs3746619 and rs3827103 
variants also showed higher scores for “slowness in eating” subscale for 
CEBQ compared to those without the minor allele(301). However, it was 
reported that older children with the risk MC3R variants had higher energy 
intake(302). Taken together, a possible explanation is that these children were 
eating more and therefore taking longer to complete meals, and mothers 
perceive this behaviour as “slow eating”. However, we cannot exclude other 
explanations for instance the possibility that the child’s adiposity influences 
the mother’s perception of their eating behaviour. To our knowledge, there are 
currently no studies on MC3R variants and energy intake in subjects younger 
than 6 years of age.  
Strengths of our study include the prospective design with high follow-
up rate, along with the study of Asian ethnic groups. To date, there are no 
published studies relating MC3R genetic variants with overweight status at one 
to three years of age, thus our study provides useful and informative data on 
this relationship. There are however limitations to consider. Although we have 
adjusted all analyses for potential confounders of adiposity, we could not rule 
out the possibility of confounding by population stratification at higher 
resolution than ethnicity. Furthermore, this study primarily used 
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anthropometry as indicators of adiposity, but lacks more detailed measures of 
body composition, such as dual x-ray absorptiometry (DXA) or air 
displacement plethysmography (BOD POD), at two- and three-years of age. 
Hence we were unable to further distinguish if these MC3R genetic variants 
were associated with fat mass or fat-free mass.  
In summary, this study has provided evidence of significant association 
between MC3R, but not FTO, genetic variants with early childhood 
overweight status at two and three years of age in a multi-ethnic Asian 
population. Our study highlighted the relative effects and roles of various 
susceptibility alleles may differ at different stages of life, and the implication 
is that different weight regulation pathways may assume varying temporal 
importance at various ages.  Follow-up studies would be necessary to examine 
if these MC3R variants would continue to influence overweight status and 











Chapter 10: Conclusions and future directions 
The primary aim of this dissertation is to examine the developmental 
factors that can predict patterns of size, growth and body composition in 
infancy and early childhood in a multi-ethnic Asian cohort. One of the first 
key objectives was to establish new references for size-at-birth based on a 
recent cohort of near-term and term Singapore infants, for the purposes of 
evaluating birth size correctly. Our study provided new reference values 
(percentiles and z-scores) for birth weight, length and head circumference for 
newborns 35-41 weeks of gestational age, allowing for more suitable 
classification of infants as small-, appropriate- or large-for-gestational age. In 
addition, we also sought to establish and validate a fat-mass estimation 
formula specific for the GUSTO cohort during the early postnatal period, 
using PEA POD® body composition measurements as reference. Our study 
also provided a new fat mass prediction reference model for use in Asian 
neonates, with weight, gender, gestational age and subscapular SFT as 
significant predictors of neonatal fat mass. This equation would be useful as a 
non-invasive method to obtain quick in-vivo estimates of fat mass in groups of 
infant subjects. More importantly, both references were important in 
establishing norms and a way to predict fat mass to explore our hypotheses on 
in-utero, postnatal, as well as genetic risk factors that would predispose an 
individual to adverse adiposity and growth outcomes 
The second objective was to examine the associations of maternal/in-
utero factors with size and adiposity of Singapore infants at birth. More 
specifically for this dissertation, we hypothesized on whether higher maternal 
glucose levels during pregnancy is associated with higher neonatal adiposity at 
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birth, utilizing the new birth size and adiposity reference models derived from 
our two earlier studies. Key findings were that maternal glucose levels during 
pregnancy measured at a single time point was effective in identifying 
excessive neonatal adiposity outcomes, and this dose-response relationship 
was graded across the range of maternal glucose levels, even at those that were 
below the diagnostic criteria for gestational diabetes, thereby confirming the 
link between maternal glycemia and neonatal adiposity. Furthermore, we 
noted that fluxes of maternal glucose during the fasting state showed slightly 
greater influence on excessive adiposity outcomes, and that the influence of 
raised maternal fasting glucose levels on neonatal ∑SFT were less pronounced 
for Indian mothers compared to Chinese mothers, highlighting the influence of 
ethnicity on the relationship between maternal glycemia and neonatal 
adiposity. 
We extended the findings of the above-mentioned study and proceeded 
to examine the relationship between maternal glycemia (fasting and post-
challenge glucose levels) and adiposity (BMI) during pregnancy on early 
postnatal growth of offspring during the first three years of life. Findings from 
this study demonstrated that maternal glycemia was associated with 
decelerated postnatal growth limited to the first 3 weeks to 3 months of life, 
followed by a transient period of accelerated growth between 9-15 months of 
life. Unlike maternal glycemia, the association between maternal adiposity 
during pregnancy with offspring adiposity persisted into early childhood till 
three years of age. In addition, the effect of increasing maternal glucose with 
increased size-at-birth was more pronounced in obese mothers compared to 
non-obese mothers. The association of increasing maternal glucose with 
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increased offspring BMI and overweight status however, was present only 
amongst non-obese women two years, and disappears at three years, whilst in 
obese mothers, the risk of offspring being overweight was unexpectedly 
highest in those who were in the lowest fasting glucose category. Furthermore 
for a subgroup of children born to multiparous and Chinese mothers, raised 
maternal glycemia levels was associated with greater weight and BMI at two 
years of age, highlighting the plausibility of ethnic and parity differences in 
the relationship between maternal glycemia and adiposity at later childhood. 
Taken together, findings from these two studies added significant, useful and 
informative data relating the maternal metabolic environment with neonatal 
body composition and early postnatal growth in a multi-ethnic Asian cohort.  
Another key objective of this study involved examining postnatal 
factors that might influence early postnatal growth and adiposity in the first 
three years of life. More specifically, we hypothesized that reduced breastmilk 
intake may result in accelerated adiposity gain in infants of GDM mothers. 
Interestingly, we demonstrated varied effects of breastmilk on early postnatal 
growth between offspring of non-GDM and GDM mothers. Whilst offspring 
of mothers without GDM who had greater breastmilk intake exhibited 
decelerated growth in the first year of life, offspring of GDM mothers 
however, do not exhibit accelerated adiposity gain during the early postnatal 
period despite reduced breastmilk intake as hypothesized, and we postulated 
that differences in breast milk constituents of GDM and non-GDM mothers, 
such as increased glucose or insulin concentrations, may have contributed to 
these observed differences.  
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Finally, we proceeded to examine potential predisposing genetic 
factors that may influence growth and adiposity in children. Firstly, we 
hypothesized that offspring with growth restriction in-utero and subsequent 
catch up growth have unique gene expression profile which is predictive of 
catch up growth, and did this by examining the transcriptomic profiles of 
umbilical cords of infants in the GUSTO cohort. Using a discovery-based 
genome-wide approach, we have uncovered gene expression changes that are 
significantly associated with fetal growth as well as subsequent postnatal 
growth. Utilizing a pathway analysis approach, these genes were also found to 
be significantly enriched in immune response, nucleotide metabolism, 
apoptotic as well as angiogenic pathways. The novelty of this study, unlike 
other studies, was the use of serial ultrasound measurements for the same fetus 
taken at different gestational periods to give a better indication and definition 
of fetal growth velocity, with minimal emphasis on birthweight to define a 
growth-restricted infant. Additionally, our study is one of the few to determine 
if variations in gene expression is associated with fetal growth among a set of 
newborns from low-risk pregnancies, hence providing greater insights into the 
transcriptomic profile of babies with differing fetal growth types.  
We also hypothesized that polymorphic variants of known adiposity-
associated genes MC3R and FTO would increase the risk of being overweight 
or obese during early childhood.  It was observed that the effect of MC3R 
minor alleles on overweight status was present at both 2- and 3-years of age, 
but not at 1-year of age, whereas the FTO polymorphic variants showed no 
significant associations with overweight status at 1-, 2- or 3-years of age, 
despite its established status as the most prominent BMI susceptibility locus at 
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later ages. Whilst other studies have documented associations of MC3R with 
adiposity in older obese children as well as adults, this study is the first to 
show that the effects of MC3R on adiposity occurs at a much earlier age as 
compared to FTO variants, highlighting how the relative effects and roles of 
various susceptibility alleles may differ at different stages of life, with the 
implication that different weight regulation pathways may assume varying 
temporal importance at various ages.  
The findings in this dissertation can have significant impact on clinical 
practices and recommendations, and pave the way for interventions at early 
stages. As illustrated in Chapter 5, the findings on maternal glycemia during 
pregnancy and neonatal adiposity demonstrated a dose-response effect across 
the range of maternal glucose levels, even at levels below the diagnostic 
criteria for gestational diabetes. Currently, all obstetric clinics in Singapore 
make use of the 2-hour 75-gram OGTT to screen at-risk pregnant mothers 
based on a set of pre-defined risk factors (e.g. obese mothers, mothers with 
GDM history etc). Our study findings however, highlight the importance of 
universal OGTT screening as a possible intervention measure to identify 
pregnant mothers who would be at risk of having an infant with an excessive 
adiposity outcome, even for those with normal glucose levels. Results from 
our gene expression microarray study may also pave the way for development 
of prognostic markers to predict growth-restriction in-utero. Accurate 
prediction of poor fetal growth at an early stage would play an important role 
in avoiding the cardio-metabolic consequences of growth-restriction later in 
life. Our results on the effects of MC3R on early childhood overweight and 
adiposity provided better insights into the molecular circuitry governing 
 201 
 
weight regulation during early childhood, which in turn can be targets for drug 
development for early prevention of overweight and obesity. In conclusion, 
the findings in this dissertation have unravelled the developmental risk factors 
that influence infant size, adiposity and growth during the first three years of 
life in a multi-ethnic Asian population. Given the scarcity of data on early-life 
outcomes in Asian populations, these results have helped to fill this gap in 
knowledge, providing new insights into growth and development during the 
early part of the human life course. These findings have also provided a 
stepping stone for hypotheses-generation for future studies, which would 
involve examining whether these risk factors that operate during early growth 
and development would have long-term repercussions on increasing 
prevalence of later obesity, diabetes and other cardio-metabolic disorders. 
Currently the infants in the GUSTO cohort would be followed-up till 9 years 
of age, with various cardio-metabolic measures taken at these later ages. This 
gives us ample opportunity to examine if the same risk factors would influence 
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 RECRUITMENT VISIT 
   ELIGIBILITY QUESTIONNAIRE
 
Study ID : _____________________ Date of interview : _____________________
Interviewer code : _____________________ Interview start time : _____________________
 
  
Date of Birth:            Age:   years 
    D D  M M  Y Y Y Y     
 




Block/House no/Building Name/Street: _______________________________________________ 
Unit no:____________________________ Postal Code: ________________ 
 
Do you intend to reside in Singapore for the next 5 years?   0: No  1: Yes 
 
Do you intend to deliver in KKH or NUH?  0: No  1: Yes 
 
Do you intend to donate cord, cord blood and placenta? 
 0: No  1: Yes  99: Don’t know 
Race:  
Baby’s mother 
 1: Chinese  2: Malay  3: Indian    4 : Others 
 
Baby’s maternal grandfather (mother’s father) 
 1: Chinese  2: Malay  3: Indian    4: Others 
 
Baby’s maternal grandmother (mother’s mother) 
 1: Chinese  2: Malay  3: Indian    4: Others 
 
Baby’s father 
 1: Chinese  2: Malay  3: Indian    4: Others 
 
Baby’s paternal grandfather (father’s father)  
 1: Chinese  2: Malay  3: Indian    4: Others 
 
Baby’s paternal grandmother (father’s mother) 
 1: Chinese  2: Malay  3: Indian    4: Others 
 
Are the grandparents of the baby of homogenous ethnicity? 
  0: No 









 RECRUITMENT VISIT 
   ELIGIBILITY QUESTIONNAIRE
 
1. OBSTETRIC HISTORY: 
1.1. When was the first day of your last menstrual period (LMP)? 
             99: Don’t know 
   D D  M M  Y Y Y Y    
 
1.2. How many weeks is your pregnancy (based on LMP)? 
   weeks 
 
1.3. Is this current pregnancy conceived through IVF? 
  0: No                 go to question 2.1  
  1: Yes               Please refer to IVF study team 
 
1.4. Have you enrolled for an IVF study? 
  0: No  
  1: Yes 
 
2. CANCER  
2.1. Have you ever been told by a doctor that you have cancer? 
  0: No                 go to question 3.1 
  1: Yes 
 
2.2. When did the doctor first tell you that you had cancer?  (Fill in one of the options below) 
   Age        Year  99: Don’t know 
 
2.3. Are you currently on chemotherapy? 
  0: No                  
  1: Yes 
 
3. MENTAL ILLNESSES 
3.1. Have you ever been told by a doctor that you are suffering from a mental or psychological 
condition? 
  0: No                 go to question 4.1 
  1: Yes, please specify: ___________________________________ 
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3.2. When the diagnosis was first made?   (Fill in one of the options below) 
Age     (or)    Year     
 
3.3. Are you currently taking any medication for mental or psychological condition? 
  0: No                  
  1: Yes, please specify: ___________________________________ 
 
4. OTHER LONG TERM ILLNESSES 
4.1. Have you ever been told by a doctor that you have other long term illnesses? 
  0: No                 go to question 5.1 
  1: Yes  
If yes, please specify: 
S/N Type of illness Age (yr) OR Year 
(YYYY) 
99:Don’t know 
1 Type 1 diabetes  OR   
If others, please specify: 
   OR   
   OR   
   OR   
 
5. MEDICATION  
5.1. In the past year (before this pregnancy), did you take any regular medications, supplements 
and/or traditional medicine? 
  0: No                 End of eligibility questionnaire 
  1: Yes 
 
 
ELIGIBILITY:   0: NO  1: YES 
 
 











 RECRUITMENT VISIT 
 1ST CLINIC VISIT QUESTIONNAIRE
 
 
NOTE TO RECRUITERS WHEN FILLING IN QUESTIONNAIRE SETS:  
(1) PLEASE USE THE CAPITAL LETTER.  
(2) PLEASE WRITE CLEARLY. 
 
CONFIDENTIAL 
GUSTO-1stClinicVisitQuestionnairefinal_12_11_09.doc Page 1 of 11 
 
Study ID : _____________________ Date of interview : _____________________
Interviewer code : _____________________ Interview start time : _____________________
 
1. DEMOGRAPHY 
I would like to start by asking you some questions about yourself.  
 
1.1.  How old were you when you left long term full time education?  
(enter current age if still studying)   years 
 
1.2.  What is the highest level of education that you have attained?  
  1: None 
  2: Primary (PSLE) 
  3: Secondary (GCE ‘O’/ ‘N’ levels) 
  4: ITE/NTC 
  5: GCE ‘A’ levels/Polytechnic/diploma 
  6: University 
  7: Others, specify:_________________________________ 
 
1.3.  What is your marital status?  
  1: Single and living with the baby’s father  
  2: Single and not living with the baby’s father  
  3: Married (living with husband)  
  4: Married but not living with husband 
  5: Separated 
  6: Divorced 
  7: Widowed  
  8: Others, specify:______________________________________ 
 
1.4.  What is your religion?  
  1: No religion 
  2: Buddhism  
  3: Christianity 
  4: Islam 
  5: Taoism 
  6: Hinduism 
  7: Others, specify:______________________________________ 
 
1.5.  Where were you born?  
  1: Singapore               go to question 2.1 
  2: Malaysia 
  3: China 
  4: India  
  5: Others, specify:______________________________________ 
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1.6.  When did you move to Singapore?  
 M M  Y Y Y Y 
        
2. OCCUPATION   
2.1.  What is your current job?  
    1:   Legislator/senior official 
    2:   Professional 
    3:   Technician & associated professional 
    4:   Clerical worker 
    5:   Service worker 
    6:   Agricultural worker 
    7:   Production craftsman 
    8:   Plant and machine operator 
    9:   Homemaker  
  10:   Retired  
  11:   Student  
  12:   Unemployed 
  13:   Others, specify:_______________________________ 
  14:   Refused 
3. HOUSING AND HOUSEHOLD COMPOSITION  
3.1.  What type of accommodation do you live in? 
  1: 1-2 room HDB flat 
  2: 3 room HDB flat 
  3: 4-5 room HDB flat 
  4: HUDC/executive flat 
  5: Condominium 
  6: Landed property 
  7: Others, specify:_________________________________ 
 
3.2.  Does anyone else live together with you? 
  0: No           go to question 4.1 
  1: Yes         please specify in the following table (next page) 
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For each person living in the household (apart from the woman herself), complete one line. 
A household is defined as a group of people who share a living room or eat together for at least one 
meal a day. 
CHILDREN 
For all children, record date of birth (or age if D.O.B. not available). 
For the woman’s own children, give the child’s birth weight. 
 
S/N Relationship to 
woman 




(Specify in gm 
or lb.oz) 
M F DD MM YYYY 
1         
2         
3         
4         
5         
ADULT 
S/N Relationship to 
woman 




No=0) M F 
6      
7      
8      
9      
10      
4. CHILDCARE ARRANGEMENTS  
4.1.  Do you have your own child or children at home under the age of 12 years? 
  0: No, go to question 5 
  1: Yes 
4.1.1 If yes, you are: 
  1: Working part time, go to question 4.2 
  2: Working full time, go to question 4.2 
  3: Stay home mother, go to question 5 
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4.2. Which of the following best describes the way you arrange for your child/children aged 12 or 
under to be looked after while you are at work? 
Please fill in numbers of relevant choices in boxes on right. You can select up to 3 choices. 
 
1: I work only while they are at school. 1st choice    
2: They look after themselves until I get home.    
3: I work from home. 2nd choice    No further choices 
4: My husband/partner looks after them.    
5: A nanny/grandparent/relative looks after them at home 3rd choice    No further choices 
6: They go to a workplace nursery.    
7: They go to a day nursery.    
8: They go to a child minder.    
9: A relative looks after them.    
10: A friend or neighbour looks after them.    
11: Others, specify___________________________    
5. PERSONAL HEALTH   
Now, I would like to ask you about your personal health and about the stress level you face.  
5.1. How is your health in general? Would you say it is: 
  1: Very good 
  2: Good 
  3: Fair 
  4: Bad 
  5: Very bad 
 
5.2. Do you have any long term illness or disability? By long term, I mean anything that has troubled 
you over a period of time? 
  0: No                go to question 5.4 
  1: Yes 
 
5.3. What is the illness/disability? _____________________________________________________ 
______________________________________________________________________________ 
(Do not record headaches, indigestion, aches and pains. We are interested in major problems 
such as diabetes, multiple sclerosis, rheumatoid arthritis, muscular dystrophy – anything which 
might affect growth or body composition.) 
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5.4. To what extent do you feel that the stress or pressure you have experience in your life has 
affected your health? 
  1: None 
  2: Slightly 
  3: Moderately 
  4: Quite a lot 
  5: Extremely  
  
5.5. In general, how much stress or pressure have you experienced in your daily living in the last 
4 weeks? 
  1: None  
  2: Just a little 
  3: A good bit 
  4: Quite a lot 
  5: A great deal 
 
5.6. Were you part of a multiple birth (twins, triplets etc.)? 
  0: No  
  1: Yes 
 
5.7. Were you born early, late or when your maternal mother was expecting you?  
  1: Early 
  2: When expected, go to question 5.9 
  3: Late 
  99: Don’t know, go to question 5.9 
 
 
5.8. How early/late were you?  
   Wks  Days  99: Don’t know 
5.9. How many children did your mother have before you were born? (including stillbirths)   
     99: Don’t know 
 
5.10. Approximately what was your weight before this pregnancy? 
     kg  99: Don’t know 
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6. ASTHMA  
6.1. Have you ever suffered from asthma, either as a child or an adult?  
  0: No        go to question 6.3          
  1: Yes      
  99: Don’t know   go to question 6.3 
 
6.1.1. If yes, was this confirmed by a doctor? 
  0: No 
  1: Yes 
  99:  Don’t know 
 
6.2. How many attacks of wheezing have you had in the last 12 months? 
  0: None  
  1: 1-3 
  2: 4-12 
  3: More than 12 
 
6.3. Did you suffer from eczema (recurrent itchy skin) in childhood?  
  0: No           go to question 6.5        
  1: Yes 
  99: Don’t know 
 
6.4. Have you had eczema (recurrent itchy skin) affecting the creases of your elbows or knees in 
the last year?  
  0: No                  
  1: Yes 
 
6.5. Have you ever had a problem with sneezing, or a runny, or blocked nose when you did not 
have a cold or flu? 
  0: No                 go to question 6.7 
  1: Yes 
  99: Don’t know   go to question 6.7 
 
6.5.1.  If “YES”, is the nose problem usually accompanied by itchy-watery eyes? 
  0: No                 
  1: Yes 
  2: Sometimes 
  99: Don’t know 
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6.6. In the last 12 months, have you had a problem with sneezing, or a runny, or blocked nose 
when you did not have a cold or the flu?  
  0: No                  
  1: Yes 
 
6.7. In the last 12 months, have you used any medicines to treat hay fever, rhinitis, or any other 
nasal problems, at any time (including sprays, solutions, pills, capsules or tablets)?  
  0: No        
  1: Yes 
7. HIGH BLOOD PRESSURE (HYPERTENSION)  
7.1. Has a doctor, a nurse or other healthcare professional ever told you that you have high blood 
pressure?  
  0: No                 go to question 8.1 
  1: Yes 
 
7.2. At what age were you diagnosed to have high blood pressure?  (Fill in one of the options 
below)  
Age   (or) Year       99: Don’t know 
8. DIABETES MELLITUS  
8.1. Has a doctor ever told you that you have diabetes?  
  0: No                 go to question 9.1 
  1: Yes 
 
8.2. How old were you when the doctor first told you that you had diabetes?  (Fill in one of the 
options below)  
Age   (or) Year       99: Don’t know 
9. MYOPIA   
9.1. Have you ever been told by a doctor or an optometrist that you need to wear glasses or 
contact lenses? 
  0: No                 go to question 10.1 
  1: Yes 
 
9.2. Did you get the glasses / contact lenses?  
  0: No                 go to question 10.1 
  1: Yes 
 
9.3. When did you first begin wearing glasses or contact lenses?  
Age   (or) Year       99: Don’t know 
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9.4. What is the purpose for the glasses / contact lenses? 
  1: Seeing far ± Astigmatism 
  2: Seeing near ± Astigmatism 
  3: Seeing both far and near 
  4: Astigmatism only 
  99: Don’t know 
10. FAMILY HISTORY 
10.1. Do you have a history of one of the following diseases in your first degree biological relatives 
(immediate family members)? 
  0: No, go to question 11 
  1: Yes, specify in the following table. 
 
Code  First degree relatives  Code Site of cancer 
1: Father  1: Breast  
2: Mother  2: Ovarian 
10-19: Sisters  3: Colorectal 
20-29: Brothers  4: Others, specify ___________ 
30-39: Sons   ________________________ 
40-49: Daughters  99: Don’t know 
 
Please use multiple rows if multiple diseases per individual 
Pre-eclampsia = high blood pressure in pregnancy 
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11. MENSTRUAL CYCLES AND PREGNANCIES  
11.1. Is your usual cycle regular, or has it varied by more than 5 days between periods in the last 6 
months? 
  1: Regular    go to question 11.2 
  2: Varied by more than 5 days   go to question 11.3 
  3: Don’t know                            go to question 11.3 
 
11.2. How long is your usual menstrual cycle between the start of one period and the start of the next 
period? 
  days  99: Don’t know 
 
11.3. How old were you when you had your first period? 
  years  99: Don’t know 
 
11.4. IF THIS IS YOUR FIRST PREGNANCY, PLEASE GO TO QUESTION 12.1 
Next, would you please tell me the ending date(s) and outcome(s) of each of your pregnancy in 
sequence? 
1: Live birth – Normal vaginal delivery 7: Premature birth – Normal vaginal delivery 
2: Live birth – Assisted delivery (Forceps/vacuum) 8: Premature birth – Assisted delivery 
3: Live birth – Caesarean section 9: Premature birth – Caesarean section 
4: Abortion 10: Ectopic pregnancies 
5: Miscarriage 11: Others, please specify: 


























































1                 
2                 
3                 
4                 
5                 
                 
 
11.5. Were you anaemic after the birth of any of your previous babies? 
  0: No 
  1: Yes 
  99: Don’t know 
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12. MEDICATION 
The questions below ask about REGULAR consumption of medications, supplements and traditional 
medicine in the past year BEFORE THIS PREGNANCY. 
 Regular refers to more than once a week for at least 1 month in past1 year. 
12.1. Have you been taking any medications regularly before this pregnancy? 
  0: No    go to question 12.2 
  1: Yes, please specify in table below 
 







12.2. Have you been taking folic acid supplement before your current pregnancy? 
  0: No    go to question 12.3 
  1: Yes 
12.2.1. How many weeks before pregnancy have you been taking folic acid supplement? 
   weeks 
 
12.3. Are you still taking folic acid supplement NOW? 
  0: No 
  1: Yes 
12.4. Have you been taking any fortified milk supplement (e.g. Anlene, Anmum) regularly before this 
pregnancy? 
  0: No     
  1: Yes 
 
12.5. Have you been taking any probiotics (e.g. Yakult, Vitagen, Yoghurt) regularly before this 
pregnancy? 
  0: No     
  1: Yes 
 
12.6. Have you been taking any other vitamins or supplements regularly before this pregnancy? 
  0: No     
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12.7. Have you been taking any traditional medicines regularly before this pregnancy? 
  0: No     
  1: Yes 
 
 
13. INCOME  
13.1.  What is your personal monthly income? 
  1: $0 - $999 
  2: $1000 - $1999 
  3: $2000 - $3999 
  4: $4000 - $5999 
  5: more than $6000 
  6: Refuse to answer 
  99: Don’t know 
 
13.2.  What is the monthly income of your household?   
  1: $0 - $999 
  2: $1000 - $1999 
  3: $2000 - $3999 
  4: $4000 - $5999 
  5: more than $6000 
  6: Refuse to answer 
  99: Don’t know 
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Study ID: _______________________         Date of interview: _________________ 




Have you changed your address or telephone number since you were seen in early 
pregnancy? 
 
  0: No                 
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1. OCCUPATIONAL ACTIVITY 
 
1.1. Have you had any jobs at any time since you became pregnant? 
  0: No                go to Section 2 
  1: Yes 
 
1.2. Would you please tell me your jobs during pregnancy and the weeks of your pregnancy 
in which you have done them? 
If started before pregnancy, week started = 0 
If job is still ongoing, week finished = 88  
 
Occupation Week started Week finished 
1.   
2.   
3   
4.   
 
1.3. How many hours in total did you work during an average week? 
 
    .    hrs (round to nearest 0.5 hr) 
 
1.4.Did this include working night shifts?  
Night shift means “working at least once a week or more from 12 midnight to 6:00am” 
  0: No 
  1: Yes 
 
1.5. At around this time, did your paid work involve any of the following activities in an 
average day at work? 
i) Standing or walking for more than four hours in total? 
  0: No                 
  1: Yes 
 
ii) Kneeling or squatting for more than an hour in total? 
 
  0: No 
  1: Yes 
iii) Standing or sitting with your trunk bent forward for more than an hour in total? 
 
  0: No 
  1: Yes 
 
iv) Lifting or carrying weight of 25kg (56lbs) or more by hand (equivalent to a sack of 
potatoes, a nine year old child, a very heavy suitcase) 
  0: No 
  1: Yes 
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1.6. Have you at any time during your pregnancy left a job or changed the type of work that 
you were doing because of a health problem?  
  0: No 
  1: Yes 
 
           1.6a. If yes, give details of health problems__________________________________  
                      ________________________________________________________________ 
           1.6b. and the stage of pregnancy                                weeks 
 
2. ACTIVITY AND EXERCISE– BEFORE THIS PREGNANCY 
 
Now I’m going to ask you about your activity and exercise patterns during the 1 year before 
your pregnancy. We would like you to divide up a “typical” day into three types of activities. 
These are:  
(1) sleeping or lying,            (2) sitting,  (3) standing or walking. 
 
2.1. Over a typical 24 hour day, how many hours do you generally spend sleeping or 
lying with your feet up? 
(ask what  time she usually goes to bed & wakes up, including any at work!)  
   .  hrs (round to nearest 0.5 hr) 
 
2.2. How many hours on a typical day do you spend sitting down? 
(e.g. includes sitting at work, mealtimes, driving, reading, watching TV)  
   .  hrs (round to nearest 0.5 hr) 
 
2.3. This would mean that you spend about xx hours a day on your feet.  
       Does this sound about right?   
   .  hrs (round to nearest 0.5 hr) 
 
Sum of hours reported in Q2.1, 2.2 and 2.3 should total up to 24 hours 
 
Total hours: ___________________________ 
Checked and signed: ____________________ 
 
 
2.4. Out of these xx hours spent on your feet, about how much of the time are you 
actively on the move (rather than standing fairly still)?  
 
  1: Very little  10% 
  2: Some 30% 
  3: About half 50% 
  4: Most 70% 
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2.5. During the 1 year before your pregnancy, how often have you done the following 
kind of exercises or activities?  
a) Strenuous exercise which normally makes your heart beats rapidly AND leaves you 
breathless e.g. jogging, vigorous swimming or cycling, aerobics 
  1: Never 
   2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
   .  hrs (round to nearest 0.5 hr) 
 
b) Moderate exercise which normally leaves you exhausted but not breathless, e.g. 
brisk walking, dancing, easy swimming or cycling, badminton, sailing.  
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
   .  hrs (round to nearest 0.5 hr) 
 
c) Gentle exercise which normally leaves you tired but not exhausted, e.g. walking, 
driving, housework (including washing windows and polishing), gardening, DIY, golf.  
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
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2.6.On a typical day, how many hours do you generally spend watching television?  
  1:  More than 5 hours 
  2:   4-5 hours 
  3:   3-4 hours 
  4:   2-3 hours 
  5:   1-2 hours 
  6:   Less than one hour 
  7:    None 
 
2.7. Which of the following best describes your walking speed?  
  1: Very slow 
  2: Stroll at an easy pace  
  3: Normal speed 
  4: Fairly brisk 
  5: Fast 
 
3. ACTIVITY AND EXERCISE –DURING THIS PREGNACY 
 
Can I now ask you about your activity and exercise patterns over the last 6 months?   
As before, we would like you to divide up a “typical” day into three types of activities.  
These are:  
(1) sleeping or lying,    (2) sitting,  (3) standing or walking. 
 
3.1. Over a typical 24 hour day, how many hours do you generally spend sleeping or 
lying with your feet up? 
(ask what time she usually goes to bed & wakes up, including any at work!)  
   .  hrs (round to nearest 0.5 hr) 
 
3.2. How many on a typical day do you spend sitting down? 
(e.g. includes sitting at work, mealtimes, driving, reading, watching TV)  
   .  hrs (round to nearest 0.5 hr) 
 
3.3. This would mean that you spend about xx hours a day on your feet.  
       Does this sound about right?  
   .  hrs (round to nearest 0.5 hr) 
 
Sum of hours reported in Q3.1, 3.2 and 3.3 should total up to 24 hours 
 
Total hours: ___________________________ 
Checked and signed: ____________________ 
 
3.4. Out of these xx hours spent on your feet, about how much of the time are you 
actively on the move (rather than standing fairly still)?  
  1: Very little  10% 
  2: Some 30% 
  3: About half 50% 
  4: Most 70% 
  5: Almost all 90% 
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3.5. During the past six months, how often have you done the following kinds of exercise 
or activities?  
 
a) Strenuous exercise which normally makes your heart beat rapidly AND leaves you 
breathless e.g. jogging, vigorous swimming or cycling, aerobics 
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
   .  hrs (round to nearest 0.5 hr) 
 
b) Moderate exercise which normally leaves you exhausted but not breathless, e.g. 
brisk walking, dancing, easy swimming or cycling, badminton, sailing.  
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
   .  hrs (round to nearest 0.5 hr) 
 
c) Gentle exercise which normally leaves you tired but not exhausted, e.g. walking, 
driving, housework (including washing windows and polishing), gardening, DIY, golf.  
  1: Never 
  2: Once every 2-3 months 
  3: Once a month 
  4: Once a fortnight 
  5: 1-2 times per week 
  6: 3-6 times per week 
  7: Once a day 
  8: More than once a day 
 
and on average about how long does each period of activity last?   
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3.7. Which of the following best describes your walking speed?  
  1: Very slow 
  2: Stroll at an easy pace  
  3: Normal speed 
  4: Fairly brisk 




4.1.How many weeks pregnant were you when you first found out that you were pregnant? 
   wks 
4.2.Was this pregnancy planned? 
  0: No    Go to question 4.4 
  1: Yes: Go to question 4.3 
 
4.3 If YES, did you change your diet when you were planning to be pregnant? 
  0: No    Go to question 5.1 
  1: Yes   Go to question 5.1 
  
4.4.If NO, this pregnancy is due to 
  1: No contraception: Go to question 5.1 
  2: Failure of contraceptive methods 
 
4.5.If NO, which was the main contraceptive method used which failed?  
  1. Safe period 
  2. Barrier e.g. condom, diaphragm 





  4. Intrauterine contraceptive device 
  5. Withdrawal  





3.6.On a typical day, how many hours do you generally spend watching television?  
  1: More than 5 hours 
  2: 4-5 hours 
  3: 3-4 hours 
  4: 2-3 hours 
  5: 1-2 hours 
  6: Less than one hour 
  7: None 
258
 Week 26-28 clinic visit 




PLEASE USE CAPITAL LETTER AND WRITE CLEARLY. 
 
Birth Cohort_26weeks_Questionnaire_22-12-09                                                                         Page 8 of 16 
5. DIET DURING PREGNANCY  
 
5.1 Are you following any special diet? 
  0: No    go to question 5.3 
  1: Yes 
 
5.2 If yes, what is your special diet? 
  1: Vegetarian (Eggs and milk allowed) 
  2: Vegan (No eggs or milk allowed) 
  3. Diabetic diet 
  4. Low fat diet 
  5. Others, specify ________________ 
 
5.3 How often do you eat eggs? 
  1: More than one egg a day 
  2: One egg a day 
  3. 4 to 6 eggs a week 
  4. 1 to 3 eggs a week 
  5. Less than one egg a week 
  6. Do not eat eggs at all 
 
5.4 How often do you eat liver (any type e.g. chicken, beef, pork)? 
  1: Every day 
  2: 4 to 6 times a week 
  3. 1 to 3 times a week 
  4. Less than once a week but more than once a month 
  5. Less than once a month 
  6. Do not eat liver at all 
 
5.5 How often do you eat out or purchase take-away foods? 
  1: Two meals a day or more 
  2: One meal a day 
  3. 4 to 6 meals a week 
  4. 1 to 3 meals a week 
  5. Less than once a week 
  6. Never/ rarely 














 Week 26-28 clinic visit 




PLEASE USE CAPITAL LETTER AND WRITE CLEARLY. 
 
Birth Cohort_26weeks_Questionnaire_22-12-09                                                                         Page 9 of 16 
5.6  I would like to find out more about your diet during pregnancy compared to what you usually ate 
before you were pregnant. I will be asking you about your eating habit for a list of foods during 
pregnancy. Please tell me if you ate more, less or similar amount of the food during pregnancy 
compared to your usual diet. 
 
 Types of Food Change in 
amount  
 
1.  Chicken  Key 
2.  Fish  1: More 
3.  Meat (beef / mutton / pork)  2: Less 
4.  Organ meats  
(e.g. liver, kidney, heart, brain) 
 3. Same as before 
9. Don’t usually eat 
5.  Seafood  
(e.g. prawn, crab, mussels, clams) 
  
6.  Egg   
7.  Vegetables (all types)   
8.  Fruits (all types)   
9.  Red, orange, yellow fruits and 
vegetables (e.g. carrots, papaya) 
  
10.  Rice, noodles, breads    
11.  Cheese, yogurt   
12.  Chocolates, sweets, biscuits, cakes   
13.  Milk   
14.  Chocolate drinks (Milo, Ovaltine)   
15.  Soft drinks  
(e.g. Coke, sprite, 7-up, Pepsi)  
  
16.  Tea   
17.  Coffee   
18.  Wine/alcohol (including tonic wine)   
 
6.   APPETITE AND NAUSEA DURING PREGNANCY  
6.1. Have you experienced any nausea or sickness since becoming pregnant? 
  0: No     go to question 6.5            
  1: Yes 
 
6.2. If yes, has this been: 
  1: Mild (nausea only) 
  2: Moderate (sometimes sick, vomiting) 
  3: Severe (regularly sick, vomiting, can’t retain meals) 
 
6.3. If yes, were you admitted to the hospital because of nausea? 
  0: No     go to question 6.5 
  1: Yes 
 
6.4. If yes, how were you treated? 
  1: Fasting, then slowly introducing food 
  2: Intravenous fluid treatment 
  3: Medication (Note: Refer to medical records/CPSS) 
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6.5. Compared with BEFORE you were pregnant, are you eating: 
  1: More                           go to question 6.5a 
  2: The same                    go to question 7.1 
  3: Less in amount           go to question 6.5b 
  99: Don’t know 
 
      6.5a. If more, is this: 
  1: Because you feel more hungry 
  2: To prevent from feeling sick 
  3: Because you feel it is best for the baby 
  4: Other reasons; specify: _________________________________ 
 
      6.5b. If less, is this: 
  1: Because you feel less hungry 
  2: Because of nausea/sickness 
  3: Don’t want to put on too much weight 
  4: Other reasons; specify: _________________________________ 
 
7. DIETING  
 
7.1  Which of the following describes you best? 
 
  1: I have NEVER been on a diet to lose weight. 
  2: I have ONLY ONCE been on a diet to lose weight. 
  3: I USED TO diet REGULARLY to lose weight but NOT ANYMORE 
  4: I go on a diet to lose weight EVERY NOW AND AGAIN. 
  5: I am USUALLY on a diet to lose weight. 
   
If answered 2, 4, 5, please ask question 7.2; otherwise go to next section. 
 
7.2     Are you currently trying to lose weight by dieting? 
 
  0: No 
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8.  ALCOHOL CONSUMPTION – BEFORE THIS PREGNANCY 
I’d like to ask you a few questions about your drinking and smoking habits. 
 
8.1  Did you ever drink alcohol before this pregnancy? 
  0: No                go to section 9 
  1: Yes 
  99: Don’t know 
 
8.2 How often did you drink the following alcoholic beverages in the 1 year before you 
became pregnant? Please select the category that best describes how often and how much 
you drank during the past year.  
Alcoholic 
beverages 
Average consumption in past year  Usual serving size 
 
Beer 
1. Never or hardly ever 
2. Once a month 
3. 2-3 times a month 
4. Once a week 
5. 2-3 times a week 
6. 4-6 times a week 
7. Once a day 
8. 2 or more times a day 
1. One small bottle 
(375ml) or less 
2. One large bottle 
(750ml) 
3. Two large bottles 




(eg. red wine) 
 1. One wine glass         
      (118ml) or less  
2. Two wine glasses  
3. Three wine glasses 
4. Four wine glasses or 




 1. One wine cup 
(30ml) or less  
2. Two wine cups  
3. Three wine cups  
4.    Four wine cups or 
more 
Hard liquor 
(eg. brandy)  
 1. One drink (30ml) 
or less  
2. Two drinks 
3. Three drinks 
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9 ALCOHOL CONSUMPTION – DURING THIS PREGNANCY 
 Did you ever drink alcohol during this pregnancy?    
  0: No                go to section 10 
  1: Yes 
  2: Refuse to answer 
 
9.1 During the past 6 months, how often did you drink the following alcoholic beverages? 
Please select the category that best describes how often and how much you drank. 
Alcoholic 
beverages 
Average consumption past 6 mth  Usual serving size 
 
Beer 
1. Never or hardly ever 
2. Once a month 
3. 2-3 times a month 
4. Once a week 
5. 2-3 times a week 
6. 4-6 times a week 
7. Once a day 
8. 2 or more times a day 
1. One small bottle (375ml) 
or less 
2. One large bottle (750ml) 
3. Two large bottles 




(eg. red wine) 
 1. One wine glass         
      (118ml) or less  
2. Two wine glasses  
3. Three wine glasses 
4. Four wine glasses or 




 1. One wine cup  
     (30ml) or less 
2. Two wine cups  
3. Three wine cups  
4.  Four wine cups or more 
Hard liquor 
(eg. brandy)  
 1. One drink (30ml) or less  
2. Two drinks 
3. Three drinks 
4. Four drinks or more 
 
10. PERSONAL VIEWS ON BREAST FEEDING 
 
10.1 Have you breastfed before? 
  0: No, go to question 10.3                  
  1: Yes 
  
                   10.1.1 If “YES”, how many children have you breastfed before? 
    Number of children 
 
                   10.1.2 If YES, please describe your type of breastfeeding for your last child: 
   1. Exclusive breastfed (Only breast milk with no water) 
   2. Predominant breastfed (Breast milk and liquids (including water) other than formula) 
   3. Partial breastfed (Breast milk, formula and liquids) 
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               10.1.3 How long did you breastfeed your last child? 
  Year   Months    weeks 
 
10.2 Are you still breastfeeding during this pregnancy? 
   0: No 
   1: Yes but I stopped at   weeks of pregnancy 
   2: Yes, I am still continuing breastfeeding 
 
10.3 Do you know people who have successfully breastfed their babies? 
 0: No 
 1: Yes 
 
10.4 Did you receive advice from family or friends about breastfeeding? 
 0: No 
 1: Yes 
 
 
10.5 Have you read books or watched programs on breastfeeding? 
 0: No 
 1: Yes 
 
10.6 Are you currently attending antenatal classes? 
 0: No 
 1: Yes 
 
10.7 Do you plan to breastfeed? 
   0: No 
   1: Yes, for how long   months , go to question 10.8 
             99: Don’t know 
 
               10.7.1 If No, please specify reason 
   1: Underlying medical problems 
   2: Painful 
 th     3: Troublesome 
   4: Inconvenient 
   5: Formula more nutritious 
   6: No reason 
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10.8 Who will be the main person helping you with the baby after delivery? 
   1. Confinement nanny 
   2. Mother / Mother-in-law 
   3. Husband 
   4. Other relatives 
   5. Others, specify__________________ 
 
11. SMOKING – BEFORE THIS PREGNANCY  
 
11.1 Have you ever smoked regularly (at least once a day for a year or more)?  
  0: No                go to question 11.5 
  1: Yes 
  2: Refuse to answer 
 
11.2 How old were you when you first smoked regularly? 
   yrs 
 
11.3 Did you smoke during the 1 year before you became pregnant? 
  0: No                go to question 11.5  
  1: Yes 
 
11.4 If yes, how many sticks per day? Record maximum stated. 
    
 
Note to interviewer: You may want to explain to the participant that even though she does not 
smoke, there is some evidence of health implications from second-hand smoke exposure. The 
following questions are to capture information on second-hand smoke exposure, i.e. where 
the participant was close enough to the smoker(s) to smell the smoke. 
 
11.5 Did anyone living in your home smoke at home on a daily basis for 6 months or longer?   
  0: No                go to question 11.7  
  1: Yes 
 
11.6 For how many years did at least 1 person living in your home smoke daily at home? 
  1:   1 year or less 
  2:   2-5 years 
  3:   5-14 years 
  4:   15-24 years 
  5.   25+ years 
 
11.7  Have you ever had a job in which, on a daily basis, you were exposed to cigarette 
smoke from others?   
  0: No                 
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12. SMOKING – DURING THIS PREGNANCY 
 
12.1  Are you currently smoking?  
  0: No                go to question 12.3 
  1: Yes 
 
12.2 If yes, how many sticks per day? Record maximum stated.  
    
 
12.3  During your pregnancy, did anyone living in your home smoke at home on a daily      
         basis?   
  0: No                 
  1: Yes 
 
12.4 During your pregnancy, have you ever had a job in which, on a daily basis, you were 
exposed to cigarette smoke from others?   
  0: No                go to section 13 
  1: Yes 
 
12.5 On average, how many hours were you exposed to cigarette smoke at work? 
  1:   1 hour or less 
  2:   1-3 hours 
  3:   More than 3 hours 
 
12.6 Are you currently exposed to cigarette smoke at work on a daily basis? 
  0: No                 
  1: Yes 
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13. MEDICATION 
 
13.1 Are you taking any medications / supplements / traditional medicine regularly DURING this 
pregnancy? 
         Regular refers to more than once a week 
  0: No    END OF QUESTIONNAIRE 
  1: Yes, please specify in table below 
 






















THANK YOU VERY MUCH FOR YOUR HELP! 
 
Interview end time: ________________ 
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Study ID: _______________________              Date of interview: __________________ 
Interviewer code: _________________                 Interview start time: _________________ 
 
 




1.  Registration   
2.  26-28 wk visit questionnaires   
2.1.  Mother’s questionnaire   
2.2.  Mother’s self administered questionnaires   
 • STAI  NA 
 • EPDS  NA 
 • BDI-II  NA 
 • LYDON Maternal  NA 
 • LYDON Domestic Helper  NA 
 • Pittsburgh Sleep Quality Index   NA 
3.  Anthropometric  measurements 
  
3.1.  Weight 
3.2.  Height 
3.3.  Mid-upper arm circumference 
3.4.  Triceps skinfold 
3.5.  Biceps skinfold 
3.6.  Subscapular skinfold 
3.7.  Suprailiac skinfold 
4.  Collection of hair    
5.  Collection of buccal swab   
6.  Pulse wave velocity   
7.  Auto Refraction    
8.  Fundus photography   
9.  Case file completed/checked   
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3. Anthropometric Measurements  
 
3.1. Weight 
   .  kg  
   .  kg  
   .  kg should be taken only if the first 2 measurements differed  
       by >200gm. 
 
3.2. Height 
   .  cm  
   .  cm  
   .  cm should be taken only if the first 2 measurements differed  
            by >1.0cm. 
 
3.3.  Mid-upper arm circumference 
  .  cm  
  .  cm  
  .  cm should be taken only if the first 2 measurements differed  
                       by >1.0cm. 
 
3.4. Triceps skinfold 
   .  mm 
   .  mm 
   .  mm 
 
3.5. Biceps skinfold 
   .  mm 
   .  mm 
   .  mm 
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3.6. Subscapular skinfold 
   .  mm 
   .  mm 
   .  mm 
 
3.7. Suprailiac skinfold 
   .  mm 
   .  mm 
   .  mm 
 
 Skin fold calipers used  
 
 
4. Hair Collection 
 
Taken  Not taken  Refused   
 
Number of hair strands    
 
 
5. Collection of buccal swab 
Done  Not done  Refused   
 
Number of swabs   
 
 
6. Pulse wave velocity  
 
Done  Not done  Refused   
     (Please attach report) 
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7. Fundus Photography: 
 
7.1. Fundus Photo 
 




          Right Eye ____________________________________ 
 





                         (RE)                                  (LE) 
 
 1. Normal 2. Abnormal 3. Unable  1.Normal 2. Abnormal 3. Unable 
Macular 
[macular]        
Disc  
[Discr]        
Media 




       
Peripheral 
retina[periretr]        
Describe lesion 
[desbr] ___________________________________  ___________________________________ 
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8. Auto-Refraction(Undilated with Table-Mounted) 
 




          
Comments___________________________________________________ 
 
         Right Eye ____________________________________ 
 
         Left Eye _____________________________________ 
 
PLEASE  WRITE THE STUDY ID AND  MAKE A COPY OF THE AUTO   REFRACTION REPORT 
AS THE DATA FADES AWAY WITHIN ONE WEEK 
 
 
   PLEASE PASTE THE COPIED REPORT PAGE HERE  
 
 
Check the following: 
• Ensure best readings 
• Cross-out readings with *and extra readings in excess of 5 
• Retake if more than 1*or SD.+/- 0.25 
• Write down comments for any rejection or unsuccessful attempts 
 
Right Eye ____________________________________ 
 
Left Eye _____________________________________ 
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Study ID: _______________________         Date: _________________ 
Interviewer code: _________________     
  
I. INFANT DATA 
 
1. Date of birth   /   /   DDMMYY 
 
2. Time of delivery   :   Hr 
 
3. Gender                            1. Male                2. Female 
 
4. Birth order       
 
5. Gestational age at delivery   Wks+  Days 
 
6. Birth weight     gm 
 
7. Birth length    .  cm (to nearest 1 decimal point) 
 
8. Head circumference   .  cm (to nearest 1 decimal point) 
 
9. APGAR SCORE                 1   at 1 minute       2   at 5 minutes  
       (Enter 99 if not recorded) 
3   at 10 minute        
 
10. Was resuscitation needed?  0. No      1. Yes           
 
10.1. If yes, specify  specific action taken:  
  1. O2 free flow 
 2. Bag and Mask 
 3. Intermittent positive pressure ventilation (IPPV) 
 4. External Cardiac Massage (ECM) 
 5. Adrenalin          No of doses_____________________ 
  Route of administration____________ 
 6. Other resuscitative measures:__________________ 
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  II. NEONATAL PROBLEMS 
1. Neonatal Jaundice: 
 0. No significant jaundice (not requiring phototherapy) 
 1. Jaundice requiring phototherapy (Peak bilirubin_________at________hr of age) 
 2.Jaundice requiring exchange transfusion 
 
2. Had the newborn have any other neonatal complication?  0. No      1. Yes           
2.1. If yes, please specify :  1. Secondary to transient tachypnoea of new born 
  2. Meconium aspiration 
  3. Congenital Pneumonia 
  4. Hypoglycemia 
  5. Feeding related disorders 
  6. Perinatal stress 
  7. Congenital malformation 
  8. GBS-related 
  9. Other perinatal infection 
  10. Others, specify __________________________ 
 
 
3. Highest level of neonatal stay  1. ICU 
  2.Special Care nursery 
  3. Well baby nursery 
 
4. Date of discharge   /   /    
 
5. Final Diagnosis:  1. Well baby 
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III. DAY 1 ASSESSMENT 
 
A. ANTHROPOMETRIC MEASUREMENTS  
 
 Interviewer code: _________________     
 Date performed:   _________________                            Start time: _______________________ 
 
 
1. Weight     gm 
     gm 
     gm 
  3rd measurement if the first 2 differ >100 grams 
 
2. Length    .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
  3rd measurement if the first 2 differ >1.0 cm 
 
3. Head circumference   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
                                                      3rd measurement if the first 2 differ >1.0cm 
 
4. Abdominal circumference   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
                                                      3rd measurement if the first 2 differ >0.5cm 
 
5. Mid-arm circumference   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
                                                      3rd measurement if the first 2 differ >0.5cm 
 
6. Foot Length   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
                                                      3rd measurement if the first 2 differ >0.5cm 
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For each of the skinfold site, take 3 measurements and record to last completed 0.2 mm. 
If any of repeated tests varies by more than 1mm, repeat the measurement.  
 
7. Triceps skinfold   .  mm  
   .  mm  
   .  mm  
   .  mm  
   .  mm  
 
 
8. Subscapular skinfold   .  mm  
   .  mm  
   .  mm  
   .  mm  











End time: __________________ 
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B. BIOELECTRICAL IMPEDANCE ANALYSIS 
 
Interviewer code: _________________     
 Date performed:   _________________                            Start time: _______________________ 
 
 
Test 1                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
  4. Unable    
 
Test 2                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
  4. Unable    
 
Test 3                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
  4. Unable    
 
Test 4                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
  4. Unable    
 
Test 5                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
  4. Unable    
 
Test 6                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
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Test 7                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
  4. Unable    
 
Test 8                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
  4. Unable    
 
Test 9                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
  4. Unable    
 
Test 10                 1. Performed Crying  0. No               Movement  0.No 
  2. Not performed   1. Yes                                            1. Yes 
  3. Refused    
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C. PEAPOD MEASUREMENT 
 
  1. Performed 
  2. Not performed 
  3. Refused 
  4. Unable 
 
Interviewer code: _________________ 
 
Date Performed: __________________ 
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Study ID: _______________________         Date: _________________ 
Interviewer code: _________________     
 
IV. DETAILS OF LABOUR AND DELIVERY 
 
1.    Gravida               Para     
 






4. Other _________________________________________ 
 
3. Antepartum Haemorrhage  1. No 
  2.Abruptio placenta 
  3. Placenta previa 
  4. Other_________________________________________ 
 
4. Onset of labour (For spontaneous and induced labour) 
  
   TIME   
 DATE (DDMMYY) 
4.1. 1st stage (Active Phase)   :     Hr   /   /   
4.2. 2nd stage (10cm to delivery of baby) 
(for vaginal delivery only)   :    
 
Hr   /   /   
4.3. 3rd stage (delivery of babyplacenta)   :     
Hr 
  /   /   
       4.4  End of stage 3   :     Hr   /   /   
 
5. State of liquor  1. Clear 
  2. Light meconium stained liquor (LMSL) 
  3. Medium meconium stained liquor (MMSL) 
  4. Thick meconium stained liquor (TMSL) 
  5. Blood stained 
 
6. Prolonged rupture of membranes >24 hrs:  0. No      1. Yes           
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8. Chorioamnionitis:  0. No      1. Yes           
 
8.1. If “yes”  1. Clinical 
  2. Bacteriological/Histopathological 
  3. Clinical and histopathological 
9. Antibiotics during labour:  0. No      1. Yes           
 
9.1. If “Yes”, please specify:  1. Ampicillin 
  2. Augmentin 
  3. Erythromycin 
  4. Others, specify_________________ 
 
10. Tocolysis:  0. No      1. Yes           
 
10.1. If “Yes”, please specify the medication 
(Tocolytics): 
 1. IV Salbutamol 
 2. Oral Nifedipine 
  3. Glyceryl Trinitrate (GTN) 
  4. Indomethacin 
  5. Others, specify_________________ 
 
11. Maternal Steroids:  1.  No 
  2. Incomplete (<24hrs before birth) 
  3. Complete, 1 course 
  4. Two courses or more 
 
11.1 Date of dexmethasone injection. 
Date of 1st course    /   /   DDMMYY 
Date of 2nd course    /   /   DDMMYY 
Date of 3rd course    /   /   DDMMYY 
 
12. Analgesia/sedation during labour  0. None          
       Please fill up the respective    
       numbers in more than one       
       box if necessary. 
 1. Entonox 
 2. Pethidine                    
  3. Regional (Epidural / Spinal) 
  4. General anaesthesia 
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13. Mode of delivery:  1. Normal Vaginal delivery 
  2. Emergency LSCS 
  3. Elective LSCS 
  4. Assisted Breech 
  5. Vacuum 
  6. Forceps 
 
14.  Main indication for operative   1. Abnormalities of labour progress  
      delivery (instrumental or caesarean)  2. Fetal distress or other fetal indications 
  3. Maternal distress or other maternal indications 




 5. Others, specify: __________________________ 
  
15. Was the labour spontaneous or induced?  1. Spontaneous           2. Induced          3. N.A.  
 
15.1 If induced, please specify indication (s)    1. Hypertension 
                 for induction    2. Diabetes 
                 Please fill up the respective                   3. IUGR 
                 numbers in more than one box if necessary.   4. Impending hypoxia 
  
  5. Pre-existing maternal condition 
  
  6. Post date (>40-41 weeks) 
  
  7. Post-term (>41 weeks) 
  
  8. Social 
  
  




10. Others (Maternal factors), please 
specify:__________________________   
    
15.2 If induced, was prostaglandin used?   0. No 1. Yes 
 
        
 
If yes, please specify 
    
 
15.2.1  Misoprostol    0. No 1. Yes 
         
  





number of doses    
  
282
 DELIVERY CASE REPORT FORM 
 
 
05-05-12                                                                                                                                            Page 11 of 16 
 
        
 
15.2.2  Prostin 
 
  0. No 1. Yes 
 
        
  







number of doses    
  
        
15.3 If induced, was I/V oxytocin used?   0. No 1. Yes 
 
        
 
If yes, please specify 
    
 
15.3.1 Maximum dose (units)    .  
 
        
    15.3.2 Duration     hours     mins 
 
16. Was augmentation conducted?  0. No             1. Yes  
     
     16.1 If yes, was I/V oxytocin used?   0. No 1. Yes 
 
                                 If yes, please specify 
    
     16.1.1    Maximum dose (units)    .  
 
        
     16.1.2 Duration     hours     mins 
 
        
17. Estimated blood loss (ml) at delivery      ml   Please tick if Not Recorded 
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V. PREGNANCY DATA 
Blood pressure recordings  
During Antenatal period Systolic BP Diastolic BP 
Date 
(DD/MM/YY) 
Not  recorded 
1. Blood pressure (mmHg) recording at 1st 
earliest clinic visit     
2. Blood pressure (mmHg) recording at 26wk  
clinic visit 
    
3. Blood pressure (mmHg) recording at last 
antenatal clinic visit     
During labour Systolic BP Diastolic BP 
Date 
(DD/MM/YY) 
Not  recorded 
1. 1st blood pressure (mmHg) recording in 
labour ward/OT 
    
2. Highest blood pressure (mmHg) during 
labour/OT     
Upon discharge Systolic BP Diastolic BP 
Date 
(DD/MM/YY) 
Not  recorded 
1. Blood pressure (mmHg) recording before 
discharge      
 
 




1. 1st recorded weight    
 Weight (Kg) Date 
(DD/MM/YY) 
Not  recorded 
2. Weight at 1st antenatal clinic visit    
3. Weight at 12±1wk gestation    
4. Weight at 20-22wk gestation    
5. Weight at 26-28wk gestation    
6. Weight at 32-34wk gestation    
7. Weight at 36-38wk gestation    
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VI. PREGNANCY COMPLICATION 
During 1st trimester (from conception to week 12) 
1. History of any bleeding during 1st trimester. 
 0. No 
 1. Yes 
 
2. If “yes”, was admission required? 
 0. No 
 1. Yes 
 
3. If “yes”, was any treatment given? 
 0. No 
 1. Yes, please specify: ________________________________________ 
 
 
During 2nd and 3rd trimester (from week 13 till delivery)  
1. History of any bleeding during 2nd and 3rd trimester. 
 0. No 
 1. Yes 
 
2. If “yes”, was admission required? 
 0. No 
 1. Yes 
 
3. If “yes”, was any treatment given? 
 0. No 
 1. Yes, please specify: ________________________________________ 
 
 





1.      Preterm labour   
 
  
2.      APH   
 
  
3.      Hypertension   
 
  
4.      Diabetes   
 
  
5.      Premature Rupture of Membrane (Leaky liquor)   
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3. Any other medications given? 
 0. No  
 1. Yes  
 
3.1. If yes, what was the medication? (Supplement will be recorded separately) 
 
    
Date Started (DD/MM/YY) 
Preterm labour 
           1. Dexamethasone   0. No 
 
    /     /     
2. Nifedipine   1. Yes 
 
    /     /     
3. I/V Salbutamol   
  
    /     /     
4. I/V Terbutaline   
  
    /     /     
5. GTN patch   
  
    /     /     
6. Indomethacin   
  
    /     /     
            Anaemia 
           1. Oral Iron, specify_________________   
  
    /     /     
2. I/V Iron   
  
    /     /     
            Antibiotics, specify 1)_______________   
  
    /     /     
Antibiotics, specify 2)________________ 




  Antibiotics, specify 3)________________ 





            Others 
           1. Aspirin    
  
    /     /     
2. Warfarin   
  
    /     /     
3. Thyroxine   
  
    /     /     
4. PTU   
  
    /     /     
5. Methyldopa   
  
    /     /     
6. Labetalol   
  
    /     /     
7. Others, specify __________________   
  
    /     /     
8. Others, specify __________________ 




  9. Others, specify __________________ 




  10. Others, specify __________________ 




  11. Others, specify __________________ 




  12. Others, specify __________________ 





            
286
 DELIVERY CASE REPORT FORM 
 
 
05-05-12                                                                                                                                            Page 15 of 16 
 
VII. LABORATORY INVESTIGATIONS 
 
Blood tests: 
1. Full Blood Count   
 Date : ________________ 
(DD/MM/YY) 
Date : _______________ 
(DD/MM/YY) 
Date : _______________ 
(DD/MM/YY) 
White Blood Cell    
Red Blood Cells    
Haemoglobin    
MCV    
MCH    
MCHC    
Haematocrit    
Platelets    
MPV    
RDW    
Differential Counts    
Neutrophils%    
Neutrophils    
Lymphocytes %    
Lymphocytes    
Monocytes %    
Monocytes    
Eosinophil %    
Eosinophils    
Basophils%    
Basophils    
LUC%    
LUC    
 
2. Hepatitis B sAg  Date of test (DD/MM/YY)______________________ 
                           Result  1. Reactive 
  2. Non reactive 
  3. Not done 
 
3. Anti-HBs                           Date of test (DD/MM/YY): ______________________ 
                           Result   IU/L  Not done 
 
  1. Positive 
  2. Negative 
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4. HIV testing Date of test (DD/MM/YY)___________________   
                           Result  1. Reactive 
  2. Non reactive 
  3. Not done 
   
5. GroupB Strept Vaginal Swab:             1. Isolated              2. Not isolated     3. Not done 
                           Result  Date of test (DD/MM/YY)______________________ 
                           Result  Date of test (DD/MM/YY)______________________ 
                           Result  Date of test (DD/MM/YY)______________________ 
 
6. High Vaginal Swab:             1. Positive             2. Negative       3. Not done 
i. Tricho. vaginalis  Date of test (DD/MM/YY)______________________ 
ii. Gard. vaginalis   
iii. Candida species   
 
i. Tricho. vaginalis  Date of test (DD/MM/YY)______________________ 
ii. Gard. vaginalis   
iii. Candida species   
 
i. Tricho. vaginalis  Date of test (DD/MM/YY)______________________ 
ii. Gard. vaginalis   
iii. Candida species   
 
 
If mother or baby had any of the further complication, the relevant Annex forms 
need to be filled in. 
 
 No  Yes  
1. Hypertension    ANNEX-1 
2. Preeclampsia    ANNEX-2 
3. Gestational Diabetes/Type 2 Diabetes    ANNEX-3 
4. IUGR    ANNEX-4 
5. Multiple Pregnancy    ANNEX-5 
6. Preterm (< 37 gestation week) OR babies in NICU    ANNEX-6 
 
 
NOTE: ALL CASES WITH COMPLICATIONS SHOULD REFER TO OBSTETRICIANS 
FOR CHECKING OF THE ENTRIES 
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Week 3 infancy CRF_281210 
Study ID: _______________________         Date: _________________ 
Examiner code: __________________                                                    Start time: _____________ 
1. ANTHROPOMETRIC MEASUREMENTS  
 
1. Weight     gm 
     gm 
     gm 
  3rd measurement if the first 2 differ >100 grams 
 
2. Length    .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
  3rd measurement if the first 2 differ >1.0 cm 
 
3. Head circumference   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
                                                      3rd measurement if the first 2 differ >1.0cm 
 
4. Abdominal circumference   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
                                                      3rd measurement if the first 2 differ >0.5cm 
 
5. Mid-arm circumference   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
                                                      3rd measurement if the first 2 differ >0.5cm 
 
6. Foot Length   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
   .  cm (to nearest 1 decimal point) 
                                                      3rd measurement if the first 2 differ >0.5cm 
Appendix C
Questionnaires are similar for 
months 3 to 36
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Week 3 infancy CRF_281210 
2. BIOELECTRICAL IMPEDANCE ANALYSIS 
 
Test 1 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
        
 
Test 2 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
        
 
Test 3 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
        
 
Test 4 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
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Week 3 infancy CRF_281210 
Test 5 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
        
 
Test 6 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
        
 
Test 7 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
        
 
Test 8 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
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Test 9 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
        
 
Test 10 Z=       .    
 
Crying   0=No Movement    0=No 




  .   ˚ 




               
 
R=       .    
       




    .    
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Study ID: _______________________                          Date of interview: ____________________ 
Interviewer code: _________________                            Interview start time: ___________________ 
1. YOUR CHILD’S HEALTH 
 
The following questions refer to the period between the last three months, or from the last home 
visit to the current visit 
1.1. At any time, has your child had running nose, blocked or congested nose, snoring or noisy 
breathing during sleep or when awake that has lasted for 2 or more weeks duration 
  0: No  
  1: Yes   
1.1.1 If yes, will you give permission for a nurse to call you for more details of your 
child’s nose problem?  It would take about 5mins. 
    0: No  
  1: Yes   
 
1.2 Has your child at any time had an itchy rash that is coming and going, other than nappy rash?  
(Refer to photo) 
  0: No                 Go to Question 1.9  
  1: Yes 
1.3 Has this itchy rash at any time affected any of the following places: folds of the elbows, behind 
the knees, in front of the ankles, on the cheeks, or around the neck, ears, or eyes? 
  0: No                  
  1: Yes 
1.4 How often, on average, has your child been kept awake at night by this itchy rash?  
 
  1: Never                
  2: About once a week 
 
 
 3: Almost every night 
 
Appendix D
Questionnaires are similar 
for months 6 to 12
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1.5 Did you use ORAL medicine to treat it? 
  0: Never 
  1: Yes, specify ________________________________________ 
  99: Don’t know 
1.6 Have you ever used creams or moisturizers on your child’s skin? 
  0: No 
  1: Yes, specify name of product ___________________________ 
  99: Don’t know 
1.7 Have you ever used topical steroids on your child’s skin? 
  0: No                  
  1: Yes 
  99: Don’t know  
1.8 Has your child ever been diagnosed with eczema? 
      * Eczema – a medical condition where the skin is red, dry, scaly, itchy and sore 
  0: No                  
  1: Yes , specify age of diagnosis       months  
  99: Don’t know  
1.9 Has your child ever wheezed? 
       * Wheeze – Noisy breathing with a high-pitch, whistling sound heard from the chest,                                                                                 
not the mouth 
  0: No                  
  1: Yes , specify no. of wheezing episodes          
  99: Don’t know  
 
1.9.1 If yes, how old was your child at the start of the first episode of wheeze? 
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1.10 Has your child ever been diagnosed with bronchiolitis /bronchitis? 
       * Bronchiolitis/Bronchitis – respiratory infection causing wheeze, cough, fever, runny nose 
and breathing difficulty 
  0: No                  
  1: Yes , specify no. of episodes          
  99: Don’t know  
1.11 Has your child ever been prescribed with nebulizer/inhaler treatment? 
  0: No                  
  1: Yes, specify ___________________________ 
  99: Don’t know  
1.12 Has your child had a cough for a long period of time (e.g. 1 month)? 
  0: No                  
  1: Yes 
  99: Don’t know  
1.13 Has your child ever had any episodes of croupy cough or been diagnosed with croup? 
* Croup – respiratory infection causing barking cough, hoarse voice, runny nose, fever, loud 
high-pitched hoarse noise when breathing in, and breathing difficulty    
  0. No 
  1: Yes , specify no. of episodes          
  99: Don’t know    
1.14 Has your child ever been diagnosed with pneumonia? 
* Exclude bronchiolitis/bronchitis    
  0. No 
  1: Yes , specify no. of episodes          
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1.15 Has your child had any bouts of vomiting lasting 2 days or longer?  
          * Do not include possetting or regurgitation 
  0. No 
   1. Yes, specify number of bouts  
 
  




1.16 Has your child had any bouts of diarrhoea lasting 2 days or longer?  
           * Diarrhoea – frequent unformed stools, not including breastfed stools 
  0. No 




  99. Don’t know  
 
  
1.17 Has your child ever been diagnosed by a doctor as having an ear infection? 
  0. No 
  1. Yes, specify number of times  
 
  
  99. Don’t know    
 
1.18 Has your child had any episodes of fever measuring more than 38.0 degrees Celsius? 
            * Include fever episodes associated with above problems 
  0. No 
  1. Yes, specify number of episodes  
 
  
  99. Don’t know    
 
1.19 Has your child had any admission to a hospital? * Including admission for above problems 
  0. No 





      
 






Level of care           
Indicate 
1=General/2=HD/3=ICU 
1     
2     
3     
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1.20 Has your child ever had antibiotics? 
  0: No                  
 1: Yes (please fill in table below)  
                            99: Don’t know  




Name of antibiotics 
Indicate 99 if unknown 
Indications 
1     
2     
3     
 
 
1.21 Has your child been diagnosed with any other medical conditions in the last three months? 
  0. No 








S/N Age (month) 
diagnosed 
Diagnosis Treatment details 
1    
2    
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2. FEEDING PRACTICES 
 
2.1 Please indicate your baby’s type of feed in the last 3 months. 










Week 4      
2nd Month     
3rd Month     
 
2.2.  Are you currently still breastfeeding?  
  0. No               






2.3 If currently you are no longer breastfeeding, when did you stop breastfeeding? 
 Please indicate End date of Breastfeeding               Go to Question 2.12 
                Age stopped  or              Date stopped 
                 
Mths  Wks  Days  M M  D D  Y Y 
 
2.4. If you are breastfeeding, how would you rate the volume of milk you are producing for your baby? 
  1: More than enough                  
  2: Just enough 
  3: Not enough 
2.5. If given a choice, how would you like to change the volume of milk you are producing? 
  1: Produce more                  
  2: Produce less 
  3: No change  
 
299
 MONTH 3 INFANCY QUESTIONNAIRES 
 
 
PLEASE USE CAPITAL LETTER AND WRITE CLEARLY. 
CONFIDENTIAL 
Version 1.2 dated 18/08/10                                                                                                                         Page 7 of 10 
 
2.6.  If you are breast feeding, how is your baby breast fed? Please choose one. 
  1: Direct breast feeding 
  2: Expressed breast feeding and feed from bottle 
  3: Mixed ( Direct and expressed breast feeding) 
2.7. If you are breastfeeding directly, how many times do you breastfeed your baby in 1 day (24 hour)? 
   Number of times 
 
2.8. If you are expressing breast milk, what is the main reason? Please choose one. 
  1: Excess breast milk after direct feeds 
  2: Want to store breast milk for future use 
  3: Need to go back to work 
4: Prefer  bottle feeding to direct breast feeding 
5: Bottle feeding is more comfortable than breast feeding 
6: Know how much milk you produce 
7: Problem with latching 
8: Convenient to express. 
2.9. If you are expressing breast milk, what are the other reasons? Tick as many as applicable. 
  1: Excess breast milk after direct feeds 
  2: Want to store breast milk for future use 
  3: Need to go back to work 
  4: Prefer  bottle feeding to direct breast feeding 
  5: Bottle feeding is more comfortable than breast feeding 
  6: Know how much milk you produce 
  7: Problem with latching 
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2.10. What proportion of expressed breast milk fed to your baby is from frozen milk? 
  1: None or hardly (0 – 10%) 
 
2: Some (11 – 40 %) 
 
3: About half (41 – 60%) 
 
4: Most (61 - 90%) 
 
5: All or almost all (91-100%) 
 
2.11 Did you have any illnesses during breastfeeding?  
   
    
 
Breastfeeding –related infections:  mastitis   0.No 1.Yes 
 
Abscess   0.No 1.Yes 
 
Respiratory tract infections   0.No 1.Yes 
 
Gastrointestinal infections   0.No 1.Yes 
 
Others,    0.No 1.Yes 
 
specify____________________________ 
    
2.12. How much expressed breast milk/formula is given to the baby during last week? 
Day 
Volume of express breast milk fed to baby 
per day (ml) 
Volume of formula fed to baby per 
day (ml) 
Day 1   
Day 2   
Day 3   
Day 4   
Day 5   
Day 6   
Day 7   
 
2.13. Are you going back to work?  
  0: No          Go to question 2.15 
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2.14. If yes, what changes have you planned for feeding your baby? 
  1:  Stop breastfeeding 
 
2:  Expressed breast milk and feed from bottle only 
 
3: Expressed breast milk and direct breastfeeding 
 
4: Switch to formula partially 
 
5: Switch to formula completely 
 
2.15. Since our last visit, which types of milk or formula are you giving your baby?  
(Refer list for formula code)     If still using formula, age/date stopped = 88 
Formula 
code 
Age started  Age stopped  Date started 
(dd/mm/yy) 
Date stopped 
(dd/mm/yy) Mths wks days Mths wks days 
         
         
         
         
 
If formula is not found in the list, please specify name:  ______________________________ 
2.16 Does your baby take any powder / drops / supplement / medicine containing probiotics
 
 (good 
 bacteria)?  
  0. No 









Age started  Age stopped  Date started 
(dd/mm/yy) 
Date stopped 
(dd/mm/yy) Mths wks days Mths wks days 
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2.17 Does your baby take any other dietary supplements (e.g. vitamins, minerals, iron, fish oil, etc)? 
 
  0. No 







Age started  Age stopped  Date started 
(dd/mm/yy) 
Date stopped 
(dd/mm/yy) Mths Wks Days Mths Wks Days 
          
          
          
          
 
 
THANK YOU VERY MUCH FOR YOUR HELP 
 
 
Interview end time: ___________________________  
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Study ID: _______________________                Date: _________________ 
 
 
BABY EATING BEHAVIOUR QUESTIONNAIRE (BEBQ) 
These questions are about your baby’s appetite over his/her first few months of life. We are 
specifically interested in the period during which your baby is fed milk only, i.e. no solid foods 
or pre-prepared baby food yet.  
How would you describe your baby’s feeding style at a typical daytime feed? 
 Never Rarely  Sometimes Often  Always 
1. My baby seems contented while 
feeding      
2. My baby frequently wants more milk 
than I provide      
3. My baby loves milk      
4. My baby has a big appetite      
5. My baby finishes feeding quickly      
6. My baby becomes distressed while 
feeding      
7. My baby gets full up easily      
8. If allowed to, my baby would take too 
much milk 
     
9. My baby takes more than 30 minutes 
to finish feeding 
     
10. My baby gets full before taking all the 
milk I think he/she should have 
     
11. My baby feeds slowly      
12. Even when my baby has just eaten 
well, he/she is happy to feed again if 
offered 
     
13. My baby finds it difficult to manage a 
complete feed 
     
14. My baby is always demanding a feed      
15. My baby sucks more and more slowly 
during the course of a feed 
     
16. If given the chance, my baby would 
always be feeding 
     
17. My baby enjoys feeding time      
18. My baby can easily take a feed within 
30 minutes of the last one 
     
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Child Eating Behaviour Questionnaire (CEBQ) [12 months] 
Please read the following statements and tick the boxes most appropriate to 














































































































































































































My child leaves food on his/her plate at the end 


























Study ID: ________________________ 
       
      Date: ________________________ 
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Even if my child is full up s/he finds room to eat 












If given the chance, my child would drink 












My child cannot eat a meal if s/he has had a 












If given the chance, my child would always be 

























My child decides that s/he doesn’t like a food, 












If given the chance, my child would always have 











My child eats more and more slowly during the 
course of a meal 
 
□ 
 
□ 
 
□ 
 
□ 
 
□ 
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